NZ709870B2 - Spiro-lactam nmda receptor modulators and uses thereof - Google Patents
Spiro-lactam nmda receptor modulators and uses thereof Download PDFInfo
- Publication number
- NZ709870B2 NZ709870B2 NZ709870A NZ70987014A NZ709870B2 NZ 709870 B2 NZ709870 B2 NZ 709870B2 NZ 709870 A NZ709870 A NZ 709870A NZ 70987014 A NZ70987014 A NZ 70987014A NZ 709870 B2 NZ709870 B2 NZ 709870B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- alkyl
- group
- mmol
- fnl
- Prior art date
Links
- 102000004868 N-methyl-D-aspartate receptors Human genes 0.000 title abstract description 30
- 108090001041 N-methyl-D-aspartate receptors Proteins 0.000 title abstract description 30
- 230000000051 modifying Effects 0.000 title abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 371
- 238000001990 intravenous administration Methods 0.000 claims abstract description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 113
- -1 9- fluorenylmethyloxycarbonyl Chemical group 0.000 claims description 72
- 229910052757 nitrogen Inorganic materials 0.000 claims description 72
- 125000004429 atoms Chemical group 0.000 claims description 43
- 239000011780 sodium chloride Substances 0.000 claims description 43
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 39
- 125000001424 substituent group Chemical group 0.000 claims description 39
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 35
- 125000001072 heteroaryl group Chemical group 0.000 claims description 35
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 35
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 34
- 125000000623 heterocyclic group Chemical group 0.000 claims description 31
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 29
- 229910052736 halogen Inorganic materials 0.000 claims description 28
- 229910052739 hydrogen Inorganic materials 0.000 claims description 28
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 25
- 150000002367 halogens Chemical class 0.000 claims description 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 23
- 125000005842 heteroatoms Chemical group 0.000 claims description 22
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 22
- 229910052760 oxygen Inorganic materials 0.000 claims description 20
- 125000004043 oxo group Chemical group O=* 0.000 claims description 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 17
- 125000001188 haloalkyl group Chemical group 0.000 claims description 15
- 229910052717 sulfur Inorganic materials 0.000 claims description 15
- 201000000980 schizophrenia Diseases 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 229940035295 Ting Drugs 0.000 claims description 11
- 125000005843 halogen group Chemical group 0.000 claims description 11
- 150000001204 N-oxides Chemical class 0.000 claims description 10
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 10
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 10
- 206010001897 Alzheimer's disease Diseases 0.000 claims description 8
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 7
- 206010002855 Anxiety Diseases 0.000 claims description 7
- 206010057666 Anxiety disease Diseases 0.000 claims description 7
- 230000036506 anxiety Effects 0.000 claims description 7
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 125000006677 (C1-C3) haloalkoxy group Chemical group 0.000 claims description 6
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 5
- 206010003736 Attention deficit/hyperactivity disease Diseases 0.000 claims description 5
- 201000006287 attention deficit hyperactivity disease Diseases 0.000 claims description 5
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 5
- 239000000546 pharmaceutic aid Substances 0.000 claims description 5
- 125000006239 protecting group Chemical group 0.000 claims description 5
- 125000001963 4 membered heterocyclic group Chemical group 0.000 claims description 4
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims description 3
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 3
- 125000002393 azetidinyl group Chemical group 0.000 claims description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 125000005331 diazinyl group Chemical group N1=NC(=CC=C1)* 0.000 claims description 3
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 3
- 125000000160 oxazolidinyl group Chemical group 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 claims description 3
- 125000000335 thiazolyl group Chemical group 0.000 claims description 3
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 claims description 2
- 125000001984 thiazolidinyl group Chemical group 0.000 claims description 2
- 230000000052 comparative effect Effects 0.000 claims 3
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 3
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims 2
- 239000000203 mixture Substances 0.000 abstract description 63
- 201000010099 disease Diseases 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 14
- 239000000243 solution Substances 0.000 description 215
- 239000011541 reaction mixture Substances 0.000 description 172
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 156
- 230000002829 reduced Effects 0.000 description 149
- 238000005160 1H NMR spectroscopy Methods 0.000 description 139
- 238000003756 stirring Methods 0.000 description 129
- 239000012044 organic layer Substances 0.000 description 118
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 116
- 239000007858 starting material Substances 0.000 description 112
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 105
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 102
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 100
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 86
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 76
- 239000000463 material Substances 0.000 description 74
- 239000007787 solid Substances 0.000 description 74
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 74
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 72
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 67
- 239000012267 brine Substances 0.000 description 59
- 235000019439 ethyl acetate Nutrition 0.000 description 58
- 238000006243 chemical reaction Methods 0.000 description 57
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 56
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 55
- 238000010898 silica gel chromatography Methods 0.000 description 52
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 50
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 40
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 37
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 34
- 229910052799 carbon Inorganic materials 0.000 description 33
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 31
- 238000004440 column chromatography Methods 0.000 description 31
- 238000004128 high performance liquid chromatography Methods 0.000 description 31
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 239000006188 syrup Substances 0.000 description 30
- 235000020357 syrup Nutrition 0.000 description 30
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 29
- 239000010410 layer Substances 0.000 description 29
- 239000012298 atmosphere Substances 0.000 description 28
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 28
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 25
- 239000002253 acid Substances 0.000 description 24
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 24
- 239000008079 hexane Substances 0.000 description 23
- 239000007788 liquid Substances 0.000 description 23
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 22
- OFBQJSOFQDEBGM-UHFFFAOYSA-N pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 22
- 230000027455 binding Effects 0.000 description 19
- 229960004132 diethyl ether Drugs 0.000 description 19
- 101700067048 CDC13 Proteins 0.000 description 18
- 239000000706 filtrate Substances 0.000 description 18
- 239000012299 nitrogen atmosphere Substances 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 16
- DNSISZSEWVHGLH-UHFFFAOYSA-N Butyramide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 15
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- 230000001225 therapeutic Effects 0.000 description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 125000004432 carbon atoms Chemical group C* 0.000 description 14
- 239000007832 Na2SO4 Substances 0.000 description 13
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 13
- 229910052938 sodium sulfate Inorganic materials 0.000 description 13
- 235000011152 sodium sulphate Nutrition 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 12
- VVWRJUBEIPHGQF-KTKRTIGZSA-N Diisopropyl azodicarboxylate Chemical compound CC(C)OC(=O)\N=N/C(=O)OC(C)C VVWRJUBEIPHGQF-KTKRTIGZSA-N 0.000 description 12
- 239000004471 Glycine Substances 0.000 description 12
- 101710027499 Os03g0268000 Proteins 0.000 description 12
- 125000000217 alkyl group Chemical group 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- AGEZXYOZHKGVCM-UHFFFAOYSA-N Benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 11
- YNESATAKKCNGOF-UHFFFAOYSA-N Lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 230000002194 synthesizing Effects 0.000 description 11
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 10
- HOKKHZGPKSLGJE-GSVOUGTGSA-N NMDA Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 10
- IJDNQMDRQITEOD-UHFFFAOYSA-N butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 10
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 9
- 206010061920 Psychotic disease Diseases 0.000 description 9
- 150000003840 hydrochlorides Chemical class 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N Thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 239000004031 partial agonist Substances 0.000 description 8
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 7
- 206010003805 Autism Diseases 0.000 description 7
- 235000019270 ammonium chloride Nutrition 0.000 description 7
- 201000002055 autistic disease Diseases 0.000 description 7
- 229940079593 drugs Drugs 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 150000002829 nitrogen Chemical group 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 7
- NYCVCXMSZNOGDH-UHFFFAOYSA-M pyrrolidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-M 0.000 description 7
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 6
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 6
- 208000004296 Neuralgia Diseases 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- FERIUCNNQQJTOY-UHFFFAOYSA-M butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 6
- OKKJLVBELUTLKV-MZCSYVLQSA-N cd3od Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 6
- 230000001684 chronic Effects 0.000 description 6
- DLLJVQNYBYOKGS-UHFFFAOYSA-N ethoxyethane;pentane Chemical compound CCCCC.CCOCC DLLJVQNYBYOKGS-UHFFFAOYSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000002953 preparative HPLC Methods 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 206010010904 Convulsion Diseases 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 238000004166 bioassay Methods 0.000 description 5
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 5
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 230000036961 partial Effects 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Inorganic materials [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 5
- AFENDNXGAFYKQO-UHFFFAOYSA-N 2-Hydroxybutyric acid Chemical compound CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 description 4
- 206010004938 Bipolar disease Diseases 0.000 description 4
- 206010007515 Cardiac arrest Diseases 0.000 description 4
- 206010012239 Delusion Diseases 0.000 description 4
- 206010015037 Epilepsy Diseases 0.000 description 4
- 208000010496 Heart Arrest Diseases 0.000 description 4
- 201000001971 Huntington's disease Diseases 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N acetaldehyde Chemical class CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating Effects 0.000 description 4
- 230000001154 acute Effects 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 230000003042 antagnostic Effects 0.000 description 4
- UDLLFLQFQMACJB-UHFFFAOYSA-N azidomethylbenzene Chemical compound [N-]=[N+]=NCC1=CC=CC=C1 UDLLFLQFQMACJB-UHFFFAOYSA-N 0.000 description 4
- HSUIVCLOAAJSRE-UHFFFAOYSA-N bis(2-methoxyethyl) benzene-1,2-dicarboxylate Chemical compound COCCOC(=O)C1=CC=CC=C1C(=O)OCCOC HSUIVCLOAAJSRE-UHFFFAOYSA-N 0.000 description 4
- 201000006474 brain ischemia Diseases 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 231100000868 delusion Toxicity 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 230000001965 increased Effects 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- 230000027928 long-term synaptic potentiation Effects 0.000 description 4
- 230000003340 mental Effects 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrugs Drugs 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003039 volatile agent Substances 0.000 description 4
- ONCCWDRMOZMNSM-FBCQKBJTSA-N 2-amino-6-[(4S,5R)-2,5-dihydroxy-2-oxo-1,3,2$l^{5}-dioxaphosphinane-4-carbonyl]-1H-pteridin-4-one Chemical compound N1=C2C(=O)NC(N)=NC2=NC=C1C(=O)[C@H]1OP(O)(=O)OC[C@H]1O ONCCWDRMOZMNSM-FBCQKBJTSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- 206010065040 AIDS dementia complex Diseases 0.000 description 3
- 210000003050 Axons Anatomy 0.000 description 3
- 210000004556 Brain Anatomy 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butanoic acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 206010007776 Catatonia Diseases 0.000 description 3
- JJWLVOIRVHMVIS-UHFFFAOYSA-N Isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 3
- 206010024094 Learning disease Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000002851 Paranoid Schizophrenia Diseases 0.000 description 3
- 206010039636 Schizophrenia simple Diseases 0.000 description 3
- 206010039638 Schizophrenia, disorganised type Diseases 0.000 description 3
- 206010039639 Schizophrenia, paranoid type Diseases 0.000 description 3
- 206010039911 Seizure Diseases 0.000 description 3
- 206010041243 Social avoidant behaviour Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 125000005133 alkynyloxy group Chemical group 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000000561 anti-psychotic Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000003197 catalytic Effects 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 210000004027 cells Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000002612 dispersion media Substances 0.000 description 3
- 230000002708 enhancing Effects 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000015654 memory Effects 0.000 description 3
- 201000008895 mood disease Diseases 0.000 description 3
- 201000008430 obsessive-compulsive disease Diseases 0.000 description 3
- 230000001242 postsynaptic Effects 0.000 description 3
- 235000015320 potassium carbonate Nutrition 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Substances [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 3
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000000707 stereoselective Effects 0.000 description 3
- 201000010874 syndrome Diseases 0.000 description 3
- 230000001131 transforming Effects 0.000 description 3
- IIFVWLUQBAIPMJ-UHFFFAOYSA-N (4-fluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C=C1 IIFVWLUQBAIPMJ-UHFFFAOYSA-N 0.000 description 2
- 150000000094 1,4-dioxanes Chemical class 0.000 description 2
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 2
- 229940005513 ANTIDEPRESSANTS Drugs 0.000 description 2
- 229940005529 ANTIPSYCHOTICS Drugs 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N Acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 241000256844 Apis mellifera Species 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N Benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 108091005504 Cation channels Proteins 0.000 description 2
- 210000003169 Central Nervous System Anatomy 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 206010008129 Cerebral palsy Diseases 0.000 description 2
- 206010070976 Craniocerebral injury Diseases 0.000 description 2
- 206010012256 Delusional disease Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 206010012374 Depressed mood Diseases 0.000 description 2
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 2
- 201000010374 Down syndrome Diseases 0.000 description 2
- ODQWQRRAPPTVAG-GZTJUZNOSA-N Doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 2
- 206010013982 Dysthymic disease Diseases 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 208000001914 Fragile X Syndrome Diseases 0.000 description 2
- 108009000484 Fragile X Syndrome Proteins 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N GABA Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 206010022114 Injury Diseases 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 206010057840 Major depression Diseases 0.000 description 2
- 208000001652 Memory Disorders Diseases 0.000 description 2
- 208000001089 Multiple System Atrophy Diseases 0.000 description 2
- 208000008238 Muscle Spasticity Diseases 0.000 description 2
- 206010028334 Muscle spasms Diseases 0.000 description 2
- 206010028570 Myelopathy Diseases 0.000 description 2
- 208000002033 Myoclonus Diseases 0.000 description 2
- LBOJYSIDWZQNJS-UHFFFAOYSA-N Neurogard Chemical compound C12=CC=CC=C2C2(C)C3=CC=CC=C3CC1N2 LBOJYSIDWZQNJS-UHFFFAOYSA-N 0.000 description 2
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical group C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 2
- NUJGJRNETVAIRJ-UHFFFAOYSA-N Octanal Chemical compound CCCCCCCC=O NUJGJRNETVAIRJ-UHFFFAOYSA-N 0.000 description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N Octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
- 208000003435 Optic Neuritis Diseases 0.000 description 2
- 241000283898 Ovis Species 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N Oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 206010061536 Parkinson's disease Diseases 0.000 description 2
- 208000001293 Peripheral Nervous System Disease Diseases 0.000 description 2
- 206010034606 Peripheral neuropathy Diseases 0.000 description 2
- 206010034912 Phobia Diseases 0.000 description 2
- 229960002429 Proline Drugs 0.000 description 2
- 206010038932 Retinopathy Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 206010039637 Schizophrenia, catatonic type Diseases 0.000 description 2
- 206010039640 Schizophrenia, residual type Diseases 0.000 description 2
- 206010039775 Seasonal affective disease Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000008513 Spinal Cord Injury Diseases 0.000 description 2
- 206010061367 Spinal cord disease Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M Tetra-n-butylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 208000005765 Traumatic Brain Injury Diseases 0.000 description 2
- FIQMHBFVRAXMOP-UHFFFAOYSA-N Triphenylphosphine oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 2
- 206010044688 Trisomy 21 Diseases 0.000 description 2
- 208000009999 Tuberous Sclerosis Diseases 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000003302 alkenyloxy group Chemical group 0.000 description 2
- 125000005206 alkoxycarbonyloxymethyl group Chemical group 0.000 description 2
- 230000003281 allosteric Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000001430 anti-depressive Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 230000003416 augmentation Effects 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- 230000000975 bioactive Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 201000009541 complex regional pain syndrome Diseases 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 description 2
- KZZKOVLJUKWSKX-UHFFFAOYSA-N cyclobutanamine Chemical compound NC1CCC1 KZZKOVLJUKWSKX-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- FCJJZKCJURDYNF-UHFFFAOYSA-N ethyl but-2-ynoate Chemical compound CCOC(=O)C#CC FCJJZKCJURDYNF-UHFFFAOYSA-N 0.000 description 2
- 230000002461 excitatory amino acid Effects 0.000 description 2
- 239000003257 excitatory amino acid Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000000302 ischemic Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 201000003723 learning disability Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 230000016273 neuron death Effects 0.000 description 2
- 201000001552 phobic disease Diseases 0.000 description 2
- 201000009916 postpartum depression Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000698 schizophrenic Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229960001153 serine Drugs 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 201000009032 substance abuse Diseases 0.000 description 2
- 231100000736 substance abuse Toxicity 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 230000000946 synaptic Effects 0.000 description 2
- 230000003956 synaptic plasticity Effects 0.000 description 2
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 229960002898 threonine Drugs 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- 230000000472 traumatic Effects 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- AELCINSCMGFISI-DTWKUNHWSA-N (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@@H]1C[C@H]1C1=CC=CC=C1 AELCINSCMGFISI-DTWKUNHWSA-N 0.000 description 1
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000005862 (C1-C6)alkanoyl group Chemical group 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 1-butanal Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- UUXHICUVBOTXQS-UHFFFAOYSA-N 2-hydroxybutanamide Chemical compound CCC(O)C(N)=O UUXHICUVBOTXQS-UHFFFAOYSA-N 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- ZFUOLNAKPBFDIJ-UHFFFAOYSA-N 25I-NBOMe Chemical compound COC1=CC=CC=C1CNCCC1=CC(OC)=C(I)C=C1OC ZFUOLNAKPBFDIJ-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-M 3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoate Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GHOKWGTUZJEAQD-ZETCQYMHSA-M 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N 5-oxoproline Chemical compound OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 102100004213 ABAT Human genes 0.000 description 1
- 101710038256 ABAT Proteins 0.000 description 1
- 102100007877 APOE Human genes 0.000 description 1
- 101700025839 APOE Proteins 0.000 description 1
- 229940022663 Acetate Drugs 0.000 description 1
- 206010001443 Affective disease Diseases 0.000 description 1
- 241001237754 Algia Species 0.000 description 1
- NTJOBXMMWNYJFB-UHFFFAOYSA-N Amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N Amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 229940025141 Anafranil Drugs 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- 229940072107 Ascorbate Drugs 0.000 description 1
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N Asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 description 1
- 229960005245 Asenapine Drugs 0.000 description 1
- MGEVGECQZUIPSV-UHFFFAOYSA-N BOP reagent Chemical compound F[P-](F)(F)(F)(F)F.C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 MGEVGECQZUIPSV-UHFFFAOYSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N Benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 206010006034 Borderline personality disease Diseases 0.000 description 1
- 241000311499 Bos grunniens x Bos taurus Species 0.000 description 1
- 206010006360 Brief psychotic disease Diseases 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N Bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 229960001058 Bupropion Drugs 0.000 description 1
- FFSAXUULYPJSKH-UHFFFAOYSA-N Butyrophenone Chemical class CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 1
- 235000003197 Byrsonima crassifolia Nutrition 0.000 description 1
- 240000001546 Byrsonima crassifolia Species 0.000 description 1
- 102100017420 CHRNA4 Human genes 0.000 description 1
- 101710006050 CHRNA4 Proteins 0.000 description 1
- KPOXRMRUMPUFEK-UHFFFAOYSA-N COC(=O)C(CC)(O)N Chemical compound COC(=O)C(CC)(O)N KPOXRMRUMPUFEK-UHFFFAOYSA-N 0.000 description 1
- AHOUBRCZNHFOSL-YOEHRIQHSA-N Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229940047493 Celexa Drugs 0.000 description 1
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 description 1
- WSEQXVZVJXJVFP-UHFFFAOYSA-N Citalopram Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 1
- 229940001468 Citrate Drugs 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N Clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- 240000007582 Corylus avellana Species 0.000 description 1
- HGCIXCUEYOPUTN-UHFFFAOYSA-N Cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 1
- 229940029644 Cymbalta Drugs 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-L D-glucarate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O DSLZVSRJTYRBFB-LLEIAEIESA-L 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- BGKFPRIGXAVYNX-UHFFFAOYSA-N DCKA Chemical compound ClC1=CC(Cl)=CC2=NC(C(=O)O)=CC(O)=C21 BGKFPRIGXAVYNX-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010012378 Depression Diseases 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- 208000001636 Diabetic Neuropathy Diseases 0.000 description 1
- 206010012680 Diabetic neuropathy Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010013754 Drug withdrawal syndrome Diseases 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N Duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- 229940098766 Effexor Drugs 0.000 description 1
- 229940011681 Elavil Drugs 0.000 description 1
- WSEQXVZVJXJVFP-FQEVSTJZSA-N Escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 1
- 206010016256 Fatigue Diseases 0.000 description 1
- 206010016759 Flat affect Diseases 0.000 description 1
- IRXSLJNXXZKURP-UHFFFAOYSA-N Fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 1
- 229960002464 Fluoxetine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-UHFFFAOYSA-N Fluvoxamine Chemical compound COCCCCC(=NOCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-UHFFFAOYSA-N 0.000 description 1
- 102000017692 GABRA5 Human genes 0.000 description 1
- 108060004389 GABRA5 Proteins 0.000 description 1
- 102100012570 GFAP Human genes 0.000 description 1
- 101700069447 GFAP Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N Gentisic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 206010019070 Hallucination, auditory Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010019233 Headache Diseases 0.000 description 1
- 210000001320 Hippocampus Anatomy 0.000 description 1
- XMXHEBAFVSFQEX-UHFFFAOYSA-N Iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 description 1
- 206010061215 Impulse-control disease Diseases 0.000 description 1
- 210000000936 Intestines Anatomy 0.000 description 1
- KDSNLYIMUZNERS-UHFFFAOYSA-N Isobutylamine Chemical compound CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 1
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N Isocarboxazid Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N Isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N Isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 101710009221 LD Proteins 0.000 description 1
- 229940001447 Lactate Drugs 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- 229940054157 Lexapro Drugs 0.000 description 1
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- PQXKDMSYBGKCJA-CVTJIBDQSA-N Lurasidone Chemical compound C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 PQXKDMSYBGKCJA-CVTJIBDQSA-N 0.000 description 1
- 229940009622 Luvox Drugs 0.000 description 1
- 229940110127 Marplan Drugs 0.000 description 1
- 206010061284 Mental disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 206010027599 Migraine Diseases 0.000 description 1
- 208000008085 Migraine Disorders Diseases 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N Mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 125000005855 N,N-di(C1-C2)alkylcarbamoyl-(C1-C2)alkyl group Chemical group 0.000 description 1
- 125000005850 N-(alkoxycarbonyl)aminomethyl group Chemical group 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-N N-Butylamine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- 101700055029 NCAM2 Proteins 0.000 description 1
- 229940087524 Nardil Drugs 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010053643 Neurodegenerative disease Diseases 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- 229940087480 Norpramin Drugs 0.000 description 1
- 125000005861 N—(C1-C6)alkoxycarbonylaminomethyl group Chemical group 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N Olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 229940049964 Oleate Drugs 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 102100002857 PDYN Human genes 0.000 description 1
- 101700030422 PDYN Proteins 0.000 description 1
- 229940055692 Pamelor Drugs 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229940087824 Parnate Drugs 0.000 description 1
- 229940001408 Paxil Drugs 0.000 description 1
- 210000001428 Peripheral Nervous System Anatomy 0.000 description 1
- 206010034703 Perseveration Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N Phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- RXBKMJIPNDOHFR-UHFFFAOYSA-N Phenelzine sulfate Chemical compound OS(O)(=O)=O.NNCCC1=CC=CC=C1 RXBKMJIPNDOHFR-UHFFFAOYSA-N 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N Propanamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N Protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
- 229940035613 Prozac Drugs 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N Quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- GIBQQARAXHVEGD-BSOLPCOYSA-N Rapastinel Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)N[C@@H]([C@@H](C)O)C(N)=O)CCC1 GIBQQARAXHVEGD-BSOLPCOYSA-N 0.000 description 1
- 229940023942 Remeron Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N Risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 229960001534 Risperidone Drugs 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N Sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 description 1
- 208000007929 Shared Paranoid Disorder Diseases 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 206010040984 Sleep disease Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 206010041466 Speech disease Diseases 0.000 description 1
- 210000000278 Spinal Cord Anatomy 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010048327 Supranuclear palsy Diseases 0.000 description 1
- 229940118176 Surmontil Drugs 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 210000000225 Synapses Anatomy 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N THP Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- WWJZWCUNLNYYAU-UHFFFAOYSA-N Temefos Chemical compound C1=CC(OP(=S)(OC)OC)=CC=C1SC1=CC=C(OP(=S)(OC)OC)C=C1 WWJZWCUNLNYYAU-UHFFFAOYSA-N 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N Tert-Butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N Thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 230000036335 Tissue distribution Effects 0.000 description 1
- 229940041597 Tofranil Drugs 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 206010044126 Tourette's disease Diseases 0.000 description 1
- 229960003991 Trazodone Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N Trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N Triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N Trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- 102100015844 UBXN11 Human genes 0.000 description 1
- 101710027909 UBXN11 Proteins 0.000 description 1
- 229940045977 Vivactil Drugs 0.000 description 1
- 206010047853 Waxy flexibility Diseases 0.000 description 1
- 229940009065 Wellbutrin Drugs 0.000 description 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N Ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
- 229940020965 Zoloft Drugs 0.000 description 1
- HDOZVRUNCMBHFH-UHFFFAOYSA-N Zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960003036 amisulpride Drugs 0.000 description 1
- 230000003444 anaesthetic Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000949 anxiolytic Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- 125000005251 aryl acyl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 201000007185 autism spectrum disease Diseases 0.000 description 1
- 201000003983 avoidant personality disease Diseases 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- VIQRCOQXIHFJND-UHFFFAOYSA-N bicyclo[2.2.2]oct-2-ene Chemical compound C1CC2CCC1C=C2 VIQRCOQXIHFJND-UHFFFAOYSA-N 0.000 description 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 229960000074 biopharmaceuticals Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- YIYSEJAAJSSNNS-UHFFFAOYSA-N but-1-en-1-one Chemical group [CH2]CC=C=O YIYSEJAAJSSNNS-UHFFFAOYSA-N 0.000 description 1
- WPTMDNDUQTZHIC-UHFFFAOYSA-N but-1-yne Chemical group [CH2-]CC#[C+] WPTMDNDUQTZHIC-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 201000008779 central nervous system disease Diseases 0.000 description 1
- 230000000973 chemotherapeutic Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000037326 chronic stress Effects 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001149 cognitive Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002860 competitive Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000001054 cortical Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- VOLSCWDWGMWXGO-UHFFFAOYSA-N cyclobuten-1-yl acetate Chemical compound CC(=O)OC1=CCC1 VOLSCWDWGMWXGO-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003001 depressive Effects 0.000 description 1
- 125000005852 di-N,N—(C1-C2)alkylamino(C2-C3)alkyl group Chemical group 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 230000000763 evoked Effects 0.000 description 1
- 230000036749 excitatory postsynaptic potential Effects 0.000 description 1
- 230000003492 excitotoxic Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N furane Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 101700027069 gliC Proteins 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 150000002373 hemiacetals Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 230000000971 hippocampal Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- KLGZELKXQMTEMM-UHFFFAOYSA-N hydride Chemical compound [H-] KLGZELKXQMTEMM-UHFFFAOYSA-N 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- COQRGFWWJBEXRC-UHFFFAOYSA-N hydron;methyl 2-aminoacetate;chloride Chemical compound Cl.COC(=O)CN COQRGFWWJBEXRC-UHFFFAOYSA-N 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- XQHOYAPYYMTFJM-UHFFFAOYSA-N hydroxymethyl pyrrolidine-1-carboxylate Chemical compound OCOC(=O)N1CCCC1 XQHOYAPYYMTFJM-UHFFFAOYSA-N 0.000 description 1
- 229960003162 iloperidone Drugs 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 230000001057 ionotropic Effects 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 229960002672 isocarboxazid Drugs 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229960001432 lurasidone Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 201000003895 major depressive disease Diseases 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 239000002609 media Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- RLXWGEUQYNIHRM-UHFFFAOYSA-N methanetriolate Chemical compound [O-]C([O-])[O-] RLXWGEUQYNIHRM-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- 102000005614 monoclonal antibodies Human genes 0.000 description 1
- 108010045030 monoclonal antibodies Proteins 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 229940113083 morpholine Drugs 0.000 description 1
- 125000005858 morpholino(C2-C3)alkyl group Chemical group 0.000 description 1
- 230000004973 motor coordination Effects 0.000 description 1
- 239000003706 n methyl dextro aspartic acid receptor stimulating agent Substances 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural Effects 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000000926 neurological Effects 0.000 description 1
- 210000002569 neurons Anatomy 0.000 description 1
- 230000002981 neuropathic Effects 0.000 description 1
- 230000000324 neuroprotective Effects 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-L oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 230000001590 oxidative Effects 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 201000008125 pain agnosia Diseases 0.000 description 1
- 229960001057 paliperidone Drugs 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- 125000001484 phenothiazinyl group Chemical class C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000005544 phthalimido group Chemical group 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 125000005856 piperidino(C2-C3)alkyl group Chemical group 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 201000008839 post-traumatic stress disease Diseases 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 210000001176 projection neuron Anatomy 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000002633 protecting Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M pyridine-4-carboxylate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- IIHQNAXFIODVDU-UHFFFAOYSA-N pyrimidine-2-carbonitrile Chemical compound N#CC1=NC=CC=N1 IIHQNAXFIODVDU-UHFFFAOYSA-N 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 description 1
- 125000005857 pyrrolidino(C2-C3)alkyl group Chemical group 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 201000001947 reflex sympathetic dystrophy Diseases 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 201000000978 schizoaffective disease Diseases 0.000 description 1
- 201000010822 schizotypal personality disease Diseases 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 229960000652 sertindole Drugs 0.000 description 1
- BLFQGGGGFNSJKA-XHXSRVRCSA-N sertraline hydrochloride Chemical compound Cl.C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 BLFQGGGGFNSJKA-XHXSRVRCSA-N 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000001954 sterilising Effects 0.000 description 1
- 231100000803 sterility Toxicity 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 150000005075 thioxanthenes Chemical class 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- OHHDIOKRWWOXMT-UHFFFAOYSA-N trazodone hydrochloride Chemical compound [H+].[Cl-].ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 OHHDIOKRWWOXMT-UHFFFAOYSA-N 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- 239000003174 triple reuptake inhibitor Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000031836 visual learning Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
- 229960004496 zotepine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
Disclosed are compounds, represented by formula I, having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed. le delivery forms of the compounds, including intravenous formulations, are also disclosed.
Description
SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
CROSS REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of United States Provisional Application No.
61/757,903, filed on January 29, 2013, which is incorporated by reference in its entirety.
BACKGROUND
An N-methyl-d-aspartate (NMDA) receptor is a postsynaptic, ionotropic receptor
that is responsive to, inter alia, the excitatory amino acids glutamate and glycine and the
tic compound NMDA. The NMDA receptor controls the flow of both divalent and
monovalent ions into the postsynaptic neural cell through a or associated channel (Foster
et al, Nature 1987, 329:395-396; Mayer et al., Trends in Pharmacol. Sci. 1990, -260).
The NMDA receptor has been implicated during development in specifying neuronal
architecture and synaptic connectivity, and may be involved in experience-dependent synaptic
modifications. In addition, NMDA ors are also thought to be involved in long term
potentiation and central nervous system disorders.
The NMDA receptor plays a major role in the ic plasticity that underlies
many higher cognitive functions, such as memory acquisition, ion and learning, as well as
in certain cognitive pathways and in the perception of pain (Collingridge et al., The NMDA
Receptor, Oxford University Press, 1994). In addition, certain properties ofNMDA ors
suggest that they may be involved in the information-processing in the brain that underlies
consciousness itself
The NMDA receptor has drawn particular st since it s to be involved in
a broad spectrum of CNS disorders. For instance, during brain ischemia caused by stroke or
traumatic injury, excessive amounts of the excitatory amino acid ate are released from
damaged or oxygen deprived neurons. This excess glutamate binds to the NMDA receptors
which opens their ligand-gated ion ls; in turn the m influx produces a high level of
intracellular calcium which activates a biochemical cascade resulting in protein degradation
and cell death. This phenomenon, known as excitotoxicity, is also thought to be responsible for
the neurological damage ated with other disorders ranging from ycemia and cardiac
arrest to epilepsy. In addition, there are preliminary reports indicating similar involvement in the
chronic neurodegeneration of Huntington's, Parkinson's, and Alzheimer's diseases. Activation of
the NMDA receptor has been shown to be responsible for post-stroke convulsions, and, in
certain models of epilepsy, activation of the NMDA receptor has been shown to be necessary for
the generation of seizures. Neuropsychiatric involvement of the NMDA receptor has also been
recognized since blockage of the NMDA receptor Ca++ channel by the animal anesthetic PCP
(phencyclidine) produces a tic state in humans similar to schizophrenia (reviewed in
Johnson, K. and Jones, S., 1990). r, NMDA receptors have also been ated in certain
types of spatial learning.
The NMDA receptor is believed to consist of several protein chains embedded in the
postsynaptic membrane. The first two types of subunits discovered so far form a large
extracellular region, which probably contains most of the eric binding sites, several
transmembrane regions looped and folded so as to form a pore or channel, which is permeable to
Ca++, and a carboxyl terminal region. The opening and closing of the l is regulated by the
binding of various ligands to domains (allosteric sites) of the protein residing on the extracellular
surface. The binding of the ligands is thought to affect a conformational change in the overall
structure of the protein which is ultimately reflected in the channel opening, partially opening,
partially closing, or closing.
[0006] NMDA receptor compounds may exert dual (agonist/antagonist) effect on the NMDA
receptor through the eric sites. These compounds are typically termed “partial agonists”.
In the presence of the principal site , a partial t will displace some of the ligand and
thus decrease Ca++ flow through the receptor. In the absence of or d level of the principal
site ligand, the partial agonist acts to increase Ca++ flow through the receptor channel.
[0007] A need continues to exist in the art for novel and more specific/potent compounds
that are capable of g the glycine binding site of NMDA receptors, and provide
pharmaceutical benefits. In addition, a need continues to exist in the medical arts for orally
rable forms of such compounds.
SUMMARY
[0007a] According to a first aspect, the present invention relates to a compound represented
by formula I:
or a ceutically acceptable salt, a stereoisomer, or an N-oxide thereof, wherein
Rb is selected from the group consisting of H, halogen, hydroxyl, cyano and C1-C6 alkyl;
R1 is H or C1-C6 alkyl;
R2 is H or C1-C6 alkyl;
R3 is selected from the group consisting of H, C1-C6 alkyl and a nitrogen protecting
group;
wherein the nitrogen protecting group is selected from the group consisting of 9-
fluorenylmethyloxycarbonyl, utoxycarbonyl, benzyloxycarbonyl, xybenzyloxycarbonyl
, acetyl, trifluoroacetyl, benzoyl, benzyl, p-methoxybenzyl, pmethoxyphenyl
, 3,4-dimethoxybenzyl, triphenylmethyl, enesulfonyl, –C(O)OR31 and –
C(O)R32; wherein
R31 is selected from the group consisting of C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl,
C2-C6 alkynyl, C3-C10 cycloalkyl, -CH2-C3-C10 cycloalkyl, -CH2-phenyl, and –CH2-pyridyl,
wherein any aforementioned lkyl is optionally substituted with from 1-3 ndently
selected C1-C3 alkyl, and wherein the phenyl is optionally substituted with from 1-2 tuents
independently selected from C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, nitro,
halo, SO2Me, cyano, and -OC(O)CH3; and
R32 is selected from the group consisting of H, C1-C6 alkyl, C1-C6 haloalkyl, phenyl, and
pyridyl, wherein the phenyl is optionally substituted with from 1-2 substituents independently
selected from C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, nitro, halo, SO2Me,
cyano, and -OC(O)CH3;
R4 and R5 are each independently selected from the group consisting of H, C1-C6 alkyl, X,
and –C1-C6 ne-X, wherein X is selected from the group ting of:
(i) C3-C6 cycloalkyl;
(ii) aryl including from 5 to 6 ring atoms wherein 1, 2, or 3 of the ring atoms are
independently selected from the group consisting of N, NH, N(C1-C3 alkyl), O, and S;
(iii) heterocyclyl including from 3 to 6 ring atoms wherein 1, 2, or 3 of the ring atoms
are ndently selected from the group ting of N, NH, N(C1-C3 alkyl), O, and S; and
(iv) phenyl;
wherein C3-C6 cycloalkyl and heterocyclyl are each unsubstituted or substituted with
from 1-3 substituents independently ed from the group consisting of halogen, cyano, oxo,
C1-C6 alkyl, hydroxyl, C1-C6 alkoxy, and R’; and heteroaryl and phenyl are each
unsubstituted or substituted with from 1-3 substituents independently selected from the group
consisting of halogen, cyano, C1-C6 alkyl, hydroxyl, C1-C6 alkoxy, and -N(R’)R’;
or R4 and R5 together with the nitrogen to which they are attached form:
heterocyclyl including from 4 to 6 ring atoms; wherein the heterocyclyl includes not
more than two ring heteroatoms (including the nitrogen atom attached to R4 and R5), and the
second ring heteroatom, when t, is independently selected from the group consisting of
N, NH, N(C1-C3 alkyl), O, and S; and wherein the heterocyclyl is unsubstituted or substituted
with from 1-3 substituents independently selected from the group consisting of halogen, cyano,
oxo, C1-C6 alkyl, hydroxyl, C1-C6 alkoxy, and R’; or
heteroaryl including from 5 to 6 ring atoms; wherein the heteroaryl includes not more
than four ring heteroatoms (including the nitrogen atom attached to R4 and R5), and each
additional ring heteroatom, when present, is independently selected from the group consisting
of N, NH, N(C1-C3 alkyl), O, and S; and wherein the heteroaryl is unsubstituted or substituted
with from 1-3 substituents ndently selected from the group consisting of halogen, cyano,
C1-C6 alkyl, hydroxyl, C1-C6 alkoxy, and -N(R’)R’;
R6 is selected from the group consisting of -OH, C1-C6 alkoxy, -OC(O)-C1-C6 alkyl, -
OC(O)phenyl, and -N(R’)R’;
R7 is H or C1-C6 alkyl; and
R’ is ndently selected for each occurrence from H and C1-C6 alkyl.
[0007b] ing to a second aspect, the present invention s to a ceutical
composition comprising a compound of the invention, and a pharmaceutically acceptable
excipient.
[0007c] According to a third aspect, the present ion relates to use of a compound of
the invention in the manufacture of a medicament for treating depression, Alzheimer’s disease,
attention deficit disorder, schizophrenia, or y.
[0007d] According to a fourth aspect, the present invention s to the compound of the
invention represented by formula I:
or a pharmaceutically acceptable salt, a stereoisomer, or an N-oxides thereof, wherein
Rb is selected from the group consisting of H, halogen, hydroxyl, cyano and C1-C6
alkyl;
R1 is H or C1-C6 alkyl;
R2 is H or C1-C6 alkyl;
R3 is selected from the group consisting of H, C1-C6 alkyl and a en protecting
group;
R4 and R5 are independently H or C1-C6 alkyl, or R4 and R5 taken together with the
nitrogen to which they are attached form a 4-, 5- or 6-membered heterocyclic or 5-6 membered
heteroaryl ring, tituted or substituted with 1-3 substituents selected from the group
consisting of halogen, cyano, C1-C6 alkyl, -OH, C1-C6 alkoxy, and -N(R’)R’, n R’ is
independently selected for each occurrence from H or C1-C6 alkyl;
R6 is selected from the group consisting of -OH, C1-C6 alkoxy, -OC(O)-C1-C6 alkyl, and
-OC(O)phenyl; and
R7 is H or C1-C6 alkyl.
Provided , at least in part, are compounds that are NMDA modulators, for
example, partial agonists of NMDA. For example, disclosed herein are compounds represented
by the formula:
3c followed by page 4
and pharmaceutically acceptable salts, stereoisomers, and N-oxides thereof, wherein
Rb is selected from the group consisting of H, halogen, yl, cyano and C1-C6
alkyl;
R1 is H or C1-C6 alkyl;
R2 is H or C1-C6 alkyl;
R3 is selected from the group consisting of H, C1-C6 alkyl and a nitrogen protecting
group;
R4 and R5 are independently H or C1-C6 alkyl, or R4 and R5 taken together with the
nitrogen to which they are attached form a 4-, 5- or ered heterocyclic or
heteroaryl ring optionally substituted with one or more substituents selected from the
group consisting of halogen, cyano, oxo, C1-C6 alkyl, -OH, C1-C6 alkoxy, and -N(R’)R’,
wherein R’ is independently selected for each occurrence from H or C1-C6 alkyl;
R6 is selected from the group consisting of -OH, C1-C6 alkoxy, -OC(O)-C1-C6 alkyl, and
-OC(O)phenyl; and
R7 is H or C1-C6 alkyl;
or in other embodiments, the variables set forth in formula (I) are defined as s:
Rb is selected from the group consisting of H, n, hydroxyl, cyano and C1-C6 alkyl
(e.g., H);
R1 is H or C1-C6 alkyl;
R2 is H or C1-C6 alkyl;
R3 is selected from the group ting of H, C1-C6 alkyl and a nitrogen protecting
group;
R4 and R5 are each independently selected from the group consisting of H, C1-C6 alkyl,
X, and —C1—C6 alkylene—X, wherein X is selected from the group consisting of:
(i) C3—C6 cycloalkyl;
(ii) heteroaryl including from 5 to 6 ring atoms wherein l, 2, or 3 of the ring atoms
are independently selected from the group consisting ofN, NH, N(C1—C3 alkyl), 0,
and S;
(iii) heterocyclyl including from 3 to 6 ring atoms wherein l, 2, or 3 of the ring
atoms are ndently selected from the group consisting of N, NH, N(Cl-C3
, 0, and S; and
(iv) phenyl;
wherein C3-C6 cycloalkyl and heterocyclyl are each optionally substituted with from 1-3
tuents independently selected from the group consisting of halogen, cyano, oxo,
C1-C6 alkyl, hydroxyl, C1-C6 alkoxy, and R’, wherein R’ is independently
selected for each occurrence from H and C1—C6 alkyl; and heteroaryl and phenyl are
each optionally substituted with from 1—3 substituents independently selected from the
group consisting of halogen, cyano, C1-C6 alkyl, yl, C1-C6 alkoxy, and -N(R’)R’;
or R4 and R5 together with the nitrogen to which they are attached form:
heterocyclyl including from 4 to 6 ring atoms; wherein the heterocyclyl includes not
more than two ring heteroatoms ding the nitrogen atom attached to R4 and R5),
and the second ring heteroatom, when present, is independently selected from the
group consisting of N, NH, N(C1—C3 alkyl), 0, and S; and wherein the heterocyclyl
is optionally substituted with from 1-3 substituents independently selected from the
group consisting of n, cyano, oxo, C1—C6 alkyl, hydroxyl, C1-C6 alkoxy, and -
N(R’)R’; or
heteroaryl including from 5 to 6 ring atoms; wherein the heteroaryl includes not
more than four ring heteroatoms (including the nitrogen atom ed to R4 and
R5), and each additional ring atom, when present, is independently ed
from the group consisting ofN, NH, N(C1-C3 alkyl), 0, and S; and wherein the
heteroaryl is optionally substituted with from 1-3 substituents independently
WO 20783
ed from the group consisting of n, cyano, C1—C6 alkyl, hydroxyl, C1—C6
alkoxy, and -N(R’)R’;
R6 is selected from the group consisting of —OH, C1—C6 alkoxy, -OC(O)—C1—C6 alkyl, —
OC(O)phenyl, and -N(R’)R’; and
R7 is H or C1-C6 alkyl.
Also provided herein are pharmaceutically acceptable compositions comprising a
disclosed compound, and a pharmaceutically acceptable excipient. For example, such
itions may be suitable for oral or intravenous administration to a patient.
In another aspect, a method of treating a condition selected from the group
consisting of autism, anxiety, depression, bipolar disorder, attention deficit er, attention
deficit ctivity disorder (ADHD), schizophrenia, a psychotic disorder, a psychotic
symptom, social withdrawal, obsessive—compulsive disorder, phobia, post—traumatic stress
syndrome, a behavior er, an e control disorder, a substance abuse disorder, a sleep
er, a memory disorder, a learning disorder, urinary incontinence, multiple system
atrophy, progressive supra-nuclear palsy, Friedrich's ataxia, Down’s syndrome, fragile X
syndrome, tuberous sclerosis, olivio-ponto—cerebellar atrophy, cerebral palsy, drug—induced
optic neuritis, ischemic retinopathy, diabetic pathy, glaucoma, dementia, AIDS dementia,
Alzheimer’s disease, Huntington’s chorea, spasticity, myoclonus, muscle spasm, te's
syndrome, epilepsy, cerebral ischemia, stroke, a brain tumor, traumatic brain injury, cardiac
arrest, myelopathy, spinal cord injury, peripheral neuropathy, acute neuropathic pain, and
chronic neuropathic, in a patient in need f is provided. Such methods may comprise
administering to the patient a pharmaceutically effective amount of a sed compound or
pharmaceutically acceptable salts, stereoisomers, N—oxides, and hydrates thereof.
In some embodiments, a contemplated method includes treating depression. For
example, sion may include one or more of major depressive disorder, dysthymic
disorder, psychotic depression, postpartum depression, al affective disorder, bipolar
disorder, mood disorder, or depression caused by a chronic l condition. In other
ments, a contemplated method may treat schizophrenia. Such schizophrenia may be,
for example, paranoid type schizophrenia, disorganized type schizophrenia, catatonic type
schizophrenia, undifferentiated type schizophrenia, residual type schizophrenia, postschizophrenic
depression, or simple schizophrenia.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows the potentiation of [3H]MK-8Ol binding in the presence of
Compound X.
Figure 2 shows results of long term potentiation in ampal slices using
Compound X.
DETAILED DESCRIPTION
[0014] This disclosure is generally directed to compounds that are capable of modulating
NMDA, e.g., NMDA nists or partial agonists, and itions and/or s of using
the disclosed compounds.
Definitions
ing” includes any effect, e. g., lessening, reducing, modulating, or
ating, that results in the improvement of the condition, disease, disorder and the like.
The term “alkenyl” as used herein refers to an unsaturated straight or branched
hydrocarbon having at least one carbon-carbon double bond, such as a straight or branched
group of 2-6 or 3—4 carbon atoms, referred to herein for example as C2_C6 alkenyl, and C3_C4
alkenyl, respectively. Exemplary alkenyl groups include, but are not limited to, vinyl, allyl,
butenyl, pentenyl, etc.
The term “alkoxy” as used herein refers to a straight or branched alkyl group
attached to an oxygen (alkyl—O—). ary alkoxy groups include, but are not d to,
alkoxys of 1-6 or 2-6 carbon atoms, referred to herein as C1-C6 alkoxy, and C2-C6 alkoxy,
respectively. Exemplary alkoxy groups include, but are not limited to methoxy, ethoxy,
isopropoxy, etc.
The term “alkenyloxy” used herein refers to a straight or branched alkenyl group
attached to an oxygen (alkenyl-O). Exemplary alkenoxy groupd include, but are not d to,
groups with an alkenyl group of 3-6 carbon atoms, (also e. g. referred to as C3—C5 alkenyloxy).
Exemplary “alkenoxy” groups include, but are not d to allyloxy, butenyloxy, etc.
[0019] The term “alkynyloxy” used herein refers to a ht or branched alkynyl group
attached to an oxygen (alkynyl-0)). Exemplary alkynyloxy groups include, but are not limited
to, C3-C6 alkynyloxy, e. g., propynyloxy.
The term “alkyl” as used herein refers to a saturated straight or branched
hydrocarbon, such as a straight or ed group of 1—6, 1-4, or 1-3 carbon atoms, referred to
herein as C1-C6 alkyl, C1-C4 alkyl, and C1-C3 alkyl, respectively. Exemplary alkyl groups
e, but are not limited to, methyl, ethyl, propyl, isopropyl, 2-methyl-l-propyl, 2-methyl
propyl, yl-l-butyl, 3-methyl-l—butyl, 3—methyl-2—butyl, 2,2-dimethyl-l-propyl, 2-
methyl-l-pentyl, 3—methyl-l—pentyl, 4-methyl—l-pentyl, 2-methylpentyl, 3-methylpentyl,
yl-2—pentyl, 2,2-dimethyl-l-butyl, 3,3-dimethyl—l-butyl, 2-ethyl-l—butyl, butyl, isobutyl,
t-butyl, pentyl, isopentyl, neopentyl, hexyl, etc. The term “haloalkyl” as used herein refers to a
saturated ht or branched alkyl groups, in which one or more hydrogen atoms of the alkyl
group are replaced with one or more independently selected halogens. The term “haloalkyl”
asses alkyl groups in which all of hydrogen atoms of the alkyl group are replaced
independently selected halogens (sometimes referred to as “perhalo” alkyl groups. ary
haloalkyl groups e, but are not limited to, CHZF, CHZCHzCl, CF3, CHFCHzCl.
The term “alkynyl” as used herein refers to an unsaturated straight or branched
hydrocarbon having at least one carbon-carbon triple bond, such as a straight or branched group
of 2-6, or 3-6 carbon atoms, referred to herein as C2-C6 l, and C3_C6 alkynyl, respectively.
Exemplary alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl,
hexynyl, methylpropynyl, etc.
The term “bridged cycloalkyl”, as used herein, is defined as a monocyclic 4— to 7—
membered cycloalkyl group in which two non—adj acent atoms are linked by a CH2 or CHZCHZ
group. A ed cycloalkyl” may be fused to one or more phenyl, partially unsaturated, or
saturated rings. Examples of bridged carbocyclic groups include but are not limited to
bicyclo[2.2.l]heptane etc.
, bicyclo[2.2.2]octane, , bicyclo[2.2.2]octene
The term “carbonyl” as used herein refers to the radical -C(O)—. The term “cyano”
as used herein refers to the radical -CN. The term “nitro” refers to the l —N02. The term
“H” refers to hydrogen.
The term “cycloalkoxy” as used herein refers to a cycloalkyl group attached to an
oxygen (cycloalkyl—O).
The term “cycloalkyl” as used herein refers to a monocyclic saturated or partically
unsatured hydrocarbon group of for example 3-6, or 4—6 s, referred to herein, e. g., as "C3.
6 cycloalkyl" or “CM cycloalkyl," and derived from a lkane. Exemplary cycloalkyl
groups include, but are not limited to, cyclohexane, cyclohexene, cyclopentane, cyclobutane,
cyclopropane or cyclopentane.
The terms “halo” or “halogen” as used herein refer to F, Cl, Br, or I.
The terms “heteroaryl” as used herein refers to a monocyclic aromatic 4-6
membered ring system containing one or more heteroatoms, for example one to three
heteroatoms, such as nitrogen, oxygen, and sulfur. Where possible, said heteroaryl ring may be
linked to the adjacent radical though carbon or nitrogen. Examples of heteroaryl rings include
but are not limited to furan, thiophene, e, thiazole, oxazole, isothiazole, isoxazole,
imidazole, pyrazole, triazole, pyridine, and pyrimidine.
[0028] The terms “heterocyclyl” or “heterocyclic group” are cognized and refer to
saturated or partially unsaturated 4— to ered ring structures, whose ring ures
include one to three heteroatoms, such as en, oxygen, and sulfur. A heterocycle may be
fused to one or more phenyl, partially unsaturated, or saturated rings. Examples of heterocyclyl
groups include but are not limited to idine, piperidine, morpholine, thiomorpholine, and
piperazine.
The term “heterocyclylalkoxy” as used herein refers to a heterocyclyl— alkyl-O—
group.
The term “heterocyclyloxyalkyl” refers to a heterocyclyl-O—alkyl- group.
The term “heterocycloxy” refers to a heterocyclyl—O— group. The term
“cycloalkyloxy” refers to a lkyl-O— group.
The term oaryloxy” referes to a heteroaryl—O— group.
The terms “hydroxy” and “hydroxyl” as used herein refers to the radical -OH.
The term “oxo” as used herein refers to the radical =0.
The term “nitrogen ting group” or “amino protecting group” is art-
ized and as used herein refers to a chemical moiety that is covalently linked to a nitrogen
atom of an amino (primary or secondary) group and that temporarily blocks the reactivity of the
amino group during a synthetic step and is selectively removed once the synthetic step is
complete. Nitrogen protecting groups include, for e, 9-Fluorenylmethyloxycarbonyl
(Fmoc), tert—butoxycarbonyl (Boc), carbobenzyloxycarbonyl (Cbz), p—
methoxybenzyloxycarbonyl, acetyl, trifluoroacetyl, benzoyl, phthalimido, benzyl (Bn), p-
ybenzyl, p-methoxyphenyl, 3,4-dimethoxybenzyl, triphenylmethyl, benzylidene, and ptoluenesulfonyl
(Ts). In some embodiments, the nitrogen protecting group can have one of the
following formulas: —C(O)OR31 or —C(O)R32 as defined herein.
As used in the present disclosure, the term “partial NMDA receptor t”
generally refers to a compound that is capable of binding to a glycine binding site of an NMDA
receptor; at low trations a NMDA receptor agonist acts substantially as agonist and at
high concentrations it acts substantially as an antagonist. These concentrations are
experimentally determined for each and every “partial agonist.
“Pharmaceutically or pharmacologically acceptable” include molecular entities and
compositions that do not produce an adverse, ic or other untoward reaction when
administered to an animal, or a human, as appropriate. For human administration, preparations
should meet sterility, pyrogenicity, l safety and purity standards as required by FDA
Office of Biologics standards.
The term “pharmaceutically acceptable carrier” or “pharmaceutically acceptable
ent” as used herein refers to any and all solvents, dispersion media, coatings, isotonic and
absorption ng agents, and the like, that are compatible with pharmaceutical
stration. The use of such media and agents for pharmaceutically active substances is
well known in the art. The compositions may also contain other active compounds providing
mental, additional, or enhanced therapeutic functions.
[0039] The term “pharmaceutical composition” as used herein refers to a composition
comprising at least one compound as disclosed herein formulated together with one or more
ceutically acceptable carriers.
“Individual,” nt,” or “subject” are used interchangeably and include any
animal, including mammals, ably mice, rats, other rodents, rabbits, dogs, cats, swine,
, sheep, horses, or primates, and most preferably humans. The compounds of the
ion can be administered to a mammal, such as a human, but can also be administered to
other mammals such as an animal in need of veterinary treatment, e. g., domestic animals (e.g.,
dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like) and
laboratory animals (e.g., rats, mice, guinea pigs, and the like). The mammal treated in the
methods of the invention is desirably a mammal in which treatment e.g., of pain or depression
is desired. “Modulation” includes antagonism (e. g., inhibition), agonism, partial nism
and/or partial agonism.
-10_
In the present cation, the term “therapeutically effective amount” means the
amount of the subject compound that will elicit the biological or medical response of a ,
system, animal or human that is being sought by the cher, veterinarian, medical doctor or
other clinician. The compounds of the invention are administered in therapeutically effective
amounts to treat a disease. Alternatively, a therapeutically effective amount of a nd is
the quantity required to achieve a desired therapeutic and/or prophylactic effect, such as an
amount which results in lessening a symptom of depression.
The term "pharmaceutically acceptable salt(s)" as used herein refers to salts of
acidic or basic groups that may be t in nds used in the present compositions.
Compounds included in the present compositions that are basic in nature are capable of forming
a wide variety of salts with various inorganic and organic acids. The acids that may be used to
prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that
form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions,
including but not limited to malate, oxalate, chloride, bromide, iodide, nitrate, sulfate, bisulfate,
phosphate, acid ate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, oleate,
tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate,
glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate,
benzenesulfonate, p-toluenesulfonate and pamoate (i.e., ethylene-bis-(2—hydroxy
naphthoate)) salts. Compounds included in the present compositions that are acidic in nature
are capable of forming base salts with various cologically acceptable cations. Examples
of such salts include alkali metal or alkaline earth metal salts and, particularly, m,
magnesium, sodium, m, zinc, potassium, and iron salts. nds included in the
present compositions that include a basic or acidic moiety may also form pharmaceutically
acceptable salts with various amino acids. The compounds of the disclosure may contain both
acidic and basic groups; for example, one amino and one carboxylic acid group. In such a case,
the compound can exist as an acid addition salt, a zwitterion, or a base salt.
The compounds of the disclosure may contain one or more chiral centers and/or
double bonds and, therefore, exist as stereoisomers, such as geometric isomers, enantiomers or
diastereomers. The term “stereoisomers” when used herein consist of all geometric s,
omers or diastereomers. These compounds may be designated by the symbols “R” or
“S,” depending on the configuration of substituents around the stereogenic carbon atom. The
present invention encompasses s stereoisomers of these nds and mixtures thereof.
Stereoisomers include enantiomers and diastereomers. Mixtures of enantiomers or
-11_
reomers may be designated “(i)” in nomenclature, but the skilled artisan will recognize
that a structure may denote a chiral center implicitly.
The compounds of the disclosure may contain one or more chiral centers and/or
double bonds and, therefore, exist as geometric isomers, enantiomers or diastereomers. The
enantiomer and diastereomers may be designated by the s “(+),” “(—).” “R” or “S,”
depending on the configuration of tuents around the stereogenic carbon atom, but the
skilled artisan will recognize that a structure may denote a chiral center implicitly. Geometric
isomers, resulting from the arrangement of substituents around a carbon—carbon double bond or
arrangement of substituents around a cycloalkyl or heterocyclic ring, can also exist in the
compounds of the present invention. The symbol denotes a bond that may be a single,
double or triple bond as described herein. Substituents around a carbon-carbon double bond
are designated as being in the “Z” or “E” configuration wherein the terms “Z” and “E” are used
in accordance with IUPAC standards. Unless otherwise specified, structures depicting double
bonds encompass both the “E” and “Z” isomers. tuents around a carbon—carbon double
bond alternatively can be referred to as “cis” or “trans,” where “cis” represents substituents on
the same side of the double bond and “trans” represents substituents on te sides of the
double bond. The arrangement of tuents around a yclic ring can also be designated
as “cis” or “trans.” The term “cis” represents substituents on the same side of the plane of the
ring and the term “trans” represents substituents on opposite sides of the plane of the ring.
Mixtures of compounds wherein the tuents are disposed on both the same and opposite
sides of plane of the ring are designated rans.”
The term oisomers” when used herein consist of all geometric isomers,
enantiomers or diastereomers. The present invention encompasses various stereoisomers of
these compounds and mixtures thereof.
[0046] Individual enantiomers and diasteriomers of compounds of the present invention can
be prepared synthetically from commercially available starting materials that contain
asymmetric or stereogenic centers, or by preparation of racemic mixtures ed by
resolution methods well known to those of ordinary skill in the art. These methods of
resolution are exemplified by (l) attachment of a mixture of enantiomers to a chiral auxiliary,
separation of the resulting mixture of diastereomers by recrystallization or chromatography and
liberation of the optically pure product from the auxiliary, (2) salt formation employing an
optically active resolving agent, (3) direct separation of the mixture of optical enantiomers on
-12_
chiral liquid chromatographic columns or (4) kinetic resolution using steroselective chemical or
enzymatic reagents. Racemic mixtures can also be resolved into their component enantiomers
by well—known s, such as chiral-phase gas tography or crystallizing the
compound in a chiral solvent. Stereoselective syntheses, a chemical or enzymatic reaction in
which a single reactant forms an unequal mixture of stereoisomers during the creation of a new
stereocenter or during the transformation of a pre-existing one, are well known in the art.
Stereoselective syntheses encompass both enantio— and reoselective transformations. For
es, see Carreira and Kvaemo, Classics in Stereoselective Synthesis, Wiley—VCH:
Weinheim, 2009.
[0047] The compounds disclosed herein can exist in solvated as well as unsolvated forms
with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is
intended that the invention embrace both solvated and unsolvated forms. In one embodiment,
the nd is amorphous. In one ment, the compound is a single rph. In
another embodiment, the compound is a e of polymorphs. In another embodiment, the
compound is in a crystalline form.
The invention also embraces ically labeled compounds of the invention which
are identical to those recited herein, except that one or more atoms are replaced by an atom
having an atomic mass or mass number different from the atomic mass or mass number usually
found in nature. es of isotopes that can be orated into compounds of the
invention include isotopes of hydrogen, carbon, nitrogen, , phosphorus, fluorine and
chlorine, such as 2H, 3H, 13 C, 14C, ”N, 18O, 17O, 31F, 32F, 358, 18F, and 36Cl, respectively. For
example, a compound of the invention may have one or more H atom replaced with deuterium.
Certain isotopically—labeled disclosed compounds (e.g., those labeled with 3H and
14C) are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3H) and
carbon—l4 (i.e., 14C) isotopes are particularly preferred for their ease of preparation and
detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2H) may afford
certain therapeutic advantages resulting from greater lic stability (e.g., increased in viva
half—life or reduced dosage requirements) and hence may be preferred in some circumstances.
Isotopically labeled compounds of the invention can generally be prepared by following
ures analogous to those disclosed in the e.g., Examples herein by substituting an
ically labeled reagent for a non—isotopically labeled reagent.
-13_
The term ug” refers to compounds that are transformed in vivo to yield a
disclosed compound or a pharmaceutically acceptable salt, hydrate or solvate of the compound.
The transformation may occur by various mechanisms (such as by esterase, e,
phosphatase, oxidative and or reductive metabolism) in various locations (such as in the
intestinal lumen or upon t of the intestine, blood or liver). Prodrugs are well known in the
art (for example, see Rautio, Kumpulainen, et al, Nature Reviews Drug Discovery 2008, 7,
255). For example, if a compound of the invention or a pharmaceutically acceptable salt,
hydrate or solvate of the nd contains a carboxylic acid functional group, a prodrug can
comprise an ester formed by the replacement of the hydrogen atom of the acid group with a
group such as (C1—C8)alkyl, (C2-C12)alkanoyloxymethy1, l-(alkanoyloxy)ethyl having from 4 to
9 carbon atoms, l-methyl-l-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms,
alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, l-(alkoxycarbonyloxy)ethyl
having from 4 to 7 carbon atoms, l-methyl-l-(alkoxycarbonyloxy)ethyl having from 5 to 8
carbon atoms, N—(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms,
alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms, 3—phthalidyl,
4-crotonolactonyl, gamma-butyrolactonyl, di-N,N—(C1-C2)alkylamino(C2-C3)alkyl (such as
B-dimethylaminoethyl), carbamoyl-(Cl—C2)alkyl, N,N-di(C1-C2)alkylcarbamoyl-(C1-C2)alkyl
and piperidino-, pyrrolidino— or morpholino(C2-C3)alkyl.
Similarly, if a nd of the invention contains an l functional group, a
prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a
group such as (C1—C6)a1kanoyloxymethyl, 1—((C1-C6)a]kanoyloxy)ethyl,
l-methyl- l—((C1-C6)alkanoyloxy)ethyl (C1-C6)alkoxycarbonyloxymethyl,
N—(C1—C6)alkoxycarbonylaminomethyl, succinoyl, (C1—C6)alkanoyl, d—amino(C1—C4)alkanoyl,
arylacyl and (x-aminoacyl, or (x-aminoacyl-(x-aminoacyl, where each oc-aminoacyl group is
independently selected from the naturally occurring L—amino acids, P(O)(OH)2,
-P(O)(O(C1-C6)alkyl)2 or glycosyl (the radical resulting from the removal of a yl group
of the hemiacetal form of a ydrate).
If a compound of the invention incorporates an amine functional group, a prodrug
can be formed, for example, by creation of an amide or carbamate, an N—acyloxyakyl
derivative, an (oxodioxolenyl)methyl tive, an N-Mannich base, imine or enamine. In
addition, a ary amine can be lically cleaved to generate a bioactive primary
amine, or a tertiary amine can metabolically d to generate a bioactive primary or
2014/013619
-14_
secondary amine. For examples, see Simplicio, et al., Molecules 2008, I3, 519 and references
therein.
Compounds
Disclosed compounds include those represented by the a:
and pharmaceutically acceptable salts, stereoisomers, and N—oxides f, wherein
Rb is selected from the group consisting of H, halogen, hydroxyl, cyano and C1-C6
alkyl;
R1 is H or C1—C6 alkyl;
R2 is H or C1-C6 alkyl;
R3 is selected from the group consisting of H, C1-C6 alkyl and a nitrogen protecting
group;
R4 and R5 are independently H or C1-C6 alkyl, or R4 and R5 taken together with the
nitrogen to which they are attached form a 4-, 5— or 6-membered heterocyclic or heteroaryl ring
optionally substituted with one or more substituents selected from the group consisting of
halogen, cyano, oxo, C1-C6 alkyl, -OH, C1-C6 alkoxy, and -N(R’)R’, wherein R’ is
independently selected for each ence from H or C1—C6 alkyl;
R6 is selected from the group ting of -OH, C1-C6 alkoxy, -C1-C6 alkyl, and
—OC(O)phenyl; and
R7 is H or C1-C6 alkyl;
or in other embodiments, the variables set forth in formula (I) are defined as follows:
Rb is selected from the group consisting of H, halogen, hydroxyl, cyano and C1-C6 alkyl
(6%., H);
R1 is H or C1—C6 alkyl;
R2 is H or C1-C6 alkyl;
-15_
R3 is selected from the group consisting of H, C1-C6 alkyl and a en protecting
group;
R4 and R5 are each independently selected from the group consisting of H, C1-C6 alkyl,
X, and —C1—C6 alkylene—X, wherein X is selected from the group consisting of:
(i) C3—C6 cycloalkyl;
(ii) heteroaryl including from 5 to 6 ring atoms wherein l, 2, or 3 of the ring atoms
are independently selected from the group consisting ofN, NH, N(C1—C3 alkyl), 0,
and S;
(iii) heterocyclyl including from 3 to 6 ring atoms wherein l, 2, or 3 of the ring
atoms are ndently selected from the group consisting of N, NH, N(Cl-C3
alkyl), 0, and S; and
(iv) phenyl;
wherein C3-C6 cycloalkyl and heterocyclyl are each optionally substituted with from 1-3
substituents independently selected from the group consisting of halogen, cyano, oxo,
C1-C6 alkyl, hydroxyl, C1-C6 alkoxy, and R’, n R’ is independently
selected for each occurrence from H and C1—C6 alkyl; and heteroaryl and phenyl are
each optionally substituted with from 1—3 substituents independently selected from the
group consisting of halogen, cyano, C1-C6 alkyl, hydroxyl, C1-C6 alkoxy, and -N(R’)R’;
or R4 and R5 together with the nitrogen to which they are attached form:
heterocyclyl including from 4 to 6 ring atoms; wherein the heterocyclyl includes not
more than two ring heteroatoms (including the nitrogen atom attached to R4 and R5),
and the second ring heteroatom, when t, is ndently selected from the
group consisting of N, NH, N(C1—C3 alkyl), 0, and S; and wherein the heterocyclyl
is ally tuted with from 1-3 substituents independently selected from the
group consisting of halogen, cyano, oxo, C1—C6 alkyl, hydroxyl, C1-C6 alkoxy, and -
N(R’)R’; or
heteroaryl including from 5 to 6 ring atoms; wherein the heteroaryl includes not
more than four ring heteroatoms (including the nitrogen atom ed to R4 and
R5), and each additional ring heteroatom, when present, is independently selected
from the group consisting ofN, NH, N(C1-C3 , 0, and S; and wherein the
heteroaryl is optionally substituted with from 1-3 substituents independently
-l6—
selected from the group consisting of n, cyano, C1—C6 alkyl, hydroxyl, C1—C6
alkoxy, and -N(R’)R’;
R6 is selected from the group consisting of —OH, C1—C6 alkoxy, —C1—C6 alkyl, —
OC(O)phenyl, and -N(R’)R’; and
R7 is H or C1-C6 alkyl.
In some embodiments is H. In other embodiments, R1 is C1—C6 alkyl, e. g., CH3.
, R1
In some embodiments, R2 is H. In other embodiments, R2 is C1—C6 alkyl, e. g., CH3.
In some embodiments, R3 is H.
In some embodiments, R3 is a nitrogen protecting group. In some embodiments, R3
has formula —C(O)OR31, wherein R31 is selected from the group consisting of: C1—C6 alkyl; C1—
C6 haloalkyl, C2-C6 alkenyl; C2-C6 l; C3-C10 cycloalkyl, wherein the C3-C10 cycloalkyl is
optionally tuted with from 1—3 ndently selected C1—C3 alkyl; —CH2—C3—C10
cycloalkyl wherein the C3-C10 cycloalkyl is ally substituted with from 1-3 independently
selected C1—C3 alkyl; —CH2—phenyl, wherein the phenyl is optionally substituted with from 1-2
substituents independently selected from C1—C3 alkyl, C1-C3 haloalkyl, C1-C3 , C1—C3
haloalkoxy, nitro, halo, SO2Me, cyano, and -OC(O)CH3; and -CH2-pyridyl. In certain
embodiments, R31 is C1—C6 alkyl (e. g., tert—butyl). In other embodiments, R3 has formula —
C(O)R32, wherein R32 is selected from the group ting of: H; C1—C6 alkyl; C1—C6
haloalkyl; phenyl, wherein the phenyl is optionally substituted with from 1-2 tuents
independently selected from C1-C3 alkyl; C1-C3 haloalkyl, C1-C3 alkoxy; C1-C3 haloalkoxy;
nitro; halo; SO2Me, cyano; and -OC(O)CH3; and pyridyl. In certain embodiments, R32 is C1—C6
alkyl (e.g., —CH3 or iso—propyl).
In some embodiments, R4 and R5 are each independently selected from the group
consisting of H, C1-C6 alkyl, X, and —C1—C5 alkylene-X. In certain embodiments, R4 and R5 are
each ndently selected from the group consisting of H and C1—C6 alkyl. In other
embodiments, R4 and R5 are each independently selected from the group consisting of H and —
C1-C6 alkylene-X. In certain embodiments, R4 and R5 are H. In other embodiments, one of R4
and R5 is H, and the other is —C1-C6 alkylene-X. In certain of these embodiments, the
compounds can e one or both (e. g., both) of the following features: (i) —C1-C6 alkylene—
X is ; and (ii) X is phenyl or heteroaryl including from 5 to 6 ring atoms wherein 1, 2,
or 3 of the ring atoms are independently selected from the group consisting of N, NH, N(Cl—C3
alkyl), 0, and S; each optionally substituted with from 1—3 substituents independently selected
-17_
from the group consisting of halogen, cyano, C1-C6 alkyl, hydroxyl, C1-C6 alkoxy, and -
In other embodiments, R4 and R5 taken together form a heterocyclic or heteroaryl
ring as defined previously and anywhere herein. In certain embodiments, R4 and R5 taken
together form a heterocyclic ring, e.g., a ring selected from the group consisting of azetidinyl,
pyrrolidinyl, lidinyl, isooxazolidinyl, imidazolidinyl, oxazolidinyl, thiazolidinyl, and
isothiazolidinyl. In a particular embodiment, R4 and R5 taken together form a pyrrolidinyl ring.
In certain ments, R4 and R5 taken together form a heteroaryl ring, e.g., a ring selected
from the group consisting of imidazolyl, pyrazolyl, yl, isoxazolyl, thiazolyl, pyridinyl,
diazinyl, oxazinyl, and thiazinyl.
In some embodiments, R1 is H; R2 is H; R3 is H; and R4 and R5 taken together form
a pyrrolidine ring. In some embodiments, R1 is H; R2 is H; R3 is H; and R4 and R5 are H. In
some embodiments, R1 is H or CH3; R2 is H or CH3; R3 is H; and R4 and R5 taken together form
a pyrrolidinyl ring. In some embodiments, R1 is H or CH3; R2 is H or CH3; R3 is H; and R4 and
R5 are H. In some embodiments, R1 is H or CH3; R2 is H or CH3; R3 is H; and one ofR4 and R5
is H, and the other is , wherein X is phenyl or heteroaryl ing from 5 to 6 ring
atoms wherein 1, 2, or 3 of the ring atoms are independently selected from the group consisting
ofN, NH, N(Cl—C3 alkyl), 0, and S; each optionally substituted with from 1-3 substituents
independently selected from the group consisting of halogen, cyano, C1-C6 alkyl, hydroxyl, C1-
C6 alkoxy, and -N(R’)R’. In some embodiments, R1 is H or CH3; R2 is H or CH3; R3 is
en protecting group (e. g., —C(O)OR31 or —C(O)R32); and R4 and R5 taken together form a
pyrrolidinyl ring. In some embodiments, R1 is H or CH3; R2 is H or CH3; R3 is nitrogen
ting group (e.g., R31 or —C(O)R32); and R4 and R5 are H. In some ments,
R1 is H or CH3; R2 is H or CH3; R3 is nitrogen protecting group (e.g., —C(O)OR31 or —C(O)R32);
and one of R4 and R5 is H, and the other is —CH2—X, wherein X is phenyl or heteroaryl
including from 5 to 6 ring atoms wherein l, 2, or 3 of the ring atoms are independently selected
from the group consisting ofN, NH, N(Cl-C3 , 0, and S; each optionally substituted with
from 1—3 substituents independently ed from the group consisting of halogen, cyano, C1-
C6 alkyl, hydroxyl, C1-C5 , and -N(R’)R’.
[0061] In some embodiments (including any of the foregoing embodiments described
above), R6 is selected from the group consisting of -OH, C1-C6 alkoxy, -OC(O)—C1-C6 alkyl,
and -OC(O)phenyl. In certain embodiments (including any of the foregoing embodiments
described above), R6 is —OH. In other embodiments (including any of the foregoing
.18_
embodiments described above), R6 is —NH2. In some embodiments (including any of the
foregoing embodiments described above), R7 is C1—C6 alkyl, e.g., CH3. In some embodiments
(including any of the ing embodiments described , R6 is —OH or —NH2, and R7 is
C1-C6 alkyl, e. g., CH3. In some embodiments (including any of the foregoing embodiments
described above), Rb is H.
In some embodiments, the compound is ed from the compounds delineated in
Table 1 and/or the Examples. In certain embodiments, a disclosed compound includes one
having the formula:
0 O
wt... QM... 9N9H NH2 NH2 0
o 0 0 OH
7 .
[0063] The compounds of the t sure and formulations thereof may have a
plurality of chiral centers. Each chiral center may be ndently R, S, or any mixture of R
and S. For example, in some embodiments, a chiral center may have an R:S ratio of n
about 100:0 and about 50:50, between about 100:0 and about 75:25, n about 100:0 and
about 85: 15, between about 100:0 and about 90:10, between about 100:0 and about 95:5,
between about 100:0 and about 98:2, between about 100:0 and about 99:1, between about 0: 100
and 50:50, between about 0: 100 and about 25:75, between about 0: 100 and about 15:85,
between about 0: 100 and about 10:90, between about 0:100 and about 5:95, n about
0: 100 and about 2:98, between about 0: 100 and about 1299, between about 75:25 and 25:75,
and about 50:50. Formulations of the disclosed compounds sing a greater ratio of one or
more isomers (i.e., R and/or S) may possess enhanced therapeutic characteristic relative to
racemic formulations of a disclosed nds or mixture of compounds. In some instances,
chemical formulas contain the descriptor “-(R)-“ or “-(S)-“ that is further attached to solid
wedge or dashed wedge. This descriptor is intended to show a methine carbon (CH) that is
attached to three other substituents and has either the indicated R or S configuration (see, e. g.,
Table 1).
Disclosed compounds may provide for efficient cation channel opening at the
NMDA receptor, e.g. may bind or associate with the glutamate site of the NMDA receptor to
assist in opening the cation channel. The disclosed compounds may be used to regulate (turn on
or turn off) the NMDA receptor through action as an agonist.
-19_
The compounds as described herein may be glycine site NMDA receptor partial
agonists. A partial t as used in this context will be understood to mean that at a low
concentration, the analog acts as an t and at a high concentration, the analog acts as an
antagonist. Glycine binding is not inhibited by glutamate or by competitive inhibitors of
glutamate, and also does not bind at the same site as glutamate on the NMDA receptor. A
second and separate binding site for glycine exists at the NMDA receptor. The ligand-gated
ion channel of the NMDA or is, thus, under the control of at least these two distinct
allosteric sites. Disclosed nds may be e of binding or associating with the
glycine g site of the NMDA receptor. In some ments, disclosed compounds may
s a potency that is 10—fold or greater than the activity of existing NMDA receptor glycine
site partial agonists.
The disclosed compounds may exhibit a high therapeutic index. The therapeutic
index, as used herein, refers to the ratio of the dose that produces a toxicity in 50% of the
population (i.e., TD50) to the minimum effective dose for 50% of the population (i.e., EDso).
Thus, the therapeutic index = (TDSO):(ED50). In some embodiments, a disclosed compound
may have a therapeutic index of at least about 10:1, at least about 50:1, at least about 100: 1, at
least about 200:1, at least about 500:1, or at least about 100021.
Compositions
In other aspects, ations and compositions comprising the disclosed
compounds and optionally a pharmaceutically acceptable excipient are provided. In some
embodiments, a contemplated formulation comprises a racemic mixture of one or more of the
disclosed compounds.
Contemplated formulations may be prepared in any of a variety of forms for use.
By way of example, and not limitation, the compounds may be prepared in a formulation
suitable for oral administration, subcutaneous injection, or other methods for administering an
active agent to an animal known in the pharmaceutical arts.
Amounts of a disclosed compound as described herein in a formulation may vary
according to s such as the e state, age, sex, and weight of the individual. Dosage
regimens may be adjusted to provide the m therapeutic response. For example, a single
bolus may be administered, several divided doses may be administered over time or the dose
may be tionally reduced or increased as ted by the exigencies of the therapeutic
situation. It is especially advantageous to formulate parenteral compositions in dosage unit
form for ease of administration and uniformity of dosage. Dosage unit form as used herein
-20_
refers to physically discrete units suited as unitary dosages for the mammalian subjects to be
treated; each unit containing a predetermined quantity of active compound calculated to
produce the d therapeutic effect in association with the required ceutical r.
The specification for the dosage unit forms of the invention are dictated by and
directly dependent on (a) the unique characteristics of the compound selected and the particular
therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding
such an active nd for the treatment of sensitivity in individuals.
Therapeutic compositions typically must be sterile and stable under the conditions
of manufacture and storage. The composition can be formulated as a on, microemulsion,
liposome, or other d structure suitable to high drug tration. The carrier can be a
solvent or dispersion medium containing, for example, water, ethanol, polyol (for example,
glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures
f The proper fluidity can be maintained, for example, by the use of a coating such as
lecithin, by the nance of the required particle size in the case of dispersion and by the use
of surfactants. In many cases, it will be preferable to include isotonic agents, for example,
sugars, cohols such as ol, sorbitol, or sodium chloride in the composition.
Prolonged absorption of the able compositions can be brought about by including in the
composition an agent which delays absorption, for example, monostearate salts and gelatin.
The compounds can be administered in a time release formulation, for example in a
composition which includes a slow e polymer. The compounds can be prepared with
carriers that will protect the compound against rapid release, such as a controlled release
ation, including implants and microencapsulated delivery systems. Biodegradable,
biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides,
polyglycolic acid, collagen, polyorthoesters, polylactic acid and polylactic, polyglycolic
copolymers (PLG). Many s for the preparation of such formulations are generally
known to those skilled in the art.
Sterile injectable solutions can be prepared by incorporating the compound in the
required amount in an appropriate solvent with one or a combination of ingredients enumerated
above, as required, ed by filtered sterilization. Generally, dispersions are prepared by
incorporating the active compound into a sterile vehicle which contains a basic dispersion
medium and the required other ingredients from those enumerated above. In the case of sterile
powders for the preparation of e inj ectable solutions, the preferred methods of preparation
-21_
are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any
additional d ingredient from a previously sterile—filtered on thereof.
In accordance with an alternative aspect of the invention, a compound may be
formulated with one or more onal compounds that enhance the solubility of the
compound.
Methods
Methods for treating a condition in a patient in need thereof by administering a
therapeutically effective dose of a compound described herein are provided. In some
ments, the condition may be a mental condition. For e, a mental illness may be
treated. In r aspect, a nervous system condition may be treated. For example, a
condition that affects the central nervous system, the peripheral nervous system, and/or the eye
may be treated. In some embodiments, neurodegenerative diseases may be treated.
In some embodiments, the methods include administering a compound to treat
patients suffering from autism, anxiety, depression, r disorder, attention deficit disorder,
attention deficit hyperactivity disorder (ADHD), schizophrenia, a psychotic er, a
psychotic symptom, social withdrawal, obsessive—compulsive disorder (OCD), phobia, post—
traumatic stress syndrome, a behavior er, an impulse control disorder, a substance abuse
er (e. g., a withdrawal symptom, opiate addiction, nicotine addiction, and ethanol
addition), a sleep disorder, a memory disorder (e. g., a deficit, loss, or d y to make
new memories), a learning disorder, urinary incontinence, multiple system atrophy, ssive
supra—nuclear palsy, Friedrich's ataxia, Down’s syndrome, fragile X syndrome, tuberous
sclerosis, olivio—ponto—cerebellar atrophy, cerebral palsy, drug-induced optic neuritis, ischemic
retinopathy, diabetic retinopathy, glaucoma, dementia, AIDS dementia, Alzheimer’s disease,
Huntington’s chorea, spasticity, myoclonus, muscle spasm, Tourette's syndrome, epilepsy,
cerebral ischemia, stroke, a brain tumor, traumatic brain injury, cardiac arrest, myelopathy,
spinal cord injury, peripheral neuropathy, acute neuropathic pain, and chronic neuropathic pain.
In some embodiments, methods of treating a memory er associated with
aging, phrenia, special learning disorders, seizures, post—stroke convulsions, brain
ischemia, ycemia, cardiac arrest, sy, migraine, AIDS dementia, Huntington’s
chorea, Parkinson’s disease, early stage Alzheimer’s disease, and mer’s disease are
contemplated.
In certain embodiments, methods for treating schizophrenia are provided. For
example, paranoid type schizophrenia, disorganized type schizophrenia (i.e., hebephrenic
-22_
schizophrenia), catatonic type phrenia, undifferentiated type schizophrenia, residual type
schizophrenia, post—schizophrenic depression, and simple schizophrenia may be treated using
the methods and compositions contemplated herein. Psychotic disorders such as
schizoaffective disorders, delusional disorders, brief psychotic disorders, shared psychotic
disorders, and psychotic disorders with delusions or hallucinations may also be treated using
the compositions plated herein.
Paranoid schizophrenia may be characterized where delusions or auditory
hallucinations are present, but t disorder, disorganized or, or affective flattening
are not. Delusions may be utory and/or grandiose, but in addition to these, other themes
such as jealousy, religiosity, or somatization may also be present. Disorganized type
schizophrenia may be characterized where thought disorder and flat affect are present together.
Catatonic type schizophrenia may be terized where the patient may be almost immobile
or exhibit agitated, purposeless movement. Symptoms can include catatonic stupor and waxy
flexibility. Undifferentiated type schizophrenia may be characterized where psychotic
symptoms are present but the criteria for paranoid, disorganized, or catatonic types have not
been met. Residual type schizophrenia may be characterized where positive symptoms are
present at a low ity only. Post-schizophrenic depression may be terized where a
depressive episode arises in the aftermath of a schizophrenic illness where some low—level
schizophrenic ms may still be present. Simple schizophrenia may be characterized by
insidious and progressive development of prominent negative symptoms with no history of
psychotic episodes.
In some embodiments, methods are provided for treating psychotic symptoms that
may be present in other mental disorders, including, but not limited to, bipolar disorder,
borderline personality disorder, drug cation, and drug-induced sis. In another
embodiment, methods for treating delusions (e.g., izarre") that may be present in, for
example, delusional disorder are provided.
Also provided are s for treating social withdrawal in conditions including,
but not limited to, social anxiety disorder, avoidant personality disorder, and schizotypal
personality disorder.
[0082] In some embodiments, methods are provided for treating athic pain. The
neuropathic pain may be acute or chronic. In some cases, the neuropathic pain may be
associated with a condition such as herpes, HIV, traumatic nerve , stroke, post-ischemia,
algia, reflex sympathetic dystrophy, complex regional pain syndrome, spinal cord
-23_
injury, ca, phantom limb pain, diabetic neuropathy, and cancer chemotherapeutic—induced
neuropathic pain. Methods for enhancing pain relief and for providing analgesia to a patient
are also plated.
Further contemplated methods include a method of treating autism and/or an autism
spectrum disorder in a patient need thereof, comprising administering an effective amount of a
compound to the t. In an embodiment, a method for reducing the symptoms of autism in
a t in need thereof is contemplated, comprising administering an effective amount of a
disclosed compound to the patient. For example, upon administration, the compound may
decrease the incidence of one or more symptoms of autism such as eye contact nce,
failure to socialize, ion deficit, poor mood, hyperactivity, abnormal sound sensitivity,
inappropriate speech, disrupted sleep, and perseveration. Such decreased incidence may be
measured relative to the incidence in the untreated individual or an untreated individual(s).
Also provided herein is a method of modulating an autism target gene expression in
a cell comprising contacting a cell with an effective amount of a compound described herein.
The autism gene expression may be for example, selected from ABAT, APOE, CHRNA4,
GABRA5,GFAP, GRINZA, PDYN, and PENK. In another embodiment, a method of
modulating synaptic plasticity in a patient suffering from a synaptic plasticity related disorder
is ed, comprising administering to the patient an effective amount of a compound.
In another embodiment, a method of treating mer’s disease, or e.g., treatment
of memory loss that e. g., accompanies early stage Alzheimer’s disease, in a patient in need
thereof is provided, comprising administering a compound. Also provided herein is a method
of modulating an Alzheimer’s amyloid n (e. g., beta amyloid peptide, e. g. the isoform
A0142), in-vitro or in—vivo (e.g. in a cell) comprising contacting the protein with an effective
amount of a compound is disclosed. For example, in some embodiments, a nd may
block the y of such amyloid n to inhibit long-term potentiation in hippocampal slices
as well as tic neuronal cell death. In some embodiments, a disclosed compound may
provide neuroprotective properties to a mer’s patient in need f, for example, may
provide a therapeutic effect on later stage Alzheimer’s —associated neuronal cell death.
In a further embodiment, a method of treating depression sing administering
a compound described herein is provided. In some embodiments, the treatment may relieve
depression or a m of depression without ing behavior or motor coordination and
without inducing or promoting seizure activity. Exemplary depression conditions that are
expected to be treated according to this aspect of the invention include, but are not limited to,
-24_
major depressive er, dysthymic disorder, psychotic depression, postpartum depression,
premenstrual syndrome, premenstrual ric disorder, seasonal affective disorder (SAD),
bipolar er (or manic depressive disorder), mood disorder, and depressions caused by
chronic medical conditions such as cancer or c pain, chemotherapy, chronic stress, and
post traumatic stress disorders. In addition, patients suffering from any form of sion
often experience anxiety. Various symptoms associated with anxiety include fear, panic, heart
ations, shortness of , fatigue, nausea, and headaches among . Anxiety or any
of the ms f may be treated by administering a compound as described herein.
Also provided herein are methods of treating a condition in treatment-resistant
patients, e. g., patients suffering from a mental or central nervous system condition that does
not, and/or has not, responded to adequate courses of at least one, or at least two, other
compounds or therapeutics. For e, ed herein is a method of ng depression in
a treatment resistant patient, comprising a) optionally fying the patient as treatment
resistant and b) administering an effective dose of a compound to said patient.
[0088] In some embodiments, a compound described herein may be used for acute care of a
patient. For example, a compound may be administered to a patient to treat a particular episode
(e.g., a severe episode) of a condition contemplated herein.
Also contemplated herein are combination therapies sing a compound in
combination with one or more other active agents. For example, a compound may be
combined with one or more antidepressants, such as tricyclic antidepressants, s, SSRI's,
and double and triple uptake inhibitors and/or anxiolytic drugs. Exemplary drugs that may be
used in combination with a compound include Anafranil, Adapin, Aventyl, Elavil, Norpramin,
Pamelor, Pertofrane, Sinequan, Surmontil, Tofranil, Vivactil, Parnate, Nardil, Marplan, Celexa,
Lexapro, Luvox, Paxil, Prozac, Zoloft, Wellbutrin, Effexor, Remeron, Cymbalta, Desyrel
(trazodone), and Ludiomill. In another example, a compound may be combined with an
antipsychotic tion. Non-limiting examples of antipsychotics include butyrophenones,
phenothiazines, thioxanthenes, clozapine, olanzapine, risperidone, quetiapine, ziprasidone,
amisulpride, asenapine, paliperidone, iloperidone, zotepine, sertindole, lurasidone, and
aripiprazole. It should be understood that combinations of a compound and one or more of the
above therapeutics may be used for treatment of any suitable condition and are not limited to
use as antidepressants or antipsychotics.
2014/013619
-25_
EXAMPLES
The following examples are provided for illustrative purposes only, and are not
intended to limit the scope of the disclosure.
Table 1 below shows some exemplary compounds of the disclosure and es
physiochemical characteristics of the compounds.
Table 1.
Compound Structure Molecular
Weight
(Da)
Compound X 227
Compound Y
Compound Z
28—19 423.5032 0.634639
“I V
—20 381.4665 0.193514
-26—
2S—21 341.4027 —0.243061 113.17
2S—24 395.4931 0.610089 90.39
2S-27 395.4931 89 90.39
2S-30 409.5197 1.02666 90.39
2S-8 383.4824 0.808343 99.18
-27_
2S—9 395.4931 0.789186 99.18
2S—FNL-10 ‘5: 417.4986 1.28851 99.18
2S-FNL—11 317.3828 0.005320 81.67
ix 9
28-FNL—12 359.4195 —0.384737 89.95
2S—FNL—13 27 0.858785 89.95
-2g_
2S—FNL—14 409.4369 294 13 8.1
2S—FNL—15 409.4369 —1.65688 138.1
2S-FNL—16 423.3444 —2.94007 120.59
2S-FNL—17 361.3956 —1.88186 115.73
ZS-FNL— 1 8 419.4748 —0.35934 124.96
ZS—FNL-19 4333823 9 107.45
ZS—FNL-Z 327.3761 —0.659636 113.17
28-FNL-20 389.4488 -0.696233 1 15.73
28—FNL_21 213.2337 —2.3594 95.66
28—FNL_22, 313.3495 107621 113.17
28—16
-30_
2S—FNL-23 405.4482 —0.769835 124.96
2S—FNL—24 305.3324 —2.01339 107.45
2S-Fqur25 22 -1 10673 115.73
2S-FNL—26 281.3507 —1.08968 72.88
28-FNL—27 359.848 —0.648554 78.95
_ 31 _
28—FNL—28 241.2869 -1.52625 95.66
If A
3 A“
U :<\ 1 3%
H7}: maxi: \f‘f 111”"!
28—FNL-29 433.5013 0.051154 124.96
28-FNL-3 227.2603 -1.94283 95.66
2S-FNL—30 55 107.45
ZS-FNL-31 403.4754 —0.285738 115.73
2S—FNL—32 295.3773 —0.673 104 72.88
‘1{5*wa.2
2: W‘“ :32»:
f.- 3'
p IE
<\ 5:
x» A m ~"$\V $va»
2,...
3" 7 ] "2
szwfi} xg‘g NN
x $55
LENS: \-
2S—FNL—33 341.4027 —0.243061 113.17
2S-FNL-34 69 -1.52625 95.66
2S-FNL—35 295.3773 —0.673 104 72.88
2S-FNL—36 355.4293 0.173514 113.17
: ‘ <.
_ 33 _
2S—FNL—37 255.3134 —1. 10968 95.66
2S—FNL—38 309.4039 —0.256529 72.88
2S-FNL-4 297.3501 -1.08936 103.94
2S-FNL—5 426.4689 —0. 121843 134.65
—6 326.3913 —0.766518 118.96
-34_
ZS—FNL—7 262.736 71 101.45
firm“
{.3 Lr.r.rm\§fl-LW (fixqu
b x a:< \ng‘o 1'36 ‘”
M :3
ZS—FNL—8 397.3899 —0.47485 81.67
ZS—FNL-9 409.4006 —0.494007 81.67
Example 1 — Synthesis of Compound X
Scheme 1.
-35_
O OBn
O O
St -3 St —4
N OCH LiHMDS
ii EtOH N 00H3 (oclzB o 3 ‘ aq.NaOH \
OH O
BOM-Cl
Step 5 OH Step 8 Step 7 Step 8
—> N“...
Pd/Ct H2 Int D,EDC| BocO DTAD PPh3 ..OBn PdC OH
\ 0
I"OBn Bot:O lice:
Step9 Step 10
Nun-- NIIII
EDCI NH4CI -IIOH
limo .‘I'FAO
Compound X
—>HO)—A?:IOH StepB StepD
Br K2003 BnBr MeOH.HCI
NHBoc Bra—iffim StepCNHBoc £918anNHBoc —>Bno>_?~o,3nNH2_HC|Int-D
S nthesis of 2S 3R tert-butox carbon 1 amino h drox butanoic acid A
To a stirred solution of L—threonine (SMl) (100 g, 0.84 mol) in 1,4—dioxane (500
mL) and water (800 mL) was added Na2C03 (178 g, 1.67 mol) and stirred at RT for 30 min.
The reaction mixture was cooled to 0°C, Boc—anhydride (219.6 g, 1.007 mol) was added drop
wise and stirring was continued for 16 h. After consumption of the starting material (by TLC),
the reaction mixture was concentrated under reduced pressure and ed residue was
neutralized using 1N HCl (pH~4). The s layer was extracted with EtOAc (2 x 250 mL).
The separated organic extracts were washed with brine, dried over anhydrous NaZSO4, filtered
and concentrated under reduced pressure to afford A (160 g, 87%).
1H-NMR: (500 MHz, DMSO-d6): 8 6.30 (d, 1H), 4.07—4.01 (m, 1H), 3.90 (d, 1H), 1.99 (s, 1H),
1.42 (s, 9H), 1.09 (d, 3H).
LCMS (m/z): 218.1 [Ml—1]
S nthesis of 2S 3R benz 10X tert-butox carbon 1 amino butanoic acid B
To a stirred solution of A (100 g, 0.45 mol) in DMF (600 mL) was added 60% NaH
(36.5 g, 0.91 mol) portion wise at —20°C under N2 here and stirred for 2 h. To this was
-36—
added benzyl bromide (66.8 mL, 0.55 mol) drop wise and the reaction mixture was stirred at
RT for 12 h. After consumption of the starting material (by TLC), the reaction mixture was
quenched with ice cold water and washed with diethyl ether (2 x 250 mL). The separated
aqueous layer was acidified using 1N HCl and extracted with EtOAc (2 x 250 mL). The
combined c layers were dried over anhydrous NaZSO4 and concentrated under reduced
pressure to afford B (100 g, 71%).
Synthesis of 12S: 3R2-benzyl 3-gbenzyloxy2g gtert—butoxycarbonylz amino! butanoate 1C1
To a stirred solution of B (100 g, 0.32 mol) in DMF (400 mL) was added K2CO3
(111.6 g, 0.81 mol) under N2 atmosphere and stirred for 30 min. To this was added benzyl
bromide (47.4 mL, 0.38 mol) drop wise and stirred at RT for 12 h. The on mixture was
quenched with ice cold water and extracted with diethyl ether (2 x 250 mL). The separated the
organic layer was washed with brine, dried over anhydrous NaZSO4 and concentrated under
reduced pressure. The crude al was purified by silica gel column chromatography
eluting with 5% EtOAc/n—hexane to afford C (80 g, 62%).
1H-NMR: (400 MHz, DMSO'dfi): 5 7.41-7.25 (m, 10H), 5.09 (s, 2H), 4.55-4.50 (m, 1H), 4.34-
4.30 (m, 1H), 2.09 (s, 3H), 1.42 (s, 9H), 1.15 (d, 3H).
S s of 2S 3R -ben lZ-amino ben 10x butanoate Int-D
To a d solution of C (80 g, 0.20 mol) in methanol (100 mL) was added
methanolic HCl (70 mL) under N2 atmosphere and stirred for 12 h. After consumption of the
starting material (by TLC), the reaction mixture was concentrated under d pressure. The
crude material was washed with n—hexane and dried under reduced pressure to afford Int-D (45
g, 75%) as HCl salt.
1H-NMR: (400 MHz, DMSO-d6): 5 7.35-7.30 (m, 10H), 5.25 (q, 2H), 4.58-4.52 (m, 3H), 4.37
(d, 1H), 4.27 (br s, 1H), .10 (m, 1H), 1.30 (d, 3H).
LCMS (m/z): 300.2 [M++1]
S nthesis of S -meth l rrolidine-Z-carbox late 2
To a d solution of ine 1 (100 g, 0.87 mol) in methanol (800 mL) was
added thionyl chloride (76.9 mL, 1.04 mol) slowly drop wise at 0°C. The reaction mixture was
heated to reflux for 12 h. After consumption of the starting material (by TLC), the reaction was
concentrated under reduced pressure. The residue was washed with n—hexane to afford 2 (143.9
g, HCl salt).
-37_
1H—NMR: (400 MHz, CDC13): 5 3.89 (s, 3H), 3.68-3.62 (m, 2H), 3.59—3.47 (m, 2H), 2.49—2.37
(m, 1H), 2.27—2.05 (m, 3H).
LCMS (m/z): 166 [M++1]
S s of tert-bu h l rrolidine—l 2-dicarb0x late 3
To a stirred solution of 2 (35 g, 0.22 mol) in CHzClz (175 mL) was added Et3N (90
mL, 0.65 mol) ed by Boc—anhydride (56.9 mL, 0.26 mol) at 0°C. The reaction mixture
was stirred at RT for 16 h. After consumption of the starting material (by TLC), the reaction
was diluted with water (100 mL) and extracted with CHzClz (2x 100 mL). The organic layer
was washed with water, brine, dried over NaZSO4 and concentrated. The crude material was
purified by silica gel column tography eluting with 30% EtOAc/n—hexane to afford 3
(41 g, 95%).
1H-NMR: (400 MHz, CDCl3): 5 4.25—4.21 (m, 1H), 3.75 (s, 3H), 3.57—3.26 (m, 2H), 2.29-2.10
(m, 1H), 1.99—1.75 (m, 3H), 1.45 (s, 9H).
LCMS (m/z): 130 [(M++1)-Boc]
S nthesis of l-tert-but lZ-meth 12- ben lox meth l rrolidine—l 2-dicarb0x late
To a stirred solution of 3 (100 g, 0.43 mol) in THF (800 mL) was added LiHMDS
(873 mL, 0.87 mol) at —78°C and stirred for l h. To this BOM-chloride (93.2 mL, 0.65 mol)
was added drop wise at —78°C and stirred for 2 h at -20°C. After consumption of the starting
material (by TLC), the reaction was quenched with aqueous NH4C1 solution and extracted with
EtOAc. The separated c layer was washed with water, dried over Na2S04 and
concentrated to afford 4 (180 g, crude). This material was directly taken for the next step
t further purification.
LCMS (m/z): 250 [(M++1)—Boc]
S nthesis 0f2- ben 10X meth l tert-butox carbon 1 rrolidine-Z-carbox lic acid
To a stirred solution of 4 (100 g, 0.28 mol) in methanol (200 mL) was added 2N
NaOH solution (300 mL) at RT. The reaction mixture was heated to reflux for 4 h. After
consumption of the starting material (by TLC), the t from the reaction was evaporated
under reduced pressure and diluted with EtOAc (100 mL). The aqueous layer was acidified
-38_
using citric acid solution and ted with CHzClz (2x 250 mL). The separated organic layer
was washed with water, dried over Na2S04 and concentrated to afford 5 (60 g, 63%).
: (400 MHz, CDC13): 5 7.37—7.32 (m, 5H), 4.61 (s, 2H), 4.05—3.88 (m, 2H), 3.65-3.42
(m, 2H), 2.54—2.46 (m, 2H), 1.95 (br s, 2H), 1.57 (s, 9H).
LCMS (m/z): 334 [Mt—1]
S nthesis of 1- tert—butox carbon 1 h drox meth l rrolidine—Z-carbox lic acid 6
To a stirred solution of 5 (10 g, 29.81 mmol) in methanol (300 mL) was added 50%
wet 10% Pd/C (5 g) at RT and stirred for 24 h under H2 atmosphere (balloon pressure). After
ption of the starting al (by TLC), the reaction mixture was filtered through a pad
of celite and the pad was washed with methanol. Obtained filtrate was trated under
reduced pressure to afford 6 (6 g, 82%).
1H-NMR: (400 MHz, DMSO—ds): 5 12.55 (br m, 1H), 3.99 (d, 1H), 3.88 (d, 1H), 7.65—7.60 (m,
1H), 3.51—3.45 (m, 1H), 3.39-3.34 (m, 1H), 2.32—2.14 (m, 1H), 1.98—1.69 (m, 3H), 1.39 (s, 9H).
S nthesis often—but 12- 2S 3R —1 3—bis benzvlox ~1—oxobutan—2- l carbamo l. —2—
ghydroxymethyl] pyrrolidine—l—carboxylate g 7 3
To a stirred solution of 6 (3 g, 12.2 mmol) in CH2C12 (100 mL) was added Int-D
(5.8 g, 14.6 mmol), EDCI.HCl (2.8 g, 14.6 mmol) followed by HOBt (1.99 g, 14.6 mmol) and
DIPEA (4.8 g, 36.7 mmol) at RT and stirred for 16 h. After consumption of the starting
material (by TLC), the reaction mixture was diluted with water (100 mL) and extracted with
CH2C12 (2 x 100 mL). The separated c layer was washed with brine, dried over
anhydrous NaZSO4, filtered and concentrated under reduced pressure. Obtained crude material
was purified by silica gel column chromatography to afford 7 (1.6 g, 25%).
1H-NMR: (400 MHz, DMSO—d6): 5 8.25—8.12 (m, 1H), 7.31—7.27 (m, 10H), 5.85 (t, 1H), 5.14
(s, 2H), 4.54-4.49 (m, 2H), 4.31 (dd, 1H), 4.15-4.07 (m, 1H), 3.91—3.50 (m, 1H), 3.52—3.37 (m,
1H), 3.31—3.27 (m, 2H), 2.35—2.07 (m, 1H), 1.95—1.90 (m, 1H), 1.73—1.52 (m, 2H), 1.39—1.27
(m, 9H), .12 (m, 3H).
Mass (ESI): m/z 527.4 [M++1]
S nthesis of ut 12- 2S 3R -1 3-bis benz 10x 0xobutan l 0xo-2 5-
diazaspiro|3.4|octane-5—carboxxlate [8]
[00102] To a stirred solution of 7 (1.4 g, 2.65 mmol) in THF (20 mL) was added
triphenylphosphine (1.1 g, 3.98 mmol) and DTAD (1.2 g, 3.98 mmol). The reaction mixture
-39_
was stirred at RT for 16 h. After consumption of the starting material (by TLC), the reaction
was concentrated under reduced pressure. The crude material was d by silica gel column
chromatography to afford 8-F1 (0.6 g) and 8-F2 (0.55 g).
S nthesis of 2S 3R 5- tert—butox carbon 1 ox0-2 5-diazas iro 3.4 octan-Z- l
hydroxybutanoic acid 191
To a stirred solution of 8—F1 and 8-F2 (0.6 g) in methanol (50 mL) was added 10%
Pd/C (120 mg) at RT and stirred for 6 h under H2 here (balloon pressure). After
consumption of the starting material (by TLC), the reaction mixture was d through a pad
of celite and the pad was washed with methanol. The filtrate was concentrated under reduced
re to give crude, ation using diethyl ether afforded 9 (0.3 g, 82%) as an off—white
solid.
1H-NMR: (500 MHz, DMSO-d6): 5 12.95 (br s, 1H), 4.97 (br s, 1H), 4.24—4.20 (m, 1H), 4.14—
4.07 (m, 1H), 3.84 (d, 1H), 3.53 (t, 1H), 3.41-3.35 (m, 1H), 3.27-3.22 (m, 1H), 2.14-2.08 (m,
2H), 1.84—1.80 (m, 2H), 1.42 (s, 9H), 1.24 (d, 3H).
LCMS (mlz): 329.6 [M++1]
S s oftert-but 12- 2S 3R amino-3—h drox 0X0butan l-l-oxo-Z 5-
piro |3.4| octane-S-carboxylate 1101
To a stirred on of 9 (5 g, 15.2 mmol) in CHzClz (100 mL) was added
ammonium chloride (2 g, 38.1 mmol), EDCI.HC1 (3.5 g, 18.2 mmol) followed by HOBt (5.9 g,
45.7 mmol) and DIPEA (5.9 g, 45.7 mmol) at RT and stirred for 16 h. After consumption of
the starting material (by TLC), the reaction mixture was diluted with water (100 mL) and
extracted with CHzClz (2 x 100 mL). The separated organic layer was washed with brine, dried
over anhydrous Na2S04, filtered and concentrated under reduced pressure. The crude material
was triturated with EtZO (50 mL) and n-pentane (50 mL) to afford 10 (2.5 g, 51%) as an off-
white solid.
1H-NMR: (400 MHz, DMSO-d5)Z 5 7.51 (br s, 1H), 7.19 (br s, 1H), 4.64 (d, 1H), 4.07—3.95 (m,
2H), 3.78 (m, 1H), 3.62—3.35 (m, 2H), 3.27—3.25 (m, 1H), 2.18—2.05 (m, 2H), 1.86-1.74 (m,
2H), 1.41 (s, 9H), 1.12 (d, 3H).
LCMS (m/z): 328.2 [M++1]
S s of 2S 3R h drox 1-0X0-2 5-diazas iro 3.4 octan-Z- lbutanamide
1C0mpound X)
-40_
To a stirred solution of 10 (2.2 g, 6.70 mmol) in CHzClz (25 mL) was added TFA
(7.6 g, 67 mmol) at 0°C and stirred at RT for 2 h. The reaction mixture was concentrated under
reduced pressure to afford Compound X (2 g, 87%) as TFA salt.
1H-NMR: (400 MHz, D20): 5 4.33—4.29 (m, 2H), 4.09 (d, 1H), 3.95 (d, 1H), 3.57-3.48 (m,
2H), 2.51—2.46 (m, 2H), 2.25—2.19 (m, 2H), 1.31 (d, 3H).
LCMS (m/z): 455 [2M++l]
Exam 1e 2— S nthesis of Com ound Z
Scheme 3.
%OH —.O\‘(MeStep1 Step 2 WOMe Step 3 Step 4
H 3'00 LiHMDS aqN30”
SOClz MeOH NHCI 0 30620 0
Bom-CI 30/ BCKS-fn
Step 8
Step 5 [KS—:40
:flN Step 7
Step6 0ND
BOG D'oxane/HC'
EDCIHOBT (Q PdCIH2 BOG u 0 "0A0
0 "OAc
Conditions
OAc 8
Step97f
a? N3 20%.,Step 10 N3
Bee O "'OH
0 -. ’OH
9 Compound Z
To a stirred solution of (2S, 3R)amino—3—hydroxybutanoic acid (SMZ) (30 g, 0.25
mol) in THF (150 mL) and water (150 mL) was added NaHCO3 (65 g, 0.75 mol) followed by
Boc—anhydride (66 mL, 0.302 mol) at 0°C. The reaction mixture was stirred at RT for 16 h.
After consumption of the starting material (by TLC), the reaction mixture was extracted with
EtOAc (2 x 150 mL). The aqueous layer was acidified using 2N HCl and then extracted with
% MeOH/CHZCIZ. The separated organic extracts were dried over ous NaZSO4,
ed and concentrated under vacuum to afford A (30 g, 63%).
1H-NMR: (400 MHz, CDC13): 5 5.92—5.70 (m, 2H), 5.55 (d, 1H), 4.42 (br s, 1H), 4.29 (d, 1H),
1.47 (s, 9H), 1.25 (d, 3H)
-41_
LCMS (m/z): 218 [Mt—1]
S nthesis of ut 1 2S 3R h drox -l-ox0 rrolidin-l- l butan l
ate [B]
To a stirred solution of A (13 g, 59.36 mmol) in DMF (65 mL) was added
EDCI.HC1 (12.5 g, 65.2 mmol) followed by HOBt (8.8 g, 65.2 mmol) at 0°C. After stirring for
min, DIPEA (30.6 mL, 0.17 mol) followed by pyrrolidine (4.6 g, 65.2 mmol) was added to
the reaction mixture and stirring was continued for another 16 h at RT. The reaction mixture
was washed with water and extracted with EtOAc (2x 100 mL). The organic layer was washed
with brine, dried over anhydrous NaZSO4 and trated under vacuum. The crude was
purified by column chromatography to afford B (5 g, 31%).
1H-NMR: (400 MHz, CDC13): 6 5.51 (br s, 1H), 4.32 (d, 1H), 4.15—4.10 (m, 1H), 3.77—3.74 (m,
1H), 3.55—3.46 (m, 3H), 1.99—1.94 (m, 2H), 1.91-1.85 (m, 2H), 1.47 (s, 9H), 1.26 (t, 1H), 1.29
(d, 3H).
S s 0f 2R 3S tert-butox carbon 1 amino 0xo—4- rrolidin-l- l Z- l
acetate 1 D [
To a stirred solution of B (4 g, 14.7 mmol) in CHzClz (40 mL) was added Et3N (5.1
mL, 36.7 mmol) followed by acetic anhydride (1.7 g, 17.6 mmol) and catalytic amount of
DMAP at 0 °C. The on mixture was stirred at RT for 16 h. After ption of the
starting material (by TLC), the reaction mixture was diluted with water and separated the
organic layer. Organic layer was washed with water, dried over anhydrous NaZSO4 and
concentrated under reduced pressure. The crude residue obtained was purified by silica gel
column chromatography to give C. To this 1,4-dioxane/HC1 (20 mL) was added and stirred at
RT for 2 h. The reaction mixture was concentrated under vacuum and the residue was washed
with EtZO (2x 15 mL) to afford D (3.5 g, 97%) as HCl salt.
: (500 MHz, DMSO—d6) (Rotamers): 5 8.49 (br s, 3H), 8.15 (br s, 1H), 5.14—5.10 (m,
1H), 4.26-4.22 (m, 1H), .95 (m, 1H), 3.59 (s, 2H), 2.09 (s, 3H), 1.98 (s, 2H), 1.87-1.80
(m, 2H), 1.26 (d, 3H).
LCMS (m/z): 215.1 [M++1]
S nthesis of meth l rrolidine—Z-carbox late 1
[00109] To a stirred solution of pyrrolidinecarboxylic acid (SMl) (100 g, 0.87 mol) in
methanol (800 mL) was added thionyl chloride (76.9 mL, 1.04 mol) slowly drop wise at 0°C.
-42_
The on mixture was heated to reflux for 12 h. After consumption of the starting material
(by TLC), the reaction was concentrated under vacuum. The e was washed with n—
Hexane and led off the solvent to afford 1 (143.9 g, HCl salt).
: (400 MHz, CDC13) (Rotamers): 5 3.89 (s, 3H), .62 (m, 2H), 3.59-3.47 (m,
2H), 2.49—2.37 (m, 1H), 2.27—2.05 (m, 3H).
LCMS (m/z): 166 [M++1]
S nthesis of -but lZ-meth l rrolidine-l 2-dicarbox late 2
To a stirred on of 1 (35 g, 0.22 mol) in CHzClz (175 mL) were added Et3N (90
mL, 0.65 mol) followed by Boc—anhydride (56.9 mL, 0.26 mol) at 0 °C. The reaction mixture
was stirred at RT for 16 h. After consumption of the starting material (by TLC), the reaction
was diluted with water (100 mL) and extracted with CHzClz (2x 100 mL). The organic layer
was washed with water, brine, dried over NazSO4 and concentrated. The crude material was
ed by silica gel column chromatography eluting with 30% EtOAc/Hexane to afford 2 (41
g, 95%).
1H-NMR: (400 MHz, CDC13) (Rotamers): 5 4.25—4.21 (m, 1H), 3.75 (s, 3H), 3.57-3.26 (m,
2H), 2.29—2.10 (m, 1H), 1.99—1.75 (m, 3H), 1.45 (s, 9H).
LCMS (m/z): 130 [(M++l)—Boc]
S nthesis of l-tert-but lZ-meth 12- ben 10x meth 1 rrolidine-l 2-dicarb0x late
[00111] To a stirred solution of 2 (100 g, 0.43 mol) in THF (800 mL) was added LiHMDS
(873 mL, 0.87 mol) at —78°C and stirred for 1 h. To this BOM-chloride (93.2 mL, 0.65 mol)
was added drop wise at —78°C and stirred for 2 h at -20°C. After consumption of the starting
material (by TLC), the reaction was quenched with NH4Cl at 0°C. The separated organic layer
was washed with water, dried over NaZSO4 and concentrated to afford 3 (180 g, crude). This
material was directly taken for the next step without further purification.
LCMS (m/z): 250 [(M++1)—Boc]
S nthesis of 2- ben 10x meth l tert-butox carbon 1 rrolidine-Z-carbox lic acid
To a stirred solution of 3 (100 g, 0.28 mol) in methanol (200 mL) was added 2N
NaOH solution (300 mL) at RT. The reaction mixture was heated to reflux for 4 h. After
consumption of the starting material (by TLC), the solvent from the reaction was evaporated
-43_
under vacuum and diluted with EtOAc (100 mL). The s layer was acidified using citric
acid solution and extracted with CHzClz (2x 250 mL). The separated organic layer was washed
with water, dried over NaZSO4 and concentrated to afford 4 (60 g, 63%).
1H-NMR: (400 MHz, CDC13) (Rotamers): 5 7.37—7.32 (m, 5H), 4.61 (s, 2H), 4.05-3.88 (m,
2H), 3.65—3.42 (m, 2H), 2.54—2.46 (m, 2H), 1.95 (br s, 2H), 1.57 (s, 9H).
LCMS (m/z): 334 [Ml—1]
S nthesis of tert-bu 12- ZS 3R acetox oxo-l- rrolidin-l- l butan-Z- l
carbamoyu-Z-g ] benzyloxy] methyl] pyrrolidine-l-carboxylate [5]
To a stirred solution of D (1 g, 2.90 mmol) in DMF (8 mL) was added EDCI.HC1
(0.63 g, 3.28 mmol) followed by HOBt (0.44 g, 3.28 mmol) at 0°C. After being stirred for 5
min, DIPEA (1.3 mL, 7.46 mmol) followed by compound 4 (0.74 g, 3.58 mmol) was added to
the reaction e and stirring was continued for another 16 h at RT. The reaction mixture
was washed with water and extracted with EtOAc (2x 500 mL). The organic layer was washed
with brine, dried over anhydrous NaZSO4 and concentrated under vacuum. The crude was
purified by column tography to afford 5 (0.6 g, 38%).
LCMS (m/z): 532 [M++1]
S'nthesis oftert—hutyl . ~3-acetoxv-1—oxo—1— rwrolidin-l—vl butan~2— s
carbamo 'l -2— h drox meth '1 rrolidine-l—carbox late 6
To a d solution of 5 (4.5 g, 8.40 mmol) in MeOH (40 mL) was added wet 10%
Pd/C (1.5 g) under inert atmosphere and stirred for 4 h under H2 atmosphere (balloon re).
The reaction mixture was filtered through celite pad and concentrated under reduced pressure
to afford 6 (3.0 g, 81%).
LCMS (m/z): 442.5 [M++1]
S nthesis oftert-but 12- 2S 3R acetox rrolidin-l- l butan-Z- l-l-oxo-Z
5-diazaspiroI3.4| octane-S-carboxylate [7]
To a stirred on of 6 (3 g, 6.70 mmol) in THF (25 mL) was added
triphenylphosphine (2 g, 7.40 mmol) ed by DTAD (2.5 g, 10.2 mmol). The reaction
mixture was stirred at RT for 16 h. After consumption of the starting material (by TLC), the
reaction was concentrated under reduced pressure. The crude al was purified by silica
gel column chromatography eluting with 10% MeOH/CH2C12 to afford 7 (1.2 g with TPPO,
43%).
-44_
1H-NMR: (400 MHz, DMSO—d6): 5 5.25—5.19 (m, 1H), 4.65 (d, 1H), 3.61—3.57 (m, 3H), 3.47—
3.42 (m, 2H), 3.41—3.25 (m, 4H), 2.05 (s, 4H), 1.95—1.71 (m, 7H), 1.42 (s, 10H).
LCMS (m/z): 424.4 [M++1]
S s 0f 2R 3S oxo—3- l-oxo-Z 5-diazas iro 3.4 octan-Z- l rrolidin-l- l
butan-Z-yl acetate 18)
A stirred solution of 7 (0.4 g, 0.94 mmol) in 1,4-dioxane/HC1 (5 mL) was cooled to
0°C and stirred at RT for 1 h. After ption of the starting material (by TLC), the reaction
mixture was concentrated under reduced pressure. The crude material was washed with n—
pentane followed by EtOAc to afford 8 (0.22 g, 65%).
: (400 MHz, D20): 5 4.62 (d, 1H), 4.41—4.29 (m, 2H), 4.24 (d, 1H), 3.89—3.77 (m,
3H), 3.54—3.49 (m, 3H), 2.57-2.52 (m, 1H), 2.49 (s, 3H), 2.42—2.00 (m, 8H), 1.30 (d, 3H).
LCMS (m/z): 324.3 [M++1]
UPLC : 99.37%
S nthesis oftert-but 12- 2S 3R h drox oxo-l- rrolidin-l- l butan-Z- l-l-oxo-
2, 5-diazaspir0 |3.4| octane-S-carboxylate 19)
A solution of 7 (0.15 g, 0.41 mmol) in s NH3 (2 mL) was stirred at RT for 4
h. After ption of the starting material (by TLC), the reaction diluted with CHzClz (75
mL). The separated c layer was dried over anhydrous Na2S04 and concentrated under
d pressure to afford 9 (0.1 g, 76%).
LCMS (m/z): 382 [M++1]
S nthesis of 2- 2S 3R h drox oxo rrolidin-l- l butan 1-2 as iro
|3.4| octan-l-one (Compound Z1
To a stirred solution of 9 (0.2 g, 0.63 mmol) in CHzClz (2 mL) was added TFA (0.3
mL) at 0 °C and stirred at RT for 1 h. The reaction mixture was concentrated under vacuum
and the residue was diluted with water and extracted with CH2C12 (2x 25 mL). The separated
organic layer was dried over anhydrous NaZSO4, filtered and concentrated under vacuum to
afford Compound Z (0.2 g, 80%) as TFA salt.
1H-NMR: (400 MHz, D20): 5 4.64 (t, 1H), 4.25-4.21 (m, 1H), 4.09 (d, 1H), 3.99—3.87 (m, 1H),
3.70 (t, 2H), 3.55—3.47 (m, 5H), 2.52—2.34 (m, 2H), 2.25-2.22 (m, 2H), 2.08-1.98 (m, 5H), 1.25
(t, 3H).
_ 45 _
LCMS (m/z): 282.4 [M++1]
Scheme 2S-I-I
o o o O
OH Step1 HO OH Step 2 Step 3
NHZ (300)20 NHBoc NaH.BnBr BnO)_?~OHNHBoc Br BnO)_?~OBnNHBoc
ZS-A ZS-B 28-0
Step 4 Bn0>_?~o|3n
Ether.HCl NHZ‘ HCI
ZS-D
S nthesis of 2S 3R tert—butox carbon 1 amino h drox butanoic acid 2S-A :
] To a stirring solution of L-threonine (50 g, 420 mol) in THF/water (500 mL/500
mL) were added NaHCO3 (111 g, 1.05 mol) and stirred at RT for 30 min. The reaction mixture
was cooled to 0 °C and Boc—anhydride (137 mL, 630 mmol) was added drop wise and the
stirring was continued at RT for 16 h. After consumption of the starting material (by TLC), the
reaction e was concentrated under reduced pressure and obtained residue was d
with water (100 mL) and acidified by using 1N HCI (pH~3). The aqueous layer was extracted
with EtOAc (2 x 250 mL). The combined organic layer was washed with brine (1 x 200 mL),
dried over anhydrous NaZSO4, filtered and concentrated under reduced pressure to afford
compound ZS-A (80 g, 87%) as thick syrup.
1H-NMR: (500 MHz, DMSO-dg): 5 12.5 (br s, 1H), 6.30 (d, J= 8.5 Hz, 1H), 4.50 (br s, 1H),
4.05-4.02 (m, 1H), 3.88-3.86 (m, 1H), 1.39 (s, 9H), 1.08 (d, J: 6.0 Hz, 3H);
LCMS m/z: 218.1 [Mil]
S nthesis of 2S 3R ben 10x tert-butox carbon 1 amino butanoic acid ZS-B:
[00120] To a stirring solution of 2S-A (40 g, 182 mmol) in DMF (400 mL) was added
60% NaH (18.2 g, 758 mmol) portion wise at —20 °C under N2 atmosphere and stirred for 2 h.
To this added benzyl bromide (66.8 mL, 0.55mol) drop wise and the reaction mixture was
stirred at RT for 3 h. After consumption of the starting material (by TLC), the reaction mixture
was quenched with ice cold water and washed with diethyl ether (2 x 250 mL). The separated
aqueous layer was acidified using citric acid on (100 mL) and ted with EtOAc (2 x
250 mL). The combined c layers were dried over anhydrous Na2S04 and concentrated
under reduced pressure to afford compound 2S—B (45 g, 80%) as thick syrup.
-46—
1H—NMR: (500 MHz, DMSO-dg): 6 12.64 (br s, 1H), 7.34-7.25 (m, 5H), 6.46 (d, J= 8.5 Hz,
1H), 4.53 (d, J: 11.5 Hz, 1H), 4.39 (d, J= 12.0 Hz, 1H), 4.00—3.98 (m, 2H), 1.39 (s, 9H), 1.15
(d, J= 6.0 Hz, 3H);
Synthesis of 12S, 3R1-bengyl 3-gbenzyloxy2ggtert-butoxycarbonyl) amino) butanoate 12S-
] To a stirring solution of compound 2S-B (45 g, 146 mmol) in DMF (400 mL)
was added K2CO3 (40 g, 292 mmol) under N2 atmosphere and stirred for 30 min. To this benzyl
bromide (21 mL, 175 mmol) was added drop wise at 0 OC and stirred at RT for 16 h. The
reaction mixture was quenched with ice cold water and extracted with diethyl ether (2 x 250
mL). The separated organic layer was washed with brine, dried over anhydrous Na2S04 and
concentrated under reduced pressure. The crude material was purified by silica gel column
chromatography eluting with 20% EtOAc/n—hexane to afford compound 2S-C (48 g, 82%) as
thick syrup.
1H-NMR: (500 MHz, DMSO—dg): 5 7.37—7.18 (m, 10H), 6.81 (d, J: 9.0 Hz, 1H), 5.08 (s, 2H),
4.49 (d, J= 12.0 Hz, 1H), 4.32 (d, J= 12.0 Hz, 1H), .22 (m, 1H), .98 (m, 1H), 1.38
(s, 9H), 1.15 (d, J: 6.0 Hz, 3H)
Mass (ESI): m/z 399.4[M++1];
Synthesis of 12S, 3R)-benzyl 2-amin01bengyloxy) butanoate 12S-D 1:
To a ng solution of compound 2S-C (48 g, 120 mmol) in diethylether (50
mL) was added diethylether saturated with HCl (350 mL) at 0 °C and stirred at RT for 10 h.
After consumption of the starting material (by TLC), the reaction mixture was trated
under reduced pressure. The crude material was triturated with diethyl ether/n-pentane (50
mL/50 mL) and dried under d pressure to afford compound 2S-D (28 g, 77%) as
semisolid (HCl salt).
1H-NMR: (400 MHz, DMSO—d6): 8 8.59 (s, 2H), 7.50—7.25 (m, 10H), 5.23 (d, J: 12.5 Hz,
1H), 5.16 (d, J: 12.5 Hz, 1H), 4.54 (d, J: 12.0 Hz, 1H), 4.36 (d, J: 12.0 Hz, 1H), .09
(m, 1H), 4.09—3.99 (m, 1H), 1.29 (d, J: 6.5 Hz, 3H)
Mass (ESI): m/z 299.4[M++1];
Scheme 2S-I-2
-47_
OH o
Step 1 0\ \
Step 2 Step 3 Step 4
fl 0 SOCI2 fl NaOH (Boc)2O | LiHMDS N
MeOH ' HCP B°° O
BOM-CI Boc
2S-E 2S-F 2S-G
WOH —>p MOHSte 5 e—p>6 0%”flSt Step7
Pd-C/H2 "OBn
. 28-D HATU
C Io DIAD PPh3 3000NHgILIOBn
ZS-H ZS-l ZS-K
Step 8
Pd-C/H2
B00 0
S nthesis of meth l rrolidine-Z-carbox late ZS-E :
To a stirring solution of L-proline (50 g, 434 mmol) in methanol was added
thionyl chloride (37.5 ml, 521 mmol) at 0 °C and heated to 70 0C for 16 h. The reaction
mixture was brought to RT and concentrated under vacuum to afford compound ZS-E as (70 g,
99 %) as thick syrup (hydrochloride salt).
1H-NMR: (500 MHz, g): 5 .13 (m, 1H), 3.65 (s, 3H), 3.35-3.30 (m, 2H), 2.23—
2.15 (m, 1H), 1.86—1.78 (m, 3H), 1.41 (s, 9H);
LCMS m/z: 129 [M++l]
S nthesis of 1-tert—but lZ-meth l rrolidine-l 2-dicarb0x late ZS-F :
] To a stirring solution of compound ZS-E (70 g, 422 mmol) in CHZCIZ (700 mL)
were added Et3N (183 mL, 1.26 mol) at 0 OC and stirred for 10 min. After added Boc-anhydride
(184 mL, 845 mmol) at 0 °C and the reaction mixture was stirred at RT for 16 h. After
consumption of the starting material (by TLC), the reaction was diluted with water (200 mL)
and extracted with CH2C12 (2 x 200 mL). The combined organic layer was washed with citric
acid (1 x 150 mL), brine (l x 200 mL). The c layer was dried over NaZSO4 and
concentrated under reduced pressure to afford crude nd which was purified by column
chromatography by eluting 50% EtOAC/n—hexane to obtain compound 2S-F (80 g, 83%) as
thick syrup.
.48_
1H—NMR: (400 MHz, DMSO—dg): 5 4.15—4.13 (m, 1H), 3.65 (s, 3H), .30 (m, 2H), 2.23—
2.15 (m, 1H), 1.86—1.78 (m, 3H), 1.41 (s, 9H);
LCMS m/z: 229 [(M++1)-Boc].
S nthesis of 1-tert-bu 12-meth 12- ben 10x meth l rrolidine—l rbox late
123-ng
To a stirring solution of compound 2S-F (25 g, 109 mmol) in THF (250 mL)
was added LiHMDS (240 mL, 240 mmol) at -20 °C and stirred for 2 h. To this BOM-chloride
(23 mL, 163 mmol) was added drop wise at —30 °C and stirred for 2 h. After consumption of the
starting material (by TLC), the reaction was quenched with aqueous NH4C1 solution (100 mL)
and extracted with EtOAc (2 x 200 mL). The combined organic layer was washed with water (2
x 150 mL) followed by brine on (2 x 100 mL). The organic layer was dried over Na2804
and concentrated to obtain crude compound which was purified by column chromatography by
eluting 10% EtOAc/n-hexane to afford compound ZS-G (30 g, 79%) as thick syrup.
1H-NMR: (500 MHz, DMSO—dg): 5 7.36—7.22 (m, 5H), 4.59—4.48 (m, 2H), .88 (m, 1H),
3.63 (s, 3H), 3.49—3.35 (m, 2H), 3.34—3.30 (m, 1H), 2.31-2.23 (m, 1H), 2.04-1.89 (m, 2H), 1.82—
1.78 (m, 1H);
LCMS m/z: 349.4 [(M++1)—Boc]
S nthesis of 2- benz 10x meth l tert-butox carbon 1 rrolidine—Z-carbox lic acid
12S-H1:
[00126] To a ng solution of compound ZS-G (30 g, 86 mmol) in methanol (70 mL)
was added NaOH solution (6.88 g in 70 mL H20) at RT. The reaction e was heated to 70
°C for 16 h. After consumption of the starting material (by TLC), the solvent from the reaction
was evaporated under reduced re and diluted with EtOAc (2 x 200 mL). The separated
aqueous layer was acidified using citric acid solution (pH~3) and extracted with EtOAc (2 x
250 mL). The combined c layer was dried over NaZSO4 and concentrated to afford crude
was triturated with n—hexane to obtain compound ZS-H (25 g, 86.8%) as an off—white solid.
1H-NMR: (400 MHz, DMSO—dg): 8 12.35 (br s, 1H), 7.37—7.29 (m, 5H), 4.56—4.48 (m, 2H),
4.06—4.00 (m, 1H), 3.92—3.89 (m, 1H), 3.66—3.45 (m, 1H), 3.37—3.28 (m, 1H), 2.31-2.20 (m,
1H), 2.05-1.97 (m, 1H), 1.87-1.75 (m, 2H), 1.38 (s, 9H);
LCMS m/z: 335.3 [M++1]
S nthesis of 1- tert-butox carbon 1 h drox meth l ine—Z-carbox lic acid
128-1):
-49_
To a stirring solution of nd 2S-H (25 g, 74 mmol) in methanol (150 mL)
was added 50% wet 10% Pd/C (7 g) at RT and stirred for 10 h under H2 atmosphere. After
consumption of the starting material (by TLC), the reaction mixture was filtered h a pad
of celite and the pad was washed with methanol (100 mL). Obtained filtrate was concentrated
under reduced pressure to afford compound 2S—1 (15 g, 82.8%) as white solid.
1H-NMR: (400 MHz, DMSO—dg): 5 4.66 (br s, 1H), 3.96—3.83 (m, 1H), 3.63—3.59 (m, 1H),
3.49-3.41 (m, 1H), 3.34-3.25 (m, 1H), 2.30-2.17 (m, 1H), 1.95-1.72 (m, 3H), 1.38 (s, 9H).
Mass (ESI): m/z 245 [M++1]
S nthesis of tert-bu l 2- 2S 3R -1 3-bis benz 10x 0xobutan l carbamo 1
h drox meth l rrolidine—l-carbox late 2S-J :
To a stirring solution of compound 2S-I (18 g, 73.4 mmol) in CH2Clz (180 mL)
were added DIPEA (40 mL, 220 mmol), ZS-D (21.9 g, 73.4 mmol), HATU (41.8 g, 110 mmol)
at RT and stirred for 16 h. After consumption of the starting material (by TLC), the reaction
mixture was diluted with water (50 mL) and extracted with CHzClz (2 x 100 mL). The
combined organic layer was washed with brine, dried over anhydrous Na2S04, filtered and
concentrated under reduced pressure. Obtained crude al was purified by silica gel column
chromatography eluting with 30% n—hexane to afford compound 2S-J (20 g, 52%) as
pale yellow thick syrup.
1H-NMR: (400 MHz, DMSO—dg): 5 8.25—8.12 (m, 1H), 7.31—7.27 (m, 10H), 5.85 (t, J= 4.8 Hz,
1H), 5.14 (s, 2H), 4.54—4.49 (m, 2H), 4.31—4.20 (m, 1H), 4.15-4.07 (m, 1H), .50 (m, 1H),
3.52—3.37 (m, 1H), 3.31—3.27 (m, 2H), 2.35—2.07 (m, 1H), 1.95—1.90 (m, 1H), 1.73—1.52 (m,
2H), 1.39 (s, 9H), 1.19 (d, J= 6.4 Hz, 3H);
Mass (ESI): m/z 527.4 [M++1]
S nthesis 0f tert-but l 2— 2S 3R -1 3-bis ben 10x 0xobutan l 0xo-2 5-
diazaspiro |3.4| -S-carboxylate {ZS-K):
] To a ng solution of triphenylphosphine (24.7 g, 94 mmol) in THF (100 mL)
was added DIAD (15.3 g, 75 mmol) at RT and stirred for 30 min. To this added compound 2S-
J (20 g, 37.9 mmol) in (10 mL) THF slowly and reaction mixture was stirred at RT for 2 h.
After consumption of the starting material (by TLC), the reaction was concentrated under
reduced pressure. The crude material was d by silica gel column chromatography eluting
% EtOAc/n—hexane to afford compound 2S-K (17 g, 88%) as pale yellow thick syrup.
-50_
1H-NMR: (400 MHz, DMSO—dg): 5 .26 (m, 5H), 7.23—7.18 (m, 5H), 5.10 (s, 2H), 4.80—
4.73 (m, 2H), 4.60 (s, 2H), 4.31 (s, 2H), 4.05-4.00 (m, 2H), 1.80—1.68 (m, 4H), 1.39 (s, 9H),
1.18 (d, J: 6.0 Hz, 3H);
Mass (ESI): m/z 509.4 [M++l]
S nthesis of 2S 3R 5- tert—butox carbon l0x0-2 5-diazas iro 3.4 octan-Z- 1
hydroxybutanoic acid {ZS-L):
To a ng solution of compound 2S—K (7 g, 13.7 mmol) in methanol (100
mL) was added 10% Pd/C (4 g) at RT and stirred for 6 h under H2 atmosphere. After
consumption of the starting material (by TLC), the reaction mixture was filtered through a pad
of celite and the pad was washed with methanol (50 mL). Obtained filtrate was concentrated
under reduced pressure to obtained crude, which was ated with n—pentane (50 mL) to
afford compound 2S—L (4 g, 88%) as white solid.
: (500 MHz, DMSO-dg): 8 12.80 (br s, 1H), 4.78-4.73 (m, 1H), 4.21—4.19 (m, 1H),
4.09 (s, 2H), 3.55-3.46 (m, 2H), 2.09—2.05 (m, 2H), 1.80 (d, .1: 7.0 Hz, 1H), 1.38 (s, 9H), 1.35—
1.28 (m, 2H), 1.17 (d, J= 6.5 Hz, 3H)
LCMS m/z: 329.6 [M++1]
Scheme 2S-I-3
0 Step 1 0 Step 2 0 Step 3
—’ —’ —>
H N2 BocHN BocHN
0“ (BoC)20 \AOH NH4C| \JWHz A
ZS-M EDC' ZS-N
BocHN\/u\ A / —>Step 4
N’\\
H Step 5 N’\\
NVt [N I N
N N / O TFAHzN O/
| NHZOHHCI BOC TFA/DCM
28-0 zs—P zs-Q
To a stirring solution of glycine (15 g, 200 mmol) in 1,4-dioxane/water (150
mL/75 mL) were added Na2C03 (53 g, 500 mmol). After added Boc-anhydride (109 mL, 500
mmol) slowly at 0 °C. The reaction mixture was stirred at RT for 12 h. After ption of
the starting material (by TLC), the on mixture was concentrated under reduced pressure.
The crude residue was acidified (pH~4) by using citric acid solution and aqueous layer was
extracted with EtOAc (2 x 150 mL). The combined organic layer was washed with brine
-51_
solution (2 x 100 mL). The organic layer was dried over anhydrous NagsO4, filtered and
concentrated under vacuum to afford compound 2S-M (30 g, 85.7%) as white solid. This
al was directly used for the next step without further purification.
1H-NMR: (500 MHz, DMSO—d6): 5 12.41 (br s, 1H), 7.04 (t, J: 5.5 Hz, 1H), 3.57 (d, J: 5.5
Hz, 2H), 1.37 (s, 9H);
Synthesis of tert-butyl (2-aminooxoethyl) carbamate (2S-N):
To a stirring solution of 2S-M (10 g, 57.14 mmol) in CHzClz (100 mL) were
added HOBt (15.43 g, 114 mmol), Cl (21.8 g, 114 mmol) followed by NH4C1 (4.54 g,
85.71 mmol) and DIPEA (30.7 mL, 171 mmol) at 0 °C. The reaction mixture was stirred at RT
for 16 h. After consumption of the starting material (by TLC), the reaction mixture was washed
with water (2 x 100 mL). Organic layer was dried over anhydrous Na2SO4 and concentrated
under reduced pressure to give crude; which was purified by silica gel column tography
eluting with 2% MeOH/CHgClz. After compound was triturated with ether (25 mL) and the
precipitated solid was filtered to afford ZS-N (2 g, 20%) as white solid.
1H-NMR: (500 MHZ, DMSO—d6): 5 7.52 (br s, 1H), 7.17 (br s, 1H), 3.46 (d, J: 6.5 Hz, 2H),
1.38 (s, 9H);
S nthesis of E -tert-but l 2- dimeth lamino meth lene amino 0X0eth l
carbamate [ZS-O [:
To a ng solution of ZS-N (7 g, 40.22 mmol) in THF (70 mL) was added
DMF.DMA (10.7 mL, 80.44 mmol) at RT and heated to 80 0C for 2 h. After consumption of
the starting al (by TLC), the reaction mixture was concentrated under d pressure to
afford 2S-O (9 g, crude) as brown syrup. This crude al was directly taken for the next
step without further purification.
1H-NMR: (500 MHz, DMSO-ds): 5 6.72 (br s, 1H), 4.35 (s, 1H), 3.64 (d, J= 5.5 Hz, 2H), 3.09
(s, 1H), 1.42 (s, 9H);
Mass (ESI): m/z 230.2 ;
S nthesis of tert-but l 1 2 4-0xadiazol l meth l carbamate ZS-P :
To a stirring solution of 2S-O (9 g (crude), 39.30 mmol) in l (80 mL) was
added hydroxylamine hydrochloride (5.45 g, 78.60 mmol) under N2 atmosphere. The reaction
mixture was heated to 90 OC and stirred for 2 h. After consumption of the starting material (by
TLC) ated solvent under reduced pressure and crude residue was diluted with water (75
mL). The aqueous layer was extracted by DCM (3 x 100 mL). The combined organic layer was
-52_
washed by brine solution (1 x 100 mL). The organic layer was dried over anhydrous NazSO4
and solvent was concentrated under reduced re to give crude; which was purified by
silica gel column chromatography eluting with 25% EtOAc/hexane to afford 2S-P (4 g, 51%).
1H-NMR: (500 MHz, DMSO-d6): 5 8.90 (s, 1H), 7.64 (s, 1H), 4.44 (s, 2H), 1.39 (s, 9H);
LCMS m/z: 198.4 [M'—1]
S nthesis of 1 2 4-oxadiazol l methanamine 2S-
To a stirring solution of 2S-P (1.1 g, 5.52 mmol) in DCM (30 mL) was added
trifluoroacetic acid (2.1 mL, 27.63 mmol) at 0 0C for 30 min. The reaction mixture was d
at RT for 4 h. After consumption of the starting al (by TLC), the reaction e was
concentrated under vacuum. The crude residue was ated with ether (20 mL) to afford 2S-
Q (850 mg, 72.6%) as white solid.
1H-NMR: (400 MHz, DMSO-dg): 5 9.13 (s, 1H), 8.90 (br s, 2H), 4.56 (s, 2H);
LCMS (ESI): 100.4 [M++1]
Scheme 2S-I-4
O Step-1 2 O Step-3
CIH.H2N \/U\O/ BocHN$O/ BocHNdL _’
(300)20 NH2NH2_H20 NHNH2 CH(OEt)3
ZS-R 28-8
N’N Step-4
l \
BocHN H N
0 2 $93
EtOAc.HC|
ZS-T 234)
S nthesis of meth l tert-butox carbon 1 l cinate 2S-R:
To a stirring solution of glycine methyl ester hydrochloride (50 g, 400 mmol) in
1,4 dioxane/water (300 mL/200 mL) were added Na2C03 (84.8 g, 800 mmol) and stirred at RT
for 10 min. The reaction mixture was cooled to 0 OC and Boc-anhydride (104 mL, 480 mmol)
was added drop wise and the stirring was continued at RT for 16 h. After consumption of the
starting material (by TLC), the reaction mixture was concentrated under reduced pressure and
obtained residue was diluted with water (100 mL) and extracted with EtOAc (2 x 250 mL). The
combined organic layer was washed with brine (1 x 200 mL) and organic layer was dried over
anhydrous NaZSO4, filtered and concentrated under reduced pressure to afford 2S-R (64 g,
84%) as thick syrup.
-53_
1H—NMR: (500 MHz, DMSO—dg): a 7.19 (t, J: 5.5 Hz, 1H), 3.67 (d, J: 6.0 Hz, 2H), 3.62 (s,
3H), 1.38 (s, 9H);
LCMS m/z: 190.2 [M++1]
S nthesis of tert-but l 2-h drazin loxoeth l carbamate 2S-S :
A solution of 2S-R (20 g, 105 mmol) in EtOH (100 mL) was added hydrazine
e (15.8 g, 315 mmol) at RT and after stirred at 100 0C for 6 h. After consumption of the
starting material (by TLC), ethanol was evaporated under d pressure. Obtained crude
material was triturated with n-pentane/diethyl ether (20 mL/20 mL) to afford ZS-S as white
solid.
1H-NMR: (400 MHz, DMSO—dé): 5 8.91 (s, 1H), 6.88 (t, J: 5.5 Hz, 1H), 4.16 (s, 2H), 3.47 (
d, J: 6.0 Hz, 2H), 1.37 (s, 9H);
LCMS m/z: 190.2 [M++1]
S nthesis of tert-but l 1 3 4-oxadiazol l meth l carbamate ZS-T:
A solution of 2S-S (14 g, 74 mmol) in yl orthoformate (140 mL) was added
p-TSA (catalytic, 140 mg) at RT and after stirred at 80 0C for 4 h. After consumption of
starting material (by TLC), triethyl orthoformate was evaporated under reduced pressure. The
crude e was purified by column chromatography eluting 20% EtOAc/hexane to afford
2S—T (6.1 g, 41.5%) as an off-white solid.
1H-NMR: (400 MHz, DMSO—d6): 6 10.74 (s, 1H), 7.45 (s, 1H), 4.03 (s, 2H), 1.47 (s, 9H);
LCMS m/z: 200.2 [M++1]
S nthesis of 1 3 4—oxadiazol l methanamine 2S-U:
To a stirring solution of ZS-T (5 g, 25 mmol) in EtOAc (10 mL) was added
EtOAc ted with HCl (60 mL) at 0 °C and stirred at RT for 16 h. After consumption of the
starting material (by TLC), the reaction mixture was trated under reduced pressure. The
crude material was triturated with diethylether/n-pentane (25 mL/25 mL) and dried under
reduced re to afford 2S—U (3 g, 88.7%) as an off—white solid (HCl salt).
1H—NMR: (500 MHZ, DMSO—d6): 5 9.55 (br s, 2H), 7.99 (s, 1H), 3.90 (s, 2H);
LCMS m/z: 100 [M++1]
Scheme 2S-I-5
-54_
Step2 Bn/hll
N~N’B
/ O+Et0f\n ©/\Br Step1 N3 N”
NaN3 DMF Ethyl but--2ynoate
ZS-V
28 W1 ZS-WZ
’Bn Bn
[N‘N ,N‘N’
N Step3
/ N’/
LiOH
EC 0 HO O
ZS-WZ zs-x2
Synthesis of (azidomethyl) benzene (ZS-V):
To a stirring solution of benzyl bromide (30 g, 175mmol) in dimethyl
formamide (300 mL) was added sodium azide (45.6 g, 701 mmol) at RT under inert
atmosphere. The resultant reaction mixture was stirred at 70 °C for 16 h. After completion of
reaction monitored (by TLC), the reaction mixture was allowed to RT; the volatiles were
diluted with water (3 00 mL) and ether (200 mL). The separated organic layer was washed by (3
x 200 mL) of d water. The separated organic layer was dried over anhydrous Na;SO4,
filtered and concentrated under reduced pressure to afford compound ZS-V (l 8 g, crude) as an
ite solid.
1H-NMR: (400 MHz, CDC13): 5 7.40-7.29 (m, 5H), 4.32 (s, 2H).
S nthesis 0f eth l l-benz lmeth l-1H—1 2 3-triazolecarbox late 2S-W2
To a stirring solution of ethyl but—2—ynoate (8.0 g, 71.3 mmol) in toluene (80
mL) was added ZS-V (12.0 g, 107 mmol) at RT under inert atmosphere. The resultant on
mixture was heated to 100 °C and stirred for 16 h. The reaction mixture was allowed to RT; the
les were evaporated under reduced pressure to which, crude residue was purified by
column chromatography by eluting 40% EtOAc/hexane to afford ZS-Wl and 2S-W2 (8.2 g,
47.1%) (separable by column chromatography)
1H-NMR: (400 MHZ, CDC13): 5 7.36—7.31 (m, 3H), 7.16 (t, J= 6.0 Hz, 2H), 5.53 (s, 2H), 4.43
(q, J= 7.2 Hz, 2H), 2.45 (s, 3H), 1.41 (t, J: 7.2 Hz, 3H);
Mass m/z: 246.3 [M++1]
S nthesis of 1-ben th l-1H-1 2 3-triazole-4—carbox lic acid 2S-X2
To a stirring solution of compound 2S-W2 (8.2 g, 33.4 mmol) in THF/HZO (82
mL/82 mL, 1:1) was added LiOH.H20 (4.2 g, 0.4 mmol) at RT and d for 16 h. After
completion of reaction (by TLC), the volatiles were evaporated under reduced pressure. The
residue was ed with aqueous 2N HCl and the precipitated solid was filtered and washed
-55_
with water (25 mL), dried under reduced re to afford compound ZS-XZ (7.0 g, 96.6%) as
an off—white solid.
1H-NMR: (400 MHz, DMSO—d6): 6 13.01 (br s, 1H), 7.40—7.32 (m, 5H), 5.63 (s, 2H), 2.45 (s,
3H);
Mass m/z: 218.3 [M++1];
Scheme 2S-I-6
fN Step 1
N/J\CN —> FNPd-C N/J\/NH2
sis of pyrimidin-Z-ylmethanamine (ZS-Y):
[00143] To a stirring solution of 2-cyanopyrimidine (2.0 g, 19.0 mmol) in methanol (50
mL) were added 10%Pd/C (300 mg), 12 N HCl (1.5 mL) under N2 atmosphere. The reaction
e was stirred under H2 atmosphere (balloon pressure) at RT for 3 h. After consumption
of the starting material (by TLC), the reaction mixture was filtered through a pad of celite and
the pad was washed with methanol. Obtained filtrate was concentrated under reduced pressure
to afford crude compound which was triturated with diethyl ether to obtained nd ZS-Y
(1.2 g, 44%) as white solid.
1H-NMR: (500 MHz, DMSO-dg): 6 8.87 (d, J= 5.0 Hz, 2H), 8.69 (br s, 2H), 7.52 (t, J: 5.0
Hz, 1H), 4.24 (s, 2H);
Mass (ESI): 110.3 [M++1]
Scheme 2S-I- 7
HoLo?—OH Step A HO\_O?-OH Step B BnO\_O?-OH
NH2 (800)20 NHBoc NaH,BnBr NHBoc
zs-z 28-AA
Step C BnO&OBn Step D Bn0\_oz¥oen
K2C03,BnBr ether-HC'
NHBOC NH2_ HCI
28-AB 28—AC
S nthesis 0f tert-butox carbon 1 amino h drox r0 anoic acid 2S-Z
WO 20783
-56—
To a stirring solution of L-serine (76 g, 723 mmol) in 1, 4 dioxane/H20 (350
mL/300 mL) were added NaOH (61 g, 1.51mol), Boc—anhydride (190 mL, 868 mmol) at 0 oC.
The reaction e was stirred at RT for 16 h. After consumption of the starting material (by
TLC), the on mixture was acidified with 2N HCl (pH~4) and extracted with EtOAc
(5x500 mL). The combined organic extracts were dried over anhydrous Na2S04 and
concentrated under reduced pressure to afford 2S-Z (100 g, 67.5%) as yellow syrup.
1H-NMR: (400 MHz, CDC13): 5 6.54 (br s, 1H), 5.77 (br s, 1H), 4.35—4.04 (m, 1H), 3.87—3.84
(m, 2H), 1.45 (s, 9H).
S nthesis 0f benz 10x tert-butox carbon 1 amino ro anoic acid 2S-AA
[00145] To a stirring solution of 2S-Z (50 g, 245 mmol) in DMF (650 mL) was added
NaH (60%) (23 g, 563 mmol) at -15 °C and stirred for 2 h. Benzyl bromide (32.8 mL, 269
mmol) was slowly added. The reaction mixture temperature was warmed to RT and stirred for
12 h. After consumption of the starting al (by TLC), the reaction e was poured into
chilled water (200 mL) and extracted with diethylether (2x 250 mL). The aqueous layer was
acidified with citric acid (pH~4) and extracted with EtOAc (2x500 mL). The combined organic
layers were washed with water (3x250 mL). The organic extracts were dried over anhydrous
NaZSO4, filtered and concentrated under d pressure to afford 2S-AA (54 g, 75%) as
brown syrup.
1H-NMR: (400 MHz, CDC13): 5 7.32—7.26 (m, 5H), 5.43 (d, J = 7.6 Hz, 1H), 4.70—4.46 (m,
1H), 4.45 (s, 2H), 4.13—3.91 (m, 1H), 3.73—3.70 (m, 1H), 1.44 (s, 9H).
S nthesis of -ben 13- benz 10x tert—butox carbon 1 amino ro anoate 2S-AB
To a stirring solution of 2S-AA (36 g, 122 mmol) in DMF (250 mL) was added
NazCO3 (20 g, 183 mmol) at 0 °C and added benzyl bromide (18 mL, 146 mmol) slowly. The
reaction mixture ature was warmed to RT and d for 12 h. After consumption of the
starting material (by TLC), the reaction mixture was poured into chilled water (200 mL) and
extracted with diethylether (2x 250 mL). The combined organic layers were washed with water
(3x250 mL). The organic extracts were dried over anhydrous NaQSO4, filtered and concentrated
under reduced pressure to afford 2S-AB (42 g, 91%) as brown syrup was used directly for next
step without any purification.
S nthesis 0f -ben no benz 10x r0 anoateh drochloride 2S-AC :
To a ng solution of 2S-AB (10 g, 25.9 mmol) in ether saturated with HCl
(50 mL) was added at 0 OC and stirred at RT for 12 h. The ed precipitate was filtered and
WO 20783
-57_
triturated with diethylether (2x100 mL). The d compound was dried under vacuum to
afford 2S-AC (5 g, 60%) as white solid.
1H-NMR: (400 MHz, DMSO-dg): 6 8.66 (s, 2H), 7.38—7.27 (m, 10H), 5.29-5.22 (m, 2H), 4.57-
4.44 (m, 3H), 3.91-3.81 (m, 2H)
Scheme 2S—I—8
OH OH 0
Step 1 H QB“
Step 2 Step 3
OH —> No, NI:-
N 28-AC,HATU "l DIAD, PPh3 N OB“ Pd--CIH2
o o .
Boc BOG OBn BocO Boc 0
23—1 28-AD 28-AE
284“:
S nthesis of tert—butl 2— -1 3-bis ben 10X ox0 r0 anl carbamo 1
h drox meth l rrolidine—l-carbox late 2S-AD:
To a stirring solution of compound 2S-I (5 g, 20.4 mmol) in CHzClz (50 mL)
were added DIPEA (10.7 mL, 61.2 mmol), 2S-AC (5.8 g, 20.4 mmol), HATU (11.6 g, 30.6
mmol) at 0 °C and stirred to RT for 12 h. After ption of the starting al (by TLC),
the on mixture was diluted with water (100 mL) and extracted with CHZCIZ (2 x 100 mL).
The combined organic layer was washed with citric acid (1 x 100 mL) followed by brine
solution (1 x 100 mL). The organic layer was dried over anhydrous NaZSO4, filtered and
concentrated under reduced pressure. Obtained crude material was purified by silica gel column
chromatography eluting with 50% EtOAc/n-hexane to afford compound 2S-AD (8 g, 76.5%) as
yellow thick syrup.
1H-NMR: (400 MHz, CD3OD)I 6 7.33—7.24 (m, 10H), 5.23-5.11 (m, 2H), 4.72—4.66 (m, 2H),
4.50—4.44 (m, 1H), 4.18—3.91 (m, 2H), 3.75—3.70 (m, 2H), 3.65—3.40 (m, 2H), 2.34—2.03 (m,
2H), 1.81-1.78 (m, 2H), 1.41 (s, 9H);
Mass (ESI): m/z 512.6 [M++l]
S nthesis 0f tert-bu 12- S -1 3-bis ben 10X oxo r0 an-Z- l-l-oxo-Z 5-diazas iro
|3.4| -S-carboxylate gZS-AE 2:
To a stirring solution of triphenylphosphine (640 mg, 2.44 mmol) in THF (5
mL) was added DIAD (392 mg, 1.94 mmol) at RT and stirred for 15 min, then compound 2S-
AD (500 mg, 0.97 mmol) in (5 mL) THF was slowly added and reaction mixture was stirred at
RT for 2 h. After consumption of the ng material (by TLC), the reaction was concentrated
2014/013619
.53_
under reduced pressure. The crude material was purified by column chromatography by eluting
2% MeOH/DCM to afford compound ZS-AE (450 mg, 93%) as yellow liquid.
: (400 MHz, : 5 7.34-7.27 (m, 10H), 5.25-5.14 (m, 2H), 4.78—4.73 (m, 1H),
4.70—4.42 (m, 2H), 4.04-3.98 (m, 1H), 3.93—3.78 (m, 1H), 3.89-3.78 (m, 1H), 3.76-3.68 (m,
1H), 3.45-3.35 (m, 2H), 2.20—2.09 (m, 2H), 1.90-1.78 (m, 2H), 1.46 (s, 9H)
LCMS (ESI): m/z 495.5 [M++1]
S nthesis of 1- tert-butox carbon 1 h drox meth l rrolidine-Z-carbox lic acid
gZS-AF):
To a stirring solution of nd 2S-AE (500 mg, 1.01 mmol) in methanol (25
mL) was added 50% wet 10% Pd/C (250 mg) at RT and stirred for 24 h under H2 atmosphere.
After consumption of the starting material (by TLC), the reaction mixture was filtered h
a pad of celite and the pad was washed with methanol (20 mL). Obtained filtrate was
concentrated under reduced pressure to afford compound 2S—AF (400 mg, crude) as white
solid.
1H-NMR: (400 MHz, CD3OD): 5 4.92-4.87 (m, 1H), 4.28-4.07 (m, 3H), 3.63-3.60 (m, 1H),
3.55—3.40 (m, 2H), 2.30—2.25 (m, 2H), .87 (m, 2H), 1.47 (s, 9H);
LCMS: 315.3 [M+l]
Scheme 2S-I-9
o O Cbz Cbz
H2”. O O O
((OH Step1 H2”. Step2 HN, Step3 HNI Step4 H2N,
OMe ((0% we 0M8
SOCI CbZ-CI
OH 2 OH TBDPS _
OH OTBDPS 251-12 OTBDPS
28-AG 28-AH 28-Al 28-AJ
S nthesis of -meth lZ-aminoh drox r0 anoate ZS-AG:
To a stirring solution of L-serine (40 g, 0.38 mol) in ol (300 mL) was
added SOClz (33.6 mL, 0.45 mol) drop wise at 0 °C and d for l h. The resulting reaction
mixture was refluxed for 24 h. After consumption of the starting material (by TLC), the
reaction mixture was warmed to RT and concentrated under vacuum and decanted with n-
hexane (2 x 200 mL) to afford compound 2S-AG (59.18 g, crude).
1H-NMR: (400 MHz, DMSO-dg): 6 8.62 (s, 3H), 4.08 (d, J: 3.2 Hz, 1H), 3.83 (d, J: 3.6 Hz,
2H), 3.78 (s, 3H);
LCMS, m/z: 120.2 [Mt-1]
-59_
S s of -meth 12- benz 10x carbon lamino h drox r0 anoate ZS-AH:
To a stirring solution of compound 2S-AG (40 g, 0.33 mol) in 1, 4—dioxane (300
mL) and water (100 mL) was added Na2C03 (71.18 g, 0.67 mol) and stirred at RT for 30 min.
The reaction mixture was cooled to 0 OC, benzyl chloroformate (68.5 g, 0.40mol) was added
drop wise and the stirring was continued at RT for 8 h. After consumption of the starting
material (by TLC), the reaction mixture was diluted with EtOAc (200 mL). The aqueous layer
was ted with EtOAc (2 x 200 mL). The separated organic ts were washed with
brine, dried over anhydrous NaZSO4, filtered and trated under reduced pressure. The
crude material was purified by silica gel column tography eluting with 20% EtOAc/n-
hexane to afford compound 2S-AH (53 g, 62%);
1H-NMR: (400 MHz, DMSO-dg): 5 7.49 (d, J= 8 Hz, 1H), 7.37-7.29 (m, 5H), 5.04 (s, 2 H),
4.93 (t, J: 6 Hz, 1H), 4.18—4.13 (m, 1H), 3.78 (s, 3H), 3.67—3.56 (m, 2H)
S nthesis of -meth l 2- ben 10x carbon lamino tert-but ldi hen lsil 10x
propanoate {ZS-AI):
] To a stirring solution of compound 2S—AH (20 g, 79.20 mmol) in DCM (700
mL) was added imidazole(l6g, 237.6mmol) at 0°C followed by TBDPS (25.9 g, 95.04 mmol)
under N2 atmosphere and stirred at RT for 8 h. After ption of the starting material (by
TLC), the reaction mixture was diluted with water (100 mL) and the aqueous layer was
extracted with DCM (2 x 200 mL). The separated organic layer was washed with brine, dried
over ous Na2S04 and concentrated under reduced pressure. The crude material was
purified by silica gel column chromatography eluting with 20% EtOAc/n-hexane to afford
compound ZS-AI (25 g, 64%).
1H-NMR: (500 MHZ, CDCl3): 5 7.23-7.68 (m, 1H), 7.58 (d, J: 7 Hz, 3H), 7.44-7.37 (m, 9H),
7.34 (d, J: 7.5 Hz, 2H), 5.65 (d, J: 9 Hz, 1H), 5.12 (d, J: 2, 2H), 4.45 (d, J: 9 Hz, 1H),
4.10—4.07 (m, 1H ), 3.91—3.88 (m, 1H), 3.74 (s, 3H), 1.04 (s, 9H);
LCMS (m/z): 492.1 [Mil]
S nthesis of S -meth lZ-amino tert-bu ldi hen lsil 10x r0 anoate 2S-AJ :
To a stirring solution of compound 2S—AI (25 g, 51.12 mmol) in ethanol (250
mL) was added 50% wet 10% Pd/C (15 g) at RT and stirred for 8 h under H2 atmosphere
(balloon pressure). After consumption of the ng al (by TLC), the reaction mixture
was filtered through a pad of celite and the pad was washed with ethanol. Obtained filtrate was
concentrated under reduced pressure to afford compound 2S—AJ (18 g, 97%) as yellow liquid.
_6()_
1H-NMR: (400 MHz, CD013): 5 7.66—7.61 (m, 4H), 7.43—7.36 (m, 6H), 4.00—3.97 (m, 2H),
3.74(s, 3H), 3.64 (t, J: 4 Hz, 1H), 2.65 (s, 2H), 1.04 (s, 9H);
LCMS m/z: 358 [M+—1]
Scheme 2S-I-I0
mOH OEt
Step 1 OEt
Step 2 Step 3 Step 4
O SOCIZ, EtOH fl 0
(800)20 NBOC O OEt
LiHMDS 1"! NaOH
Boc O
23-AK 23-AL 23-AM
Step 5 0
H Step 6 Step 7
OrrOH T ‘
23-DEDCI B“ DIAD PPh3 ”'OBn pd_-C/H2
Boc o
Boc .
"OBn BocO
28-AN ZS-AO 28-AP 28-AQ
S nthesis of eth l rrolidine-Z-carbox lateh drochloride ZS-AK:
To a stirring solution of L-proline (110 g, 956.5 mmol) in ethanol was added
thionyl chloride (141 ml, 1911.3 mmol) and refluxed for 16 h. The reaction mixture was
brought to RT and concentrated under vacuum to afford nd ZS-AK as the
hydrochloride salt (170 g, 99 %).
1H-NMR: (400 MHz, CDC13): 5 4.15-4.10 (m, 2H), 3.68—3.62 (m, 2H), 3.59—3.47 (m, 2H),
.37 (m, 1H), 2.27—2.05 (m, 3H), 1.18 (t, J: 3.6 Hz, 3H);
LCMS, m/z: 143 [M++1]
S nthesis of 1-tert-but lZ-eth l rrolidine—l 2-dicarb0x late ZS-AL :
To a stirring solution of compound ZS-AK (70 g, 0.391 mol) in CH2C12 (700
mL) were added Et3N (170.7 mL, 1.22 mol) followed by hydride (133 g, 0.61 mol) at 0
OC. The reaction mixture was stirred at RT for 12 h. After consumption of the starting material
(by TLC), the reaction was d with water (100 mL) and extracted with CH2C12 (2x 200
mL). The organic layer was washed with water (1 x 150 mL), brine (1 x 200 mL), dried over
NaZSO4 and concentrated under reduced pressure to afford compound ZS-AL (90 g, 90%) as
thick syrup.
1H-NMR: (400 MHz, g): 6 4.15—4.10 (m, 2H), 4.09-4.02 (m, 1H), 3.36—3.29 (m, 2H),
2.25—2.13(m, 1H), 1.87—1.76 (m, 40(s, 9H), 1.18 (t, J= 3.6 Hz, 3H);
LCMS, m/z: 144 [(M++1)-Boc];
-61—
HPLC: 96.11%
S nthesis of l-tert-but l 2-eth l 2- 1-h drox eth l rrolidine—l 2-dicarb0x late 2S-
AM):
To a stirring solution of compound 2S-AL (5 g, 20.5 mmol) in THF (50 mL)
was added LiHMDS (20.3 mL, 20.5 mmol) at —20 °C and stirred for 1 h. To this acetaldehyde
(1.2 mL, 20.5 mmol) was added se at -20 °C and stirred for 1 h at -20 °C. After
consumption of the starting al (by TLC), the reaction was quenched with aqueous NH4C1
solution and ted with EtOAc (1 x 50 mL). The separated organic layer was dried over
Na2SO4 and concentrated to afford crude compound was purified by column chromatography
eluting 10% EtOAc/hexane to afford compound 2S-AM (1.8 g, 30%) as pale yellow syrup.
1H-NMR: (500 MHz, g): 5 5.10 (d, J: 8.5 Hz, 1H), 4.54-4.36 (m, 2H), 4.05-3.99 (m,
2H), 3.60-3.49 (m, 1H), 1.97—1.74 (m, 4H), 1.40 (s, 9H), 1.18, 1.15 (dd, J= 7.5 Hz, 6.5 Hz,
3H), 0.96 (d, J= 9.5 Hz, 3H);
LCMS, m/z: 188 [(M++1)—Boc]
S nthesis of 1- tert—butox carbon 1 l-h drox eth l rrolidine—Z-carbox lic acid
jZS-AN):
To a stirring solution of compound 2S-AM (10 g, 34.8 mmol) in methanol (30
mL) were added NaOH (2.7 g, 69.6 mmol), HZO/THF (30 mL/30 mL)) at 0 °C. The reaction
mixture was heated to 80 0C for 5 h. After consumption of the starting al (by TLC), the
solvent was evaporated under reduced pressure. The aqueous layer was acidified using citric
acid solution and extracted with EtOAc (2x 100 mL). The separated organic layer was washed
with water (1 x 50 mL), dried over NaZSO4 and concentrated to afford compound 2S-AN (4.8
g, 53.3%) as brown sticky solid.
1H-NMR: (500 MHz, DMSO-dg): 6 4.60-4.54 (m, 1H), 3.98 (d, J= 10.0 Hz, 1H), 3.90—3.77
(m, 2H), 3.44—3.34 (m, 1H), 2.01—1.68 (m, 4H), 1.40 (s, 9H), 1.26 (d, J= 10.0 Hz, 3H);
LCMS, m/z: 258 (Mil);
HPLC (purity): 91.7%
S nthesis 0f tert-but l 2— 2S 3R -1 3-bis ben 10x ox0butan l carbamo l
hydroxyethyl)pyrrolidine-l-carboxylate (ZS-A0 ):
[00159] To a stirring on of nd 2S-AN (2.0 g, 7.72 mmol) in CH2C12 (50
mL) were added DIPEA (4.2 mL, 22.4 mmol), EDCI.HC1 (2.2 g, 11.5 mmol) followed by
HOBt (1.5 g, 11.5 mmol), compound D (2.8 g, 8.35 mmol) a1: 0 °C and stirred for 12 h. After
-62—
consumption of the starting material (by TLC), the reaction mixture was diluted with water (30
mL) and extracted with CHgClz (2 x 50 mL). The combined organic layer was washed with
brine (2 x 50 mL), dried over anhydrous NaZSO4, filtered and trated under reduced
pressure. ed Ciude material was purified by silica gel column chromatography eluting
% EtOAc/n—hexane to afford compound 2S-AO (1.5 g, 36%) as ess liquid.
1H-NMR: (400 MHz, g): 5 8.47 (t, J= 8.8 Hz, 1H), 7.31—7.19 (m, 10H), 5.73—5.58 (m,
1H), 5.18 (s, 2H), 4.64 (s, 2H), 4.60—4.49 (m, 1H), 4.29 (d, J: 12.0 Hz, 1H), 4.15—4.12 (m,
1H), 3.59—3.59 (m, 1H), 3.24-3.13 (m, 1H), .60 (m, 2H), 1.43—1.38 (m, 2H), 1.35 (s, 9H),
1.18 (d, J: 6.0 Hz, 3H), 1.04 (d, J: 6.4 Hz, 3H);
Mass (ESI): m/z 540 [M'-1]
S nthesis 0f tert—but l 2- 2S 3R -1 3-bis benz lox 0xobutan l h lox0-2 5-
diazaspiro|3.4|0ctane—5—carboxylate (ZS-AP):
To a stirring on of triphenylphosphine (1.45 g, 5.53 mmol) in THF (30
mL) was added DIAD (1.12 g, 5.53 mmol) at RT and stirred for 30 min. To this added
compound 2S-AO (1.5 g, 2.77 mmol) in (10 mL) THF slowly and reaction mixture was stirred
at RT for 2 h. After consumption of the starting material (by TLC), the reaction was
concentrated under reduced pressure. The crude material was purified by silica gel column
chromatography eluting 20% EtOAc/hexane to afford nd ZS-AP (800 mg, 57%) as pale
yellow syrup.
1H-NMR: (400 MHz, DMSO—dg): 5 .18 (m, 10H), 5.07 (s, 2H), 4.61 (s, 2H), 4.38—4.31
(m,1H), 3.77-3.75 (m, 1H), 3.28—3.24 (m, 1H), 2.67—2.66 (m, 1H), 2.22—2.12 (m, 1H), 1.98-1.92
(m, 3H), 1.72—1.60 (m, 1H), 1.40 (s, 9H), 1.18 (d, J= 5.6 Hz, 3H), 1.13 (d, J= 6.4 Hz, 3H)
Mass (ESI): m/z 523 [M++1]
S nthesis of 2S 3R 5- tert—butox carbon 1 meth o-2 5—diazas iro 3.4 octan-
2-y11hydroxybutanoic acid (ZS-Ag 2):
To a ng solution of compound 2S-AP (900mg) in methanol (30 mL) was
added 10% Pd/C (300 mg) at RT and stirred for 16 h under H2 atmosphere (balloon pressure).
After consumption of the starting material (by TLC), the reaction mixture was filtered through
a pad of celite and washed with methanol (10 mL). Obtained filtrate was concentrated under
reduced pressure to afford compound 2S-AQ (480 mg, 82%) as yellow thick syrup.
1H-NMR: (400 MHz, DMSO—dg): 812.80 (br s, 1H), 5.11—4.96 (m, 1H), 4.83—4.04 (m, 3H),
3.40—3.35 (m, 1H), 2.11 (s, 3H), 2.10—2.03 (m, 2H), 1.46 (s, 9H), 1.43—1.39 (m, 6H).
2014/013619
_ 63 _
LCMS: 342 [M'—1]
Scheme 2S-I-II
CE 0
Step 1 Step 2 Step 3 H Step 4
. , /N ,
O N Bee
O O 0
SOCI2 EtOH (800)20 13°C MeMgBr TFA
COOEt
28-AR 28-AS 23-AT
WOEt Step 5 wit Step 6 Wit Step 7 Step 8
N o Pd--CIH2 (BOC)2)0 LiHMDS BocO aqNaOH
BOM-Cl
28-AU 28-AV 23-AW 23-AX
m;MC; OH
Step 9 MFR-oStep 10 fiMNI-"OStep 11 Step 12
I Pd/C H2 23DEDC' Bee 0 n,D|AD PPh3 ”OB” C/H-—:
BocO Pd
’OBn
28-AY 28-AZ ZS-BA OC-zsBB
NIH..-
N ”to
| o
28-80
S nthesis of eth lS-oxo rrolidine-Z-carbox late ZS-AR:
] To a stirring solution of 5-oxopyrrolidine—2—carboxylic acid (10 g, 77.4 mmol) in
ethanol (100 mL) was added thionyl de (6.7 mL, 92.9 mmol) at 0 °C. The reaction
mixture was stirred at RT for 16 h. After consumption of the starting material (by TLC), the
solvents from the reaction mixture were removed under vacuum. The residue was diluted with
EtOAc (50 mL) and stirred over K2CO3. The organic layer was dried over anhydrous Na2804
and concentrated under reduced pressure. Obtained crude material was purified by silica gel
column chromatography to afford compound ZS—AR (9 g, 74%).
: (400 MHZ, DMSO—dg): 5 7.98 (br s, 1H), 4.16 (t, 3H), 2.37-2.30 (m, 1H), 2.15 (q,
2H), 2.03-1.97 (m, 1H), 1.22 (t, 3H);
LCMS, m/z: 157.9 [M++1]
S nthesis of 1-tert-but lZ-eth lS-oxo rrolidine-l 2-dicarb0x late ZS-AS :
To a stirring solution of compound ZS-AR (9 g, 57.3 mmol) in CHzClz (90 mL)
was added DMAP (7.0 g, 57.3 mmol) followed by Et3N (15.9 mL, 114.6 mmol) and Boc-
anhydride (36.7 mL, 171.9 mmol) at 0 OC. The reaction mixture was stirred at RT for 16 h. The
reaction mixture was d with CH2C12 (50 mL) and washed with aqueous 1N HCl solution
2014/013619
-64—
followed by brine. The separated organic layer was dried over anhydrous Na2SO4 and
concentrated under vacuum. Obtained crude material was purified by column chromatography
eluting with 50% EtOAc/Hexane to afford compound 2S—AS (12 g, 82%).
1H-NMR: (400 MHz, DMSO-dg): 5 4.61 (dd, 1H), 4.19 (q, 2H), 2.46-2.40 (m, 2H), 2.37-2.25
(m, 1H), 1.91—1.85 (m, 1H), 1.42 (s, 9H), 1.22 (t, 3H).
S nthesis of eth 12- tert-butox carbon 1 amino hexanoate 2S-AT :
To a ng on of compound 2S-AS (12 g, 46.6 mmol) in THF (120 mL)
under inert atmosphere was added MeMgBr (3M in ether) (20.2 mL, 60.6 mmol) at 0 °C and
stirred for 2 h. After consumption of the starting material (by TLC), the reaction mixture was
quenched with aqueous NH4C1 solution and the aqueous layer was ted with EtOAc (2 x
200 mL). The combined organic extracts were dried over anhydrous NagsO4 and concentrated
under reduced pressure. The crude residue obtained was purified by silica gel column
chromatography eluting with 20% EtOAc/Hexane to afford compound 2S-AT (10 g, 79%).
1H-NMR: (400 MHz, CDC13): 5 5.14 (br s, 1H), 4.23 (q, 2H), 2.62—2.47 (m, 2H), 2.17 (s, 4H),
1.91-1.82 (m, 1H), 1.45 (s, 10H), 1.26 (t, 3H).
S nthesis of eth lS-meth l rrolidine—Z-carbox late ZS-AU & ZS-AV :
To a stirring solution of compound 2S-AT (10 g, ol) in CH2C12 (100
mL) was added TFA (14.89 mL, 194.6 mmol) at 0°C. After being d for 2 h at RT, the
reaction mixture was trated under reduced pressure to get compound 2S-AU. Obtained
al was dissolved in ethanol (100 mL) and 10% Pd/C (50% wet, 3 g) under N2
atmosphere. The on mixture was stirred under H2 atmosphere (balloon pressure) for 16 h.
The reaction mixture was filtered through a pad of celite and filtrate was concentrated under
reduced pressure to afford compound 2S-AV (15 g, crude). This material was directly taken for
the next step without further purification.
LCMS, m/z: 158.1 [M++1]
S nthesis 0f 1-tert—but lZ-eth lS-meth l rrolidine—l 2-dicarb0x late 2S-AW :
To a stirring solution of compound 2S-AV (30 g, 191 mmol) in CH2C12 (150
mL) was added DMAP (23.3 g, 191 mmol) followed by Et3N (79.8 mL, 573 mmol) and Boc—
anhydride (104 mL, 477 mmol) at 0 °C. The reaction mixture was stirred at RT for 16 h. The
reaction mixture was d with CHZCIZ (50 mL) and washed with water (2x150 mL)
followed by brine. The separated c layer was dried over anhydrous Na2SO4 and
concentrated under vacuum. Obtained crude material was purified by column chromatography
2014/013619
-65—
g with 6% hexane to afford compound ZS-AW (30 g, 61.22%) as pale yellow
liquid.
1H-NMR: (500 MHZ, DMSO—d6): 5 4.13—3.86 (m, 4H), 2.15 (d, J: 3.5 Hz, 1H), 1.99—1.82 (m,
2H), 1.52 (t, J: 4.5 Hz, 1H), 1.38 (s, 9H), 1.24 (t, J= 5.5 Hz, 3H), 1.16 (d, J: 6.5 Hz, 3H).
LCMS, m/z: 258 [(M++1)
S nthesis of 1-tert-but l 2-eth l 2- benz 10x meth l meth l rrolidine-l 2-
dicarboxxlate (ZS-AX):
To a stirring on of compound ZS-AW (8.0 g, 31.12 mmol) in THF (70 mL)
was added LiHMDS (59 mL, 41.72 mmol) at —78 OC and d for 2 h. To this BOM-chloride
(6.56 mL, 41.72 mmol) was added dropwise and stirred for 2 h at —30 °C. After consumption of
the starting material (by TLC), the reaction was quenched with aqueous NH4C1 solution (20
mL) and extracted with DCM (30 mL). The separated organic layer was dried over Na2S04 and
concentrated to afford crude material was purified by column chromatography eluting with
% EtOAc/Hexane to afford compound ZS-AX (11 g, 94.2%) as pale yellow liquid.
1H-NMR: (500 MHZ, DMSO—ds): 6 7.33—7.25 (m, 5H), 4.38 (d, J: 10.5 Hz, 2H), 4.08—3.98 (m,
1H), 3.88 (d, J: 9.5 Hz, 2H), 2.20—2.08 (m, 2H), 1.38 (s, 9H), 1.37—1.29 (m, 4H), 1.19 (t, J:
7.5 Hz, 3H), 1.14-1.10 (m, 3H);
LCMS, m/z: 378 (M++1)
S nthesis of 2- meth l tert-butox carbon 1
ylic acid gZS-AY 1:
To a ng solution of compound 2S-AX (11 g, 29.17 mmol) in CH3OH/THF
(22 mL/20 mL) were added 2N NaOH solution (33 mL) at RT. The reaction e was
heated to 65 °C for 8 h. After consumption of the starting material (by TLC), the solvent from
the reaction was evaporated under reduced pressure and diluted with EtOAc (50 mL). The
aqueous layer was acidified using citric acid solution and extracted with CH2C12 (2x 100
mL).The separated organic layer was washed with water (1 X 50 mL), dried over Na2804 and
concentrated to afford compound 2S-AY (8 g, 80%).
1H-NMR: (400 MHz, g): 5 12.58 (s, 1H), 7.34—7.28 (m, 5H), 4.54—4.47 (m, 2H), 4.05—
3.87 (m, 2H), 3.70—3.62 (m, 1H), 2.28-2.08 (m, 3H), 1.46—1.37 (m, 1H), 1.28 (s, 9H);
LCMS, m/z: 350 [M++1].
Synthesis of 1-(tert-butoxycarbonyl)(hydr0xymethyl)—5-methylpyrrolidine—Z-carb0xylic
acid (ZS-AZ):
2014/013619
-66_
To a stirring solution of compound 2S-AY (8 g, 1.45 mmol) in methanol (40
mL) was added 10%Pd/C (4 g) under N2 atmosphere. The reaction mixture was stirred under
H2 atmosphere (balloon pressure) at RT for 16 h. After consumption of the starting material (by
TLC), the reaction e was filtered through a pad of celite and the pad was washed with
ol. Obtained filtrate was concentrated under reduced pressure to afford crude compound
which was triturated with n-pentane to obtained compound 2S-AZ (4.5 g, 75.2%) as white
solid.
1H-NMR: (500 MHz, DMSO—dg): 5 12.37 (br s, 1H), 4.61 (br s, 1H), 3.95—3.85 (m, 3H), 2.18—
2.06 (m, 3H), 1.44-1.41 (m, 1H), 1.38 (s, 9H), 1.09 (d, J= 6.0 Hz, 3H);
LCMS (ESI): m/z 260 [M++1]
S nthesis 0f tert-but l 2- 2S 3R -1 3-bis benz 10x 0xobutan l carbamo 1
1hydroxymethyll-S-methylpyrrolidine-l-carboxylate (ZS-BA I:
] To a stirring solution of compound 2S-AZ (3 g, 11.58 mmol) in DCM (30 mL)
were added N, N-diisopropylethylamine (6 mL, 34.7 mmol), Int D (5 g, 13.8 mmol), followed
by EDCI (2.7 g, 13.8 mmol), HOBT (1.9 g, 13.8 mmol) at 0 °C and stirred at RT for 16 h. After
consumption of the starting material (by TLC), the reaction mixture was diluted with water (20
mL). The separated organic layer was washed with ted NaHCO3 solution (1x50 mL), 2N
HCl solution (30 mL) followed by brine solution (1x40 mL). The separated organic layer was
dried over anhydrous NaZSO4 and concentrated under reduced pressure to afford crude
compound which was purified by column chromatography to obtained compound ZS-BA (2 g,
32.5%) as pale yellow liquid.
1H-NMR: (500 MHz, DMSO—dg): 5 .17 (m, 10H), 5.16—5.10 (m, 2H), 4.50 (t, J= 5.2
Hz, 2H), 4.28 (t, J= 12.0 Hz, 1H), 4.13—4.07 (m, 1H), 3.95 (s, 2H), 2.10—1.85 (m, 4H), 1.40—
1.35 (m, 1H), 1.30 (s, 9H), 1.18, 1.16 (dd, J= 6.4 Hz, 6H);
LCMS (ESI): m/z 440.3 [M++1]
S nthesis of tert-but 12- 2S 3R -1 3-bis ben 10x 0x0butan-2— th l-l-oxo-Z
-diazaspiro |3.4| octane-S-carboxylate ):
To a stirring solution of compound ZS-BA (1.0 g, 1.85 mmol) in THF (10 mL)
was added triphenylphosphine (0.935 g, 4.62 mmol) and DIAD (0.75 g, 3.70 mmol). The
reaction mixture was stirred at RT for 8 h. After consumption of the starting material (by
TLC), the reaction e was concentrated under reduced pressure. The crude material was
-67—
purified by silica gel column chromatography eluting 20% EtOAc/hexane to afford compound
2S—BB (0.8 g, 51%) as yellow liquid.
1H-NMR: (400 MHz, g): 6 .17 (m, 10H), 5.17(s, 2H), 4.79, 4.76 (dd, J: 6.0
Hz, 2H), 4.73 (s, 2H), 4.31-4.18 (m, 2H), 3.84 (t, J: 6.8 Hz, 2H), 2.12 (t, J: 6.8 Hz, 1H),
1.98—1.91 (m, 2H), 1.39 (s, 9H), 1.32, 1.25 (dd, J: 6.0 Hz, 6.4 Hz, 3H), 1.18, 1.09 (dd, J: 6.0
Hz, 6.4 Hz, 3H);
LCMS (ESI) :m/z 523.3 [M++1]
Synthesis of (2S, 3R)(5-(tert-butoxycarb0nyl)methyl0X0-2, S-diazaspiro [3.4]
octan-Z-yl)hydroxybutanoic acid (ZS-BC):
To a stirring solution of compound 2S-BB (1 g, 1.91 mmol) in methanol (20
mL) was added 10%Pd/C (400 mg) under N2 atmosphere. The reaction mixture was stirred
under H2 atmosphere (balloon pressure) at RT for 16 h. After ption of the starting
material (by TLC), the reaction mixture was d through a pad of celite and the pad was
washed with methanol. Obtained filtrate was concentrated under reduced pressure to afford
compound ZS-BC (0.80 g, crude) as white solid.
: (400 MHz, DMSO-dg): 5 12.75 (br s, 1H), 4.80—4.73 (m, 3H), 4.20—4.05 (m, 2H),
3.40, 3.36 (dd, J= 6.8 Hz, 1H), 2.21—2.13 (m, 1H), 2.06—1.99 (m, 2H), 1.53 (t, J: 6.0 Hz, 1H),
1.40 (s, 9H), 1.11, 1.10 (dd, J= 4.8 Hz, 5.2 Hz, 6H);
LCMS (ESI): m/z 343.3 [M++1]
Scheme 2S-I-12
HO HO
Step 1 Step 2 Step 3
N OEt
. N 28-DHATU
‘BOC LIHMDS, I}! f anaOH , o
CH3CHO Boco Boc ,,0Bn
ZS'AW ZS'BD
28-BE 28-BF
_>/E><;NHOOBStep 4 NIH"-
”OB“
BocO _)/f>¢O:HStep 5 DIAD PPh3 PdC/H2
ZS-BG 28-BH
S nthesis of -but l 2—eth l 2— 1-h drox eth l-S-meth l rrolidine—l 2-
dicarboxylate gZS-BD ):
.68_
To a stirring solution of compound 2S-AW (20 g, 77.8 mmol) in THF (200 mL)
was added LiHMDS (84 mL, 155 mmol) dropwise at -20 °C and stirred for 30 min. To this
acetaldehyde (8.77 mL, 155mmol) was added drop wise and stirred at RT for 3h. After
consumption of the starting material (by TLC), the reaction was quenched with s NH4Cl
solution (100 mL) and ted with DCM (2 x 150 mL). The combined organic layer was
washed with brine solution (1 x 150 mL). The separated organic layer was dried over Na2S04
and concentrated to afford crude material was purified by column chromatography eluting with
% EtOAc/Hexane to afford compound ZS-BD (16 g, 23.1%) as colorless syrup.
: (500 MHz, DMSO-ds): 8 7.33-7.25 (m, 5H),4.38 (d, J= 10.5 Hz, 2H), 4.08-3.98 (m,
1H), 3.88 (d, .1 = 9.5 Hz, 2H), 2.20-2.08 (m, 2H), 1.38 (s, 9H), 1.37—1.29 (m, 4H), 1.19 (t, .1 =
7.5 Hz, 3H), 1.14—1.10 (m, 3H);
LCMS m/z: 378 (M++1)
S nthesis of 1- utox carbon 1 1-h drox eth lmeth l rrolidine—Z-carbox lic
acid {ZS-BE):
] To a stirring solution of compound 2S-BD (15 g, 49 mmol) in EtOH/THF (10
mL/20 mL) were added NaOH (3.98 g, 99 mmol) in water (10 mL) at RT. The reaction mixture
was heated to 90 °C for 4 h. After consumption of the ng material (by TLC), the solvent
from the reaction was evaporated under reduced pressure and acidified by using citric acid
(pH~4). The aqueous layer was extracted with DCM (2 x 200 mL) and the combined organic
layer was washed with brine solution (1 x 150 mL). The separated organic layer was dried over
NazSO4 and trated to obtained crude nd, which was purified by column
chromatography eluting 40% EtOAc/n—hexane to afford compound 2S—BE (8.2 g, 60.7%) as
brown syrup.
1H-NMR: (500 MHz, DMSO—dg): 8 12.15 (br s, 2H), 4.54—4.50 (m, 1H), 4.03—4.02 (m, 1H),
2.17—1.77 (m, 3H), 1.41(s, 9H), 1.39-1.09 (m, 3H), 0.99—0.94 (m, 3H);
LCMS m/z: 272.4 [M'—1]
S nthesis of tert—bu l 2- 2S 3R -1 3-bis benz 10x ox0butan mo 1 1-
hydroxyethylQ-S-methylpyrrolidine—l-carboxylate 128-13ng
To a stirring on of compound 2S-BE (8 g, 29.3 mmol) in DCM (100 mL)
were added N, N—diisopropylethylamine (15.12 mL, 87 mmol), 2S—D (12.13 g, 40.6 mmol)
followed by HATU (16.5g, 43.5 mmol) at 0 °C and stirred at RT for 12 h. After consumption of
-69_
the starting material (by TLC), the on mixture was diluted with water (100 mL). The
separated organic layer was washed with citric acid on (1 x 75 mL) followed by brine
solution (1x100 mL). The organic layer was dried over anhydrous NaZSO4 and concentrated
under reduced pressure to afford crude nd which was purified by column
chromatography by eluting with 40% EtOAc/n-hexane to obtain compound ZS-BF (11g,
68.4%) as pale yellow liquid.
1H-NMR: (400 MHz, DMSO—dg): 5 7.31—7.19 (m, 10H), 5.14-5.06 (m, 2H), 4.59—4.48 (m, 3H),
4.31—4.26 (m, 1H), .00 (m, 2H), .89 (m, 2H), 1.41 (s, 9H), 1.39—1.35 (m, 3H), 1.28—
1.17 (m, 6H), 1.16-1.00 (m, 3H);
LCMS (ESI): 555.6 [Mt+1]
S nthesis of tert-but l 2- 2S 3R -1 3-bis benz 10x oxobutan l -1 6-dimeth o-
2,5—diazaspiroI3A |0ctane-5—carboxylate {ZS—BC):
To a stirring solution of triphenylphosphine (3.5 g, 13.5 mmol) in THF (10 mL)
was added DMD (2.72 g, 13.5 mmol) as portion-wise and stirred for 20 min at RT. To this
added compound 2S-BF (3 g, 5.4 mmol) in THF (10 mL) slowly at RT and stirred for 3 h.
After consumption of the starting material (by LCMS), the reaction mixture was concentrated
under reduced pressure. The crude material was purified by silica gel column chromatography
eluting 20% EtOAc/hexane to afford compound 2S-BG (2.5 g, 86.5%) as yellow liquid.
1H-NMR: (400 MHz, DMSO—dg):57.39—7.18 (m, 10H), 5.19—5.10(m, 2H), 4.78-4.49 (m, 3H),
4.34-4.25 (m, 2H), 3.85-3.76 (m,1H), 2.10-1.69 (m, 4H), 1.40 (s,9H), 1.35-1.26 (m, 3H), 1.18-
1.12 (m, 6H);
S nthesis of 2S 3R 5— tert—butox carbon 1 -1 6-dimeth l0xo-2 as iro 3.4
octan-Z-yl 2hydr0xybutanoic acid gZS-BH I:
To a stirring on of compound 2S—BG (2 g, 3.72 mmol) in methanol (20
mL) was added 10%dry Pd/C (200 mg) under N2 atmosphere. The on mixture was stirred
under H2 atmosphere at RT for 12 h. After consumption of the starting material (by TLC), the
reaction mixture was filtered through a pad of celite and the pad was washed with ol (10
mL). Obtained filtrate was concentrated under reduced pressure to afford nd 2S-BH
(1.8 g, 60.4%) as yellow solid.
1H-NMR: (400 MHz, DMSO-dg): 5 12.72 (br s,1H), 5.11—4.97 (m, 1H), 4.30—4.15(m,2H), 3.91—
3.76 (m, 2H), 2.18-1.90 (m,3H), 1.40 (s, 9H), 1.37—1.29 (m, 1H), 1.26-1.22(m, 3H), 1.21—1.10
(m. 6H);
_ 70 _
LCMS (ESI): 357.5 [M++l]
Scheme 2S-I-I3
Step1 BAN 3000
Mop: Step2 HN, CIH
Step 3
-,I pyrrolidine OHNQ ()CH3CO20 3 NO dioxane.HCI [42:12:42
0H OAc GAO
ZS-A ZS-Bl ZS—BJ ZS-BK
S nthesis of tert—but 1 2S 3R h drox 0xo rrolidin-l- l butan-Z- l
carbamate (ZS-BI)
To a stirring solution of compound ZS-A (13 g, 59.36 mmol) in DMF (65 mL)
was added Cl (12.5 g, 65.2 mmol) followed by HOBt (8.8 g, 65.2 mmol) at 0 °C. After
being stirred for 5 min, DIPEA (30.6 mL, 0.17 mol) followed by pyrrolidine (4.6 g, 65.2 mmol)
was added to the on mixture and ng was continued for another 16 h at RT. The
reaction mixture was washed with water and extracted with EtOAc (2x 100 mL). The organic
layer was washed with brine, dried over anhydrous Na2804 and concentrated under vacuum.
The crude was purified by column tography to afford nd ZS-BI (5 g, 31%).
1H-NMR: (400 MHz, : 55.51 (br s, 1H), 4.32 (d, 1H), 4.15-4.10 (m, 1H), 3.77-3.74 (m,
1H), 3.55-3.46 (m, 3H), 1.99-1.94 (m, 2H), 1.91—1.85 (m, 2H), 1.47 (s, 9H), 1.26 (t, 1H), 1.29
(d, 3H).
S nthesis 0f 2R 3S tert-butox carbon 1 amino oxo rrolidin-l- l butan-Z- l
acetate gZS-BJ and :
To a stirring solution of compound 2S-BI (4 g, 14.7 mmol) in CH2C12 (40 mL)
was added Et3N (5.1 mL, 36.7 mmol) followed by acetic anhydride (1.7 g, 17.6 mmol) and
catalytic amount of DMAP at 0 °C. The reaction mixture was stirred at RT for 16 h. After
consumption of the starting material (by TLC), the reaction mixture was diluted with water and
separated the organic layer. Organic layer was washed with water, dried over anhydrous
NaZSO4 and trated under reduced pressure. The crude residue obtained was purified by
silica gel column chromatography to give compound ZS-BJ. To this 1, 4—dioxane/HC1 (20 mL)
was added and stirred at RT for 2 h. The reaction mixture was concentrated under vacuum and
obtained material was washed with Et20 (2x 15 mL) to afford compound ZS-BK (3.5 g, 97%)
as HCl salt.
WO 20783
-71_
1H-NMR: (500 MHz, s) (Rotamers): 5 8.49 (br s, 3H), 8.15 (br s, 1H), 5.14—5.10 (m,
1H), 4.26—4.22 (m, 1H), 3.97-3.95 (m, 1H), 3.59 (s, 2H), 2.09 (s, 3H), 1.98 (s, 2H), 1.87-1.80
(m, 2H), 1.26 (d, 3H).
LCMS (ESI): 215.1 .
Scheme 2S-I-I4
Boo 800
O O O
fiOHHN_ Step1 JANHN, Step2
' HiNHN
OEtherH .
'2 EDCI a E
OBn OBn CI OBn
ZS-B 2S-BL ZS-BM
S nthesis 0f tert—butl 2S 3R ben 10X 0xo rrolidin-l-l butan-Z-l
carbamate ):
[00180] To a ng solution of compound 2S-B (8 g, 25.8 mmol) in DCM (80 mL)
were added N, N—diisopropylethylamine (11 mL, 87.4 mmol), pyrrolidine (2.5 mL, 35.4 mmol),
followed by EDCI (7.39 g, 38.7 mmol), HOBT (5.2 g, 38.7 mmol) at 0 °C and stirred at RT for
16 h. After consumption of the starting material (by TLC), the reaction mixture was diluted
with water (20 mL). The separated organic layer was washed with saturated NaHCO3 solution
(1x25 mL), followed by brine solution (1x30 mL). The separated organic layer was dried over
anhydrous Na2SO4 and concentrated under reduced re to afford crude compound which
was purified by column chromatography eluting 1% MeOH/DCM to obtained compound 2S-
BL (8 g, 86%) as white solid.
1H-NMR: (400 MHz, DMSO—d6): 5 7.34-7.24 (m, 5H), 6.57 (d, J= 4.0 Hz, 1H), 4.53, 4.44 (dd,
J: 12.0 Hz, 12.0 Hz, 2H), .28 (m, 1H), 3.74 (t, J= 6.0 Hz, 1H), 3.58—3.53 (m, 1H), 3.42-
3.38 (m, 1H), 3.28-3.24 (m, 2H), 1.82-1.70 (m, 4H), 1.37 (s, 9H), 1.11 (d, J: 6.4 Hz, 3H)
Mass (ESI): m/z 363.4 [M++l].
Synthesis of (2S, 3R)amino(benzyloxy)—1-(pyrrolidinyl) butan-l-one ):
To a stirring solution of compound 2S-BL (6 g, 16.52 mmol) in ether saturated
with HCl (30 mL) was added at 0 °C and stirred at RT for 2 h. After consumption of the
starting material (by TLC), the reaction mixture was concentrated under reduced pressure to
afford crude compound which was triturated with pentane (15 mL) to obtained compound 2S-
BM (4 g, 93%) as white solid.
-72_
1H—NMR: (500 MHz, DMSO—dg): 5 8.25 (s, 2H), 7.36—7.29 (m, 5H), 4.58, 4.48 (dd, J: 12.0,
11.5 Hz, 2H), 4.12 (t, J: 4.5 Hz, 1H), 3.87 (t, J: 5.5 Hz, 1H), 3.60—3.57 (m, 1H), 3.37—3.33
(m, 3H), 1.78—1.70 (m, 4H), 1.22 (d, .1: 6.5 Hz, 3H).
Mass (ESI): M++1].
Scheme 2S-I
o OCH3 0 OCH3
fifggioomN‘“ Thr-OMe A020
ZS-H NBOCOBn COB”
23—1 23-2
o OCH3
Step 3 HNL step 4 OCH3
Pd/C, H2 0 DTAD, PPh3 ...OAC
[)1 8000
—3 ZS-FNL-1
Synthesis of tert—ButylZ-((benzyloxy)methyl)(((2S,3R)—3-hydroxy—l-methoxy—1-
oxobutan-Z-yl)carbamoyl) pyrrolidine-l-carboxylate (ZS-1):
[00182] To a d on of nd ZS-H (2.0 g, 5.97 mmol) in CHzClz (10 mL)
was added DIPEA (2.6 mL, 14.92 mmol) followed by HATU (2.26 g, 5.94 mmol) at 0 °C and
stirred for 10 minutes. A solution of methyl 2-aminohydroxybutanoate hydrochloride (1 g,
.97 mmol) in CHzClz (10mL) was added to the reaction mixture at 0 °C. The resultant reaction
e was allowed to warm to RT and stirring was ued for another 3 h. The volatiles
were evaporated under reduced pressure. The obtained residue was diluted with water (25 mL)
and extracted with CHzClz (2 x 75mL). The organic layer was dried over anhydrous NaZSO4
and concentrated under reduced pressure. The crude was purified by silica gel column
chromatography eluting with 40%EtOAc/Hexane to afford nd 28-1 (1.8 g, 67%) as a
liquid.
1H-NMR: (400 MHz, DMSO—dg): 5 7.38—7.31 (m, 5H), 5.16 (br s, 1H), 4.54 (s, 2H), 4.28—4.26
(m, 1H), 4.17—4.12 (m, 1H), 3.84—3.82 (m, 1H), 3.62 (s, 3H), 3.54—3.51 (m, 1H), 2.32—2.27 (m,
4H), 1.84—1.78 (m, 2H), 1.42 (s, 9H), 1.06 (d, 3H);
LCMS m/z: 451.6 [M++1]
S nthesis of tert—Bu 1 2S 3R acet0x methox oxobutan learbamo 1
jgbengyloxflmethgl) pyrrolidine-l-carboxylate (ZS-2):
-73_
To a stirred solution of compound 2S-1 (1.0 g, 2.22 mmol) in CHzClz (15 mL)
was added Et3N (0.34 mL, 2.44 mmol) drop wise at 0 °C under inert atmosphere. To this ACZO
(0.27 mL, 2.64 mmol) ed by DMAP (50 mg, 0.40 mmol) was added at 0 oC and allowed
to stir at RT for 2 h. The reaction mixture was d with water and the aqueous layer was
extracted with CHzClz (2 x 25 mL). The combined c extracts were dried over anhydrous
Na2S04 and concentrated under reduced pressure to afford compound 2S-2 (0.8 g, 73%) as a
liquid.
1H-NMR: (400 MHz, DMSO—dg): 6 7.41—7.34 (m, 5H), 5.26—5.24 (m, 1H), 4.54 (s, 2H), 4.06—
3.97 (m, 1H), .72 (m, 1H), 3.62 (s, 3H), 3.52—3.49 (m, 1H), 2.68 (s, 6H), 2.34—2.31 (m,
1H), 1.87 (s, 3H), 1.78—1.74 (m, 2H), 1.42 (s, 6H), 1.14 (d, 3H).
Mass m/z: 493.8 [M++1]
S nthesis 0f tert—But 1 2S 3R acet0x hox -l-0xobutan lcarbamo 1
(hydroxymethyl) pyrrolidine- l-carboxylate 12S-3 2:
To a stirred solution of compound 2S-2 (0.8 g, 1.62 mmol) in EtOAc (15 mL)
was added 10% Pd—C (0.15 g) and stirred at RT for 24 h under H2 atmosphere (balloon
pressure). The reaction mixture was filtered through a celite pad and washed with EtOAc. The
filtrate was concentrated under d pressure. The crude nd was purified by silica
gel column chromatography eluting with 40% hexane to afford compound 2S-3 (0.5 g,
77%) as a liquid.
1H-NMR: (500 MHz, DMSO—dg): 8 8.16 (br s, 1H), 5.78—5.74 (m, 1H), 5.23 (d, J= 9.5 Hz,
1H), 4.64-4.58 (m, 1H), 4.03—3.98 (m, 1H), 3.61 (s, 3H), 3.52 (d, J= 10.0 Hz, 1H), 3.43 (d, J=
6.5 Hz, 1H), 2.29—2.27 (m, 1H), 1.96-1.94 (m, 4H), 1.74—1.68 (m, 2H), 1.38—1.30 (m, 9H), 1.14
(d, J= 6.5 Hz, 3H);
LCMS m/z: 403.6 [M++1]
S nthesis of tert-But 1 2S 3R acetox methox oxobutan l-l-oxo-Z 5—diaza
spiro|3.4 e-S-carboxylate gZS-FNL-l 2:
To a stirred solution of compound 2S-3 (0.35 g, 0.87mmol) in THF (15 mL) was
added PPh3 (274 mg, 1.04 mmol) at RT and stirred for 30 minutes under inert atmosphere.
Then the reaction mixture was cooled 0 °C, DTAD (0.22 g, 0.95 mmol) was added to the
reaction mixture and allowed to warm to room temperature and stirring was ued for
another 20 h. It was quenched with saturated citric acid and washed with saturated NaCl
solution and extracted with EtOAc (2 x 20mL). The combined organic extract were dried over
anhydrous Na2S04 and concentrated under reduced pressure. The obtained crude material was
-74_
purified by silica gel column tography eluting with 40% EtOAc/Hexane to afford NRX-
1076 (ZS-FNL-l) (160 mg, 48%) as a liquid.
1H-NMR: (400 MHz, DMSO—dg): 5 5.21—5.18 (m, 1H), 4.57 (d, 1H), 3.82 (d, 1H), 3.64 (d, 3H),
3.42 (d, 2H), 3.24—3.21 (m, 1H), 2.14—2.11 (m, 2H), 1.97 (s, 3H), 1.84-1.78 (m, 2H), 1.37 (s,
9H), 1.18 (d, 3H);
Mass m/z: 383.1 [M—l]
Scheme 2S-2:
WgzOI-I NH2
1'3000 Step1 Step 2 NH2 Step 3
NH4Cl 5%“!ES: [28"Ogjcm iso butyryl {I}?NW“§:'OH
EDCI chloride 0:370
ZS—L 28—FNL—2 28—FNL—3 28—FNL—5
Step 4 I zs_x2
MN0,;---OH
dN o
28—FNL—5
S nthesis 0f tert—but 12- 2S 3R amino-3—h drox butan l 0X0-2 5-
diazas iro 3.4 octane-S-carbox late 2S-FNL-2 :
] To a stirring solution of compound 2S-L (500 mg, 1.52 mmol) in CH2C12 (5 mL)
were added DIPEA (0.8 mL, 4.57 mmol), EDCI.HC1 (350 mg, 1.82 mmol) followed by HOBt
(280 mg, 1.82 mmol), NH4Cl (161 mg, 3.04 mmol) at 0 OC and stirred for 16 h at RT. After
consumption of the starting material (by TLC), the reaction e was diluted with water (10
mL) and extracted with CH2C12 (2 x 30 mL). The combined organic layer was washed with
citric acid solution (2 x 30 mL). The organic layer was dried over anhydrous Na2SO4, filtered
and concentrated under reduced pressure. ed crude material was purified by silica gel
column chromatography eluting 2% MeOH/DCM to afford compound (ZS-FNL-Z) (200 mg,
40%) as colorless liquid.
1H-NMR: (500 MHz, DMSO—dg): 5 7.53 (s, 2H), 4.59 (s, 1H), 4.02 (s, 1H), 3.77—3.70 (m, 2H),
.53 (m, 2H), 3.46-3.33 (m, 1H), .03 (m, 2H), 1.88-1.71 (m, 2H), 1.38 (s, 9H), 1.18
(d, J: 6.5 Hz, 3H);
Mass (ESI): 328.3 [M++1]
S nthesis of 2S 3R h drox l-oxo-Z 5—diazas iro 3.4 octan-Z- l butanamide 2S-
FNL-3):
To a stirring on of compound (ZS-FNL-Z) (200 mg, 0.61 mmol) in CHzClz
(5 mL) was added TFA (0.5 mL, 6.1 mmol) at 0 °C and stirred at RT for 3 h. After completion
of reaction (by TLC), the reaction mixture was concentrated under reduced pressure to obtained
crude nd which was triturated with n—pentane/diethylether (5 mL/5 mL) to afford
compound (2S-FNL-3) (100 mg) as white solid (TFA salt).
: (400 MHz, D20): 5 4.33-4.29 (m, 2H), 4.09 (d, 1H), 3.95 (d, 1H), 3.57—3.48 (m,
2H), 2.51-2.46 (m, 2H), 2.25-2.19 (m, 2H), 1.31 (d, 3H);
LCMS, m/z: 455 [2M++1]
S nthesis of 2S 3R h drox 5-isobut r l-l-oxo-Z 5-diazas iro 3.4 octan-Z- l
butanamide 12S-FNL-4 ):
To a stirring on of (2S-FNL-3) (500 mg ), 2.20 mmol) in CHZCIZ
(10 mL) was added TEA (1 mL, 7.70 mmol) followed by SM3 (256 mg, 2.42 mmol) at 0 OC
and stirred for 16 h at RT. After consumption of the ng material (by TLC), the reaction
mixture was diluted with water (10 mL) and extracted with CHzClz (2 x 30 mL). The combined
organic layer was washed with citric acid solution (2 x 30 mL). The organic layer was dried
over anhydrous Na2S04, ed and concentrated under reduced pressure. Obtained crude
material was purified by silica gel column chromatography eluting 2% MeOH/DCM to afford
(ZS-FNL-4) (100 mg, 15.2%) as white solid.
1H-NMR: (500 MHz, D20): 5 .52 (m, 1H), 4.41-4.37 (m, 1H), 4.27 (d, J= 3.6 Hz, 1H ),
4.04 (t, J: 6.5 Hz, 1H), 3.85—3.72 (m, 1H), 3.71—3.66 (m, 1H), 2.92-2.87 (m, 1H), 2.38—2.27
(m, 2H), 2.12—2.05 (m, 2H), 1.30 (d, J= 6.5 Hz, 3H), 1.14 (d, J= 6.5 Hz, 6H);
Mass (ESI): 298.3 [M++l]
S nthesis of 2S 3R 5— 1-benz l-S-meth l-1H-1 2 3-triazole-4—carbon lox0—2 5-
diazas iro 3.4 octan-Z- lh drox butanamide 2S-FNL-5 :
To a stirring solution of 2S-X2 (200 mg, 0.92 mmol) in CHZCIZ (10 mL), DMF
(0.1 mL) were added oxalyl chloride (0.16 mL, 1.84 mmol) at 0 OC. The reaction mixture was
warmed to RT and stirred for 2 h. The volatiles were evaporated under reduced pressure in
presence ofN2 atmosphere to afford acid de (300 mg, crude). To a stirred solution of acid
chloride (300 mg, crude) in DCM (5 mL) was added (2S-FNL-3) (220 mg, 0.92 mmol), N, N-
-76_
diisopropylethylamine (0.53 mL, 2.76 mmol) at 0 °C. The resulting reaction mixture was
stirred at RT for 1 h. After consumption of the starting material (by TLC), the reaction mixture
was diluted with water (10 mL) and extracted with CHzClz (2 x 20 mL). Combined organic
ts were washed by brine solution (2 x 10 mL) and dried over anhydrous Na2S04
trated under reduced re to obtain crude product, which was purified by silica gel
column chromatography eluting with 3% MeOH/CHZCIZ to afford compound (2S—FNL-5) (200
mg, 48.6%) as pale brown solid.
1H-NMR: (500 MHz, DMSO—ds): 5 7.77 (s, 2H), 7.38-7.31 (m, 3H), 7.18 (d, J= 7.5 Hz, 2H),
.65 (s, 2H), 4.89 (d, J= 5.5 Hz, 1H), 4.76 (d, J= 4.0 Hz, 1H), 4.07-3.91 (m, 4H), .48
(m, 1H), 2.39 (s, 3H), 2.26—2.12 (m, 2H), 1.98—1.91 (m, 2H), 1.13 (d, J= 6.5 Hz, 3H);
LCMS m/z: 427.6 [M++1];
HPLC: 95.5% (both enantiomers)
Scheme 2S-2:
HOOBn HOBnO HOH 0
Step— 1 Step——2 N,“ Step—3 N,
OCH3 —> N OCH3 OCH3
Thr(OMe) EDCI B000 l O Pd/C H2
2:0H "'0 BOO "OAc "OAc
%N:OCH3;Step--5 O
Step-4 N Step——6 NH:
MeOH.NH3
DTAD, PPh3
Boo‘ (fiNO m”
Boo {:1 NH2
.HCIO
ZS-FNL—6 28—FNL—7
S nthesis oftert-but 12- benz lox meth 1 2S 3R h drox methox
oxobutan-Z- lcarbamo l rrolidine—l-carbox late 2S-4 :
To a stirring solution of nd 2S-H (50 g, 0.15 mol) in CHzClz (500 mL)
was added methyl 2-aminohydroxybutanoate (23.8 g, 0.18 mol), EDCIHCI (34.2 g, 0.18
mol) followed by HOBt (24.1 g, 0.18 mol) and DIPEA (57.8 g, 0.45 mol) at RT and stirred for
2 h. After consumption of the starting material (by TLC), the reaction mixture was diluted with
water (250 mL) and extracted with CHZCIZ (2 x 250 mL). The separated organic layers were
washed with water, brine, dried over anhydrous NaZSO4, filtered and concentrated under
reduced pressure. Obtained crude material was purified by silica gel column chromatography
g with 50% Hexane to afford nd 2S-4 (53 g, 78.9%) as light green liquid.
-77_
To a stirring solution of compound 2S-4 (15 g, 33.3 mmol) in CHgClz (150 mL)
was added DIPEA (6.4 g, 49.9 mmol) followed by acetic ide (4 g, 39.9 mmol) and
DMAP (408 mg, 3.33 mmol) at RT and d for 2 h. After consumption of the starting
material (by TLC), the reaction mixture was diluted with water (100 mL) and extracted with
CHgClz (2 x 100 mL). The separated organic layer was washed with brine, dried over
anhydrous NaZSO4, filtered and concentrated under reduced pressure to afford compound 2S-5
(16 g, crude) as light brown liquid.
1H-NMR: (400 MHZ, CDC13): 5 7.35 (d, 5H), 5.47—5.44 (m, 1H), 4.80 (dd, 1H), 4.64—4.61 (m,
2H), 4.15-4.11 (m, 1H), 3.86-3.83 (m, 1H), 3.75 (s, 4H), 3.54-3.50 (m, 2H), 2.42-3.38 (m, 1H),
1.91—1.85 (m, 5H), 1.45—1.41 (m, 10H), 1.27 (d, 2H);
LCMS (ESI): 492 [M+]
S nthesis of ut l 2- 2S 3R acet0x h0x 0xobutan lcarbamo 1
1hydroxymethyl{pyrrolidine-l-carboxylate (ZS-62:
To a stirring solution of compound 2S-5 (16 g, 32.5 mmol) in methanol (100
mL) and EtOAc (100 mL) was added 10% Pd on Charcoal (3 g) at RT and stirred for 4 h under
H2 atmosphere (balloon pressure). After consumption of the starting material (by TLC), the
reaction mixture was filtered through a pad of celite and the pad was washed with methanol.
Obtained te was concentrated under reduced pressure to afford compound 2S-6 (10 g,
crude) as brown thick syrup. This material was directly used for the next step without further
purification.
S nthesis of Z -tert—but l 2- l-methox buten l-l-oxo-Z 5-diazas iro 3.4
octane-S-carboxylate :
[00193] To a stirring solution of compound 2S-6 (10 g, 24.8 mmol) in THF (50 mL) was
added triphenylphosphine (13 g, 49.7 mmol) and DTAD (11.15 g, 37.3 mmol). The reaction
e was stirred at RT for 16 h. After consumption of the starting material (by TLC), the
reaction was concentrated under d re. The crude material was purified by silica gel
column chromatography eluting with 40% EtOAc/hexane to afford compound 2S-7 (2 g,
24.8%).
S nthesis of tert—but 12- 1 3—diamin0-l-0xobutan l-l-oxo-Z 5-diazas iro 3.4 octane-
oxylate gZS-FNL-6 2:
.73_
A solution of compound 28-7 (2 g, 6.16 mmol) in methanolc.NH3 (50 mL) was
stirred at RT for 4 h. After consumption of the starting material (by TLC), the reaction mixture
was concentrated under reduced pressure. ed crude material was washed with EtZO (25
mL) and n—pentane (25 mL) to afford (ZS-FNL-6) (0.35 g, 16.6%) as white solid.
1H—NMR: (500 MHz, DMSO-dg): 5 7.70 (br s, 1H), 7.07 (s, 1H), 3.85 (d, 1H), 3.73 (d, 1H),
.38 (m, 2H), 3.29-3.25 (m, 1H), 3.12—3.07 (m, 1H), 2.09 (t, 2H), 1.95 (br s, 1H), 1.84—
1.81 (m, 2H), 1.93 (s, 9H), 1.12 (d, 1H), 0.99 (d, 2H);
LCMS (ESI) m/z: 327.3 [M++1]
S nthesis 0f 3-amin0 l-oxo-Z 5-diazas iro 3.4 octan-Z- l butanamide ZS-FNL-7 :
[00195] To a ng solution of (ZS-FNL-6) (0.25 g, 0.76 mmol) in CHzClz (10 mL)
was added ether.HCl (5 mL) at RT and d for 4 h. To this was added 1, ane-HC1 (5
mL) and stirring was continued for 2 h. After consumption of starting material (by TLC), the
solvent from the reaction was d under reduced pressure and obtained crude material was
washed with ACN (25 mL) and EtZO (25 mL) to afford (ZS-FNL-7) (0.11 g, 63.5%) as an off-
white solid.
1H-NMR: (400 MHz, D20): 5 4.69—4.55 (m, 1H), 4.12—3.86 (m, 3H), 3.62—3.51 (m, 2H), 2.56—
2.23 (m, 2H), 2.25—2.21 (m, 2H), .43 (m, 3H).
LCMS (ESI) m/z: 227.2 [M++1];
UPLC (Purity): 97.96%
SchemeZS—3:
0t??? 0
Step 1 NHJ\
In ). Step 2 NH\)\
NI- NI“ —> m).I-
BocO BocO O
28-L 28-8 28-FNL-8
5-diazas iro 3.4 octane-S-carbox late 28-8:
To a stirring solution of compound 2S-L (300 mg, 0.91 mmol) in CH2C12 (10
mL) were added DIPEA (354 mg, 2.74 mmol), EDCI.HC1 (210 mg, 1.09 mmol) followed by
HOBt (165 mg, 1.09 mmol), isobutylamine (80 mg, 1.09 mmol) at 0 °C and stirred for 16 h at
RT. After consumption of the ng material (by TLC), the reaction mixture was diluted with
water (10 mL) and extracted with CHzClz (2 x 30 mL). The combined organic layer was
-79_
washed with brine (2 x 30 mL), dried over anhydrous Na2SO4, filtered and concentrated under
reduced pressure. ed crude al was purified by silica gel column chromatography
g 2% MeOH/DCM to afford compound ZS-8 (250 mg, 71.5 %) as white solid.
1H-NMR: (400 MHz, DMSO-dg): 5 8.02 (t, J: 5.2 Hz, 1H), 4.37 (s, 2H), 4.04 (t, J= 5.6 Hz,
1H), 4.00 (d, J= 5.6 Hz, 1H), 3.77-3.72 (m, 1H), 3.61 (d, J: 6.0 Hz, 1H), 3.44—3.38 (m,1H),
2.98-2.84 (m, 3H), 2.19—2.08 (m, 3H), 1.84—1.79 (m, 1H), 1.42 (s, 9H), 1.39 (d, J: 5.5 Hz, 3H),
0.84 (d, J: 6.4 Hz, 6H);
Mass (ESI): m/z 384.4 [M++1]
S nthesis of 2S 3R h drox but 1 l-oxo-Z 5—diazas iro 3.4 octan-Z- l
butanamide gZS-FNL-S):
To a ng solution of compound 2S-8 (250 mg, 0.65 mmol) in CH2C12 (5 mL)
was added TFA (0.6 mL, 6.52 mmol) at 0 °C and stirred at RT for 3 h. After completion of
reaction (by TLC), the reaction mixture was trated under reduced pressure to obtained
crude compound which was triturated with n-pentane/diethylether (3 x 5 mL) to afford (2S-
FNL-8) (125 mg, 67.9 %) as an white solid (TFA salt).
1H-NMR: (500 MHz, D20): 5 4.26 (s, 2H), 4.09 (t, J: 8.0 Hz, 1H), 3.95 (t, J: 7.5 Hz, 1H),
3.56-3.51 (m, 2H), 3.14—3.06 (m, 2H), 2.50—2.43 (m, 2H), 2.25-2.21 (m, 2H), 1.85—1.82 (m,
1H), 1.30 (d, J: 5.5 Hz, 3H), 0.96 (d, J: 7.0 Hz, 6H);
Mass (ESI): m/z 284.3 [M++1]
Scheme 2S-4:
0 -33 0
0“ NH N“
Step 1 Step 2 J3
N' " N' "
1:1 -nOH cyclobutyl N «OH
3000 amine BocO H
ZS-L 28—FNL-9
S nthesis 0f ut 12- 2S 3R c clobu lmeth 1 amino h drox 0X0butan
loxo-2 5—diazas iro 3.4 octane-S-carbox late 2S-9:
To a stirring solution of compound 2S-L (500 mg, 1.52 mmol) in CHZClz (10
mL) were added DIPEA (0.8 mL, 4.57 mmol), EDCIHCl (350 mg, 1.82 mmol) followed by
HOBt (280 mg, 1.82 mmol), cyclobutylamine (155 mg, 1.82 mmol) at 0 OC and stirred for 16 h
at RT. After consumption of the starting material (by TLC), the reaction mixture was diluted
with water (10 mL) and the separated organic layer was washed with citric acid (2 x 20 mL),
-80—
brine (2 x 20 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered
and concentrated under reduced pressure. Obtained crude material was purified by silica gel
column chromatography eluting 80% EtOAc/n—hexane to afford nd 2S-9 (250 mg, 41.5
%) as colorless syrup.
1H-NMR: (500 MHz, DMSO—dg): 5 8.20 (t, J: 11.5 Hz, 1H), 4.53 (s, 2H), 4.03 (t, J: 7.5 Hz,
1H), 3.88 (t, J: 8.5 Hz, 2H), .33 (m, 2H), 3.32-3.24 (m, 2H), 2.41—2.33 (m, 3H), 2.32—
2.27 (m, 2H), 2.24—2.17 (m, 2H), 2.10—1.90 (m, 2H), 1.68 (t, J: 8.5 Hz, 2H), 1.40 (s, 9H), 1.18
(d, J: 6.4 Hz, 3H);
Mass (ESI): m/z 396.4 [M++l]
S nthesis of 2S 3R -N— c clobu lmeth l h drox l-oxo-Z as iro 3.4 octan-
2-yl) mide (ZS-FNL-91:
To a stirring solution of compound 2S-9 (250 mg, 0.63 mmol) in CHzClz (5 mL)
was added TFA (0.5 mL, 5.06 mmol) at 0 °C and stirred at RT for 3 h. After completion of
reaction (by TLC), the reaction mixture was concentrated under reduced pressure to obtained
crude nd which was triturated with diethylether (5 mL) to afford (2S-FNL-9) (90 mg,
48.3%) as hygroscopic white solid (TFA salt).
1H-NMR: (500 MHz,DZO): 5 4.23 (s, 2H), 4.08 (t, J= 7.0 Hz, 1H), 3.94 (t, J= 8.5 Hz, 1H),
3.56—3.51 (m, 2H), 3.32—3.24 (m, 2H), 2.56—2.53 (m, 3H), .43 (m, 2H), 2.25—2.21 (m,
2H), 2.07-1.88 (m, 2H), 1.71 (t, J= 8.5 Hz, 2H), 1.28 (d, J= 6.4 Hz, 3H);
Mass (ESI): m/z 296.3 [M++1];
Scheme 2S-5:
O O O
m Step 1 NH NH
Step 2
NI I - —> NI .. <:> _> Q?NI .. ...0H BnNHz m --IOH TFA -I|OHLC)
’ H
Boc o Boc o o
.TFA
ZS-L 23-FNL-10 ZS-FNL-11
Step4 l isobutyryl
chloride
0 0
NH NH
&, N... N...
AcCI 3: "'OHLC} N «OH\_©
O 00
ZS-FNL-12
ZS-FNL-13
-81—
S nthesis of tert-but l 2- 2S 3R benz lamino h drox 0x0butan l0x0-2
-diazaspir0 |3.4| octane-S-carboxylate [2S-FNL-10]:
To a stirring solution of compound 2S—L (1 g, 3.04 mmol) in CHgClz (15 mL)
were added DIPEA (1.6 mL, 9.14 mmol), EDCI.HCl (700 mg, 3.66 mmol) followed by HOBT
(560 mg, 3.66 mmol), benzylamine (325 mg, 3.04 mmol) at 0 °C and stirred for 16 h at RT.
After consumption of the starting material (by TLC), the reaction mixture was diluted with
water (20 mL) and extracted with CH2C12 (2 x 30 mL). The combined organic layer was
washed with citric acid solution (2 x 30 mL) and organic layer was dried over anhydrous
NaQSO4, filtered and concentrated under reduced pressure. Obtained crude material was
purified by silica gel column chromatography eluting 5% MeOH/DCM to afford (2S-FNL—10)
(800 mg, 63.5 %) as white solid.
: (400 MHz, CD30D): 5 7.38—7.20 (m, 5H), 4.62—4.60 (m, 1H), 4.49—4.43 (m, 2H),
4.33-4.25 (m, 1H), 4.04 (d, J= 5.6 Hz, 1H), 3.96-3.92 (m, 1H), 3.51-3.45 (m, 1H), .31
(m, 1H), .21 (m, 2H), 1.98—1.86 (m, 2H), 1.39 (s, 9H), .22 (m, 3H);
Mass (ESI): m/z 418.4 [M++l];
HPLC:91.8% (both isomers)
S s of 2S 3R -N-benz lh drox l-oxo-2 5-diazas iro 3.4 octan l
butanamide [2S-FNL-11]:
To a ng solution of (2S-FNL—10) (700 mg, 1.67 mmol) in CHzClz (10 mL)
was added TFA (1.9 mL, 16.7 mmol) at 0 °C and d at RT for 4 h. After completion of
reaction (by TLC), the reaction mixture was trated under reduced pressure to obtained
crude nd which was triturated with n-pentane/diethylether (5 mL/5 mL) to afford (2S-
FNL-l 1) (400 mg, 75.6 %) as an white solid (TFA salt).
1H-NMR: (400 MHz, D20): 5 .34 (m, 5H), 4.45 (s, 2H), 4.29-4.21 (m, 2H), 4.06—3.85
(m, 2H), 3.52—3.47 (m, 2H), 2.45—2.35 (m, 2H), 2.22—2.16 (m, 2H), 1.24—1.20 (m, 3H);
Mass (ESI): m/z 318.4 [M++l];
HPLC: 891% (both isomers).
S nthesis of 2S 3R —2— S—acctvl—l—oxo—Z S—diazas iro
hydroxybutanamide [2S-FNL-12 [:
[00202] To a stirring solution of (2S-FNL—11) (240 mg, 0.75 mmol) in CHzClz (10 mL)
were added TEA (0.31 mL, 2.25 mmol) at RT. After added acetyl chloride (0.1 mL, 0.9 mmol)
slowly at 0 oC and stirred to RT for 2 h. After consumption of the starting material (by TLC),
WO 20783
-82—
the reaction mixture was diluted with water (5 mL) and extracted with CHZClz (2 x 20 mL).
The combined organic layer was washed with citric acid solution (1 x 20 mL), brine (l x 20
mL). The separated organic layer was dried over anhydrous NazSO4, filtered and concentrated
under reduced pressure. ed crude material was d by silica gel column
chromatography eluting with 2% MeOH/DCM to afford (2S-FNL-12) (90 mg, 33.4%) as an
off-white solid.
1H-NMR: (400 MHz, CD30D): 5 7.32-7.20 (m, 5H), 4.58-4.55 (m, 1H), 4.52—4.42 (m, 2H),
4.36—4.22 (m, 1H), 4.08—3.93 (m, 1H), .65 (m, 2H), 3.64—3.53 (m, 2H), .22 (m,
2H), 2.20 (s, 3H), 2.04—1.95 (m, 2H), .20 (m, 3H);
Mass (ESI): m/z 360.3 [M++1];
HPLC:97.5% (both isomers)
S nthesis of 2S 3R -N-ben lh drox 5—isobu r l-l-oxo-Z S-diazas iro 3.4
octan-Z-yl! butanamide 1NRX-2563! gZS-FNL-l3 2:
To a stirring solution of (ZS-FNL-ll) (244 mg, 0.76 mmol) in CHzClz (10 mL)
was added TEA (0.37 mL, 2.66 mmol) at 0 °C. After added Int-F (89 mg, 0.84 mmol) and
stirred at RT for 2 h. After completion of reaction (by TLC), the reaction mixture was diluted
with water (10 mL) and extracted with CHzClz (2 x 20 mL). The combined organic layer was
washed with citric acid on (2 x 30 mL) and c layer was dried over anhydrous
Na2SO4, filtered and concentrated under reduced pressure. Obtained crude material was
purified by silica gel column chromatography eluting 60% EtOAc/n—hexane to afford (2S-
FNL-13) (150 mg, 51 %) as an off—white solid.
1H-NMR: (400 MHz, CD30D): 5 7.35—7.20 (m, 5H), 4.82—4.49 (m, 1H), 4.46—4.31 (m, 1H),
4.29-4.03 (m, 1H), 3.90—3.70 (m, 2H), 3.69—3.57 (m, 2H), 3.46-3.31 (m, 1H), 2.77—2.73 (m,
1H), 2.28—2.21 (m, 2H), 2.06—1.97 (m, 2H), 1.22 (d, J: 6.8 Hz, 3H), 1.08—0.98 (m, 6H);
Mass (ESI): m/z 388.4 [M++l];
HPLC: 95.2% (both isomers)
2014/013619
-83_
Scheme 2S-6:
OH E0}? §:0H—>ZS-Q, HATU g;Step1 NH
Boc 0
B00 0
ZS-L 28-FNL-14
S nthesis 0f ut 12- 2S 3R 1 2 4—0xadiazol—5-
oxobutan-Z- l-l-oxo-Z 5-diazas iro 3.4 octane-S-carbox late -14:
To a stirring solution of compound 2S-L (600 mg, 1.82 mmol) in DMF (10 mL)
were added DIPEA (708 mg, 5.48 mmol), ZS-Q (290 mg, 1.82 mmol) HATU (761 mg, 2.00
mmol) at 0 °C and stirred for 16 h at RT. After consumption of the ng material (by TLC),
the reaction mixture was diluted with water (50 mL) and EtOAc (100 mL). The organic layer
was washed with water (2 x 50 mL) followed by brine solution (2 X 30 mL). The organic layer
was dried over anhydrous NaZSO4, filtered and concentrated under reduced re. Obtained
crude material was purified by silica gel column chromatography eluting 2% MeOH/DCM. The
obtained solid was triturated with ether/n-pentane (5 mL/5 mL) to afford (2S-FNL-14) (100
mg, 13.5 %) as white solid.
1H-NMR: (400 MHz, CD30D): 5 8.61 (s, 1H), 4.85 (s, 2H), 4.78—4.63 (m, 1H), 4.59—4.55 (m,
1H), 4.30—4.25 (m, 1H), 3.52—3.46 (m, 2H), 3.43—3.29 (m, 1H), 2.31—2.23 (m, 2H), 1.96-1.88
(m, 2H), 1.45 (s, 9H), 1.26—1.20 (m, 3H);
Mass (ESI): m/z 410.4 [M++1];
HPLC:98. 14% (both isomers)
Scheme 2S- 7:
o ,N
OH N1)
Step1 NH N‘
0 \>
Step-2
N“. NH\)\O
N NI:-
"IOH 28-UBOP TFA
13000 N
BocO “CH
,Tfl O
ZS-L 28-FNL-15
28-FNL-16
To a stirring solution of compound 2S—L (1 g, 3.04 mmol) in DMF (10 mL)
were added DIPEA (1.58 mL, 9.12 mmol), BOP reagent (2.01 g, 4.56 mmol) followed by 2S-U
(496 mg, 3.64 mmol) at 0 °C and stirred for 16 h at RT. After consumption of the starting
.84_
material (by TLC), the reaction mixture was diluted with water (100 mL) and extracted with
EtOAc (2 x 30 mL). The combined organic layer was washed with brine solution (2 x 50 mL)
and organic layer was dried over anhydrous Na2S04, filtered and concentrated under reduced
pressure. Obtained crude material was purified by silica gel column chromatography eluting
80% EtOAc/n-hexane followed by preparative HPLC purification to afford (2S-FNL-15) (67
mg, 5.4 %) as an off-white solid.
: (400 MHz, DMSO—d6): 6 10.92 (s, 1H), 7.83 (s, 1H), 4.97—4.88 (m, 2H), 4.07 (d, J=
7.2 Hz, 2H), 3.83—3.65 (m, 2H), 3.57—3.40 (m, 1H), .25 (m, 2H), .01 (m, 2H), 1.83—
1.80 (m, 2H), 1.40 (s, 9H), 1.22 (d, J: 6.4 Hz, 3H)
Mass (ESI): m/z 410.4 [M++1];
HPLC:90.6%
S nthesis of 2S 3R -N- 1 3 4-0xadiazol—2- l meth l h drox 1-0x0—2 5-
diazaspiro |3.4| octan-Z-yl) butanamide L-161:
To a stirring solution of compound (2S-FNL-15) (70 mg, 0.71 mmol) in CHzClz
(5 mL) was added TFA (195 mg, 1.71 mmol) at 0 °C and d at RT for 1 h. After
completion of reaction (by TLC), the reaction mixture was concentrated under reduced pressure
to obtained crude nd which was triturated with n—pentane/diethylether (5 mL/5 mL) to
afford compound (ZS-FNL-l6) (60 mg, 84.5%) as an off—white solid (TFA salt).
1H-NMR: (400 MHz,, D20): 5 7.83 (s, 1H), 5.20-5.10 (m, 1H), 4.80 (s, 1H), 4.39-4.30 (m, 2H),
4.13-4.04 (m, 2H), 3.53—3.48 (m, 2H), 2.44-2.41 (m, 2H), 2.21—2.16 (m, 2H), 1.31 (d, J: 6.4
Hz, 3H); Mass (ESI): m/Z 310.1 [M++1];
HPLC: 90.99%
Scheme 2S-8:
OBn I§:OBnStep-2 WNIII§OBn Step-3
N "'03”
.lOBn AC???“ ..OBn Acetyl A00 Pd-C/H2
BocO Chloride
ZS-K 28-10 28-11
OH / Q)
NH N
N... Step-4
—> NII'
N "'OH
Int-F, EDCI N ”10H
28-12 28-FNL-17
-35_
S nthesis of hen 1 2S 3R ben 10x l-oxo-Z 5—diazas iro 3.4 octan-Z-l
butanoate 18):
To a stirring solution of compound 2S-K (800 mg, 1.57 mmol) in DCM (10 mL)
was added TFA (1.2 mL) at 0 OC and stirred at RT for 2 h. After consumption of the starting
material (by TLC), the reaction mixture was concentrated under reduced pressure to afford
compound 2S-10 (500 mg, 78%) as an off—white solid (HCl salt) was used directly for next
step.
1H-NMR: (500 MHz, D20): 5 7.48 (m, 5H), 7.24-7.21 (m, 5H), 5.29 (s, 2H), 4.96 (s, 2H),
4.80-4.62 (m, 1H), 4.29-4.18 (m, 2H), 4.01-3.89 (m, 1H), 3.52-3.46 (m, 2H), 2.43-2.38 (m,
2H), 2.24—2.14 (m, 2H), 1.35—1.28 (m, 3H);
LCMS: 408 [M++1]
jbenzyloxy) butanoate (ZS-11 1:
] To a stirring solution of compound 2S-10 (500 mg, 1.22 mmol) in DCM (5 mL)
was added TEA (0.46 mL, 3.36 mmol) followed by acetyl chloride (0.1 mL, 1.47 mmol) at 0
°C and stirred at RT for 2 h. After consumption of the starting material (by TLC), reaction
mixture was d with water (10 mL). The organic layer was dried over ous Na2SO4,
filtered and concentrated under reduced re. Obtained crude material was purified by
silica gel column chromatography eluting 2% MeOH/DCM to afford compound 2S-11 (300
mg, 54.5 %) as white solid.
1H-NMR: (400 MHZ, CD30D): 7.36-7.29 (m, 5H), .16 (m, 5H), 5.13 (s, 2H), 4.59 (s,
2H), 4.32-4.29 (m, 2H), 4.16—4.13 (m, 1H), 3.65—3.61 (m, 1H), 3.60-3.46 (m, 2H), 2.21—2.09
(m, 2H), 2.02 (s, 3H), 2.01—1.91 (m, 2H), 1.21 (d, J: 6.4 Hz, 3H);
LCMS: 451.3 [M++1]
S nthesis of 2S 3R 5-acet l-l-oxo-Z S-diazas iro 3.4 octan-Z- lh drox butanoic
acid 1:
To a stirring solution of compound 2S-11 (1 g, 2.22 mmol) in ol (30 mL)
was added 10% Pd/C (500 mg) at RT and stirred for 24 h under H2 atmosphere. After
consumption of the ng al (by TLC), the reaction mixture was filtered through a pad
of celite and the pad was washed with methanol (20 mL). Obtained filtrate was concentrated
under reduced pressure to afford compound 2S—12 (500 mg, 83.3%) as an off—white solid.
.86_
1H-NMR: (400 MHz, CD30D): 5 4.35—4.30 (m, 1H), 4.29—4.17 (m, 1H), 4.09—4.04 (m, 1H),
3.76—3.67 (m, 1H), 3.59—3.48 (m, 1H), 3.34—3.31 (m, 1H), 2.29—2.24 (m, 2H), 2.15 (s, 3H), 2.04—
1.96 (m, 2H), 1.28 (d, J: 6.4 Hz, 3H);
LCMS m/z: 270.4 [M++1]
S s of 2S 3R 5-acet l-l-oxo-Z 5—diazas iro 3.4 octan-Z- lh drox -N-
rimidin-Z- lmeth l butanamide 2S-FNL-17 :
] To a stirring solution of compound 2S-12 (700 mg, 2.59 mmol) in DCM (15
mL) were added DIPEA (1.35 mL, 7.77 mmol), ZS-Y (410 mg, 2.84 mmol), EDCI (593 mg,
3.1 mmol) followed by HOBT (474 mg, 3.1 mmol) at 0 °C and stirred for 16 h at RT. After
consumption of the starting al (by TLC), the reaction mixture was diluted with water (40
mL). The organic layer was dried over anhydrous , filtered and concentrated under
reduced pressure. Obtained crude material was purified by silica gel column chromatography
eluting 3% MeOH/DCM to afford (2S-FNL-17) (100 mg, 10.7 %) as white solid.
1H-NMR: (400 MHz, D20): 5 8.78 (d, J= 5.2 Hz, 2H), 7.49 (t, J= 5.2 Hz, 1H), 4.79 (s, 2H),
4.55-4.47 (m, 1H), 4.40—4.37 (m, 2H), 3.79—3.56 (m, 3H), 2.37-2.26 (m, 2H), 2.14—2.03 (m,
2H), 2.01 (s, 3H), 1.28 (d, J: 6.4 Hz, 3H);
Mass (ESI): m/z 362.4 [M++1];
HPLC: 92.3% (both isomers)
SchemeZS—9:
o o 0
OH NH N— NH N_
Don- —"» Dow- %Ste 1 —"» Dou- H9Ste 2
1“ "'OH
28-Y,EDC| 5“ "'OH N
TFA fl "'OH N
Boc O Boc O TFAO
ZS-L 28—FNL-18 28-FNL-19
NH N_
Step 3 N"' \—<\ :/>
E N ---OH N
Isobu yryt l
chloride 0: O
28-FNL-20
S nthesis 0f tert-bu l 2- 2S 3R h drox n-Z- lmeth 1 amino
butan-Z- l-l-oxo-Z 5-diazas iro 3.4 octane-S-carbox late 2S-FNL-18:
2014/013619
.37_
To a stirring solution of compound 2S-L (1 g, 3.04 mmol) in CHzClz (30 mL)
were added DIPEA (1.63 mL, 9.14 mmol), EDCI.HC1 (696 mg, 3.64 mmol) ed by
HOBT (558 mg, 3.64 mmol), ZS-Y (241 mg, 3.34 mmol) at 0 °C and d for 16 h at RT.
After consumption of the starting material (by TLC), the on mixture was diluted with
water (30 mL). The organic layer was washed with citric acid solution (2 x 30 mL) followed
by brine solution (2 x 25 mL). The organic layer was dried over anhydrous NaZSO4, filtered and
trated under reduced pressure. Obtained crude material was purified by silica gel column
chromatography eluting 5% MeOH/DCM to afford (ZS-FNL-18) (800 mg, 63 %) as white
solid.
1H-NMR: (400 MHz, CD3OD): 5 8.72 (t, J= 4.8 Hz, 2H), 7.36 (t, J= 4.8 Hz, 1H), 4.81-4.76
(m, 1H), 4.62—4.49 (m, 1H), 4.34—4.29 (m, 1H), 4.18-4.03 (m, 2H), 3.56 (d, J: 5.6 Hz, 2H),
3.52—3.46 (m, 1H), 2.30—2.25 (m, 2H), .88 (m, 2H), 1.46 (s, 9H), 1.31—1.28 (m, 3H);
Mass (ESI): m/z 420.4 [M++1];
HPLC:99.6% (both isomers)
S nthesis of 2S 3R
ylmethyl) butanamide L-19):
To a stirring on of (2S-FNL-18) (280 mg, 0.66 mmol) in CHzClz (5 mL)
was added TFA (0.3 mL, 4.0 mmol) at 0 OC and stirred at RT for 4 h. After completion of
reaction (by TLC), the reaction mixture was concentrated under reduced pressure to obtained
crude compound that was triturated with ane/diethyl ether (5 mL/5 mL) to afford (2S-
FNL-19) (95 mg, 44.6 %) as an white solid (TFA salt).
1H-NMR: (500 MHz, D20): 5 8.81 (d, J= 4.5 Hz, 2H), 7.53 (t, J= 5.0 Hz, 1H), 4.80—4.65 (m,
2H), 4.46 (d, J: 6.0 Hz, 1H), 4.36—4.31 (m, 2H), 4.10 (d, J= 7.5 Hz, 1H), 3.95 (t, J= 8.0 Hz,
1H), 3.58—3.49 (m, 1H), 2.51—2.40 (m, 2H), 2.26—2.17 (m, 2H), 1.34 (d, J: 6.0 Hz, 3H);
Mass (ESI): m/z 320.3 [M++l]
S nthesis of 2S 3R h drox 5-is0but r l-l-oxo-Z 5-diazas iro 3.4 octan-Z- l -N-
jpyrimidin-Z-ylmethyl) butanamide gZS-FNL-20 2:
To a stirring solution of (2S-FNL-l9) (300 mg, 0.94 mmol) in CHzClz (5 mL)
was added TEA (0.4 mL, 2.82 mmol) followed by SM-4 (120 mg, 1.12 mmol) at 0 OC and
d at RT for 2 h. After completion of reaction (by TLC), the reaction mixture was diluted
with water (10 mL) and extracted with CHzClz (2 x 20 mL). The combined organic layer was
dried over anhydrous Na2S04, filtered and concentrated under reduced pressure. Obtained
-88_
crude material was purified by silica gel column chromatography eluting 2% CM to
afford L-20) (100 mg, 27.3 %) as white solid.
: (400 MHz, CD30D): 5 8.73 (t, J: 5.2 Hz, 2H), 7.36 (t, J: 4.8 Hz, 1H), 4.83—4.55
(m, 1H), 4.51—4.29 (m, 3H), 4.21—4.02 (m, 1H), 3.75—3.69 (m, 1H), 3.64—3.60 (m, 1H), 3.31—
3.30 (m, 1H), 2.79-2.72 (m, 1H), 2.28—2.25 (m, 2H), 2.08—1.97 (m, 2H), 1.31 (d, J: 6.4 Hz,
3H), 1.07—1.02 (m, 6H).
Mass (ESI): m/z 390.4 [M++l],
HPLC: 97.75%
Scheme 2S-I0:
OH OHH O
OMe 99 3 Step 1 Step 2
N OH NI
—> N I. NH:
0M6 —> —>
i N
HATU l o o Mitsunobu I OTBDPS MeOH.NH3
BOO BoC OTBDPS BocO
'”
2S-I 25—13
o o o
NH2 Step 4
N_ NH2 Step 5 NH2
—> N‘ 'l —> N-.,
N N
\ NEWS TBAF I H*
0 H OH
800 3000 O
2S-15 2S-16 28-FNL-21
tert—Bu 12- S ut ldi hen lsil 10X methox 0X0 r0 an-Z-
lcarbamo 1 h drox meth l rrolidine-l-carbox late 2S-13 :
] To a stirring solution of compound ZS-I (11 g, 44.89 mmol) in CHzClz (110 mL)
was added compound 2S-AJ (16.07 g, 44.89 mmol), HATU (20.4 g, 53.68 mmol) followed by
DIPEA (17.37 g, 0.13 mol) at RT and stirred for 10 h. After consumption of the starting
material (by TLC), the reaction mixture was diluted with water (100 mL) and extracted with
CHzClz (2 x 100 mL). The separated organic layer was washed with brine, dried over
anhydrous Na2S04, filtered and concentrated under reduced pressure. Obtained crude material
was purified by silica gel column chromatography to afford compound 2S-13 (16 g, 61%) as
yellow liquid.
1H-NMR: (500 MHz, : 5 7.58—7.37 (m, 10H), 4.67 (s, 1H), 4.12—4.08 (m, 2H), 3.93(s,
1H), 3.75 (s, 3H), 3.72—3.64 (m, 2H), 2.8 (s, 1H), 2.35 (s, 1H), 2.04 (s, 1H), 1.98-1.82 (m, 3H),
1.25 (s, 9H), 1.03 (s, 9H);
Mass (ESI): m/z 583.5[M+-1].
S nthesis of tert-bu l 2- tert—but ldi hen lsil 10x meth0x 0x0 ro an-Z-
y] )—1-0X0-2,5—diazaspiro|3.4|0ctane-5—carboxylate (ZS-14 1:
To a stirring solution of compound 2S-13 (1.6 g, 2.73 mmol) in THF (20 mL)
was added triphenylphosphine (0.994 g, 4.10 mmol) and DTAD (0.788 g, 3.00 mmol). The
reaction mixture was stirred at RT for 8 h. After consumption of the starting material (by
TLC), the reaction mixture was diluted with water and extracted with EtOAc (2x 30 mL). The
separated organic layer was dried over anhydrous , filtered and concentrated under
reduced pressure. The crude material was purified by silica gel column chromatography to
afford compound 2S-14 (0.8 g, 51%) as yellow sticky compound.
1H-NMR: (400 MHz, CDC13): 5 7.63—7.58 (m, 4H), 7.45—7.30 (m, 6H), 4.1 (s, 3H), 3.80—3.67
(m, 4H), 3.56-3.44 (m, 3H), 2.04-1.95 (rn, 4H), 1.59 (s, 9H), 1.04 (s, 9H).
Mass (ESI): m/z 567.4 [M++1]
S nthesis of u 12- amino ten-but ldi hen lsil lox oxo r0 an-Z- l
0x0-2,5—diazaspiro|3.4|0ctanecarb0xylate {ZS-15 2:
[00216] To a stirring solution of nd 2S-l4 (6 g) in methanol (50 mL) was added
methanolic ammonia (50 mL)) at 0°C and stirred for 12 h at RT. After consumption of the
starting material (by TLC), the reaction mixture was concentrated under reduced re and
purified the crude residue by silica gel column chromatography eluting 40% EtOAc:hexane to
afford nd—2S—15 (1 g, 17%) as an pale yellow solid.
: (400 MHz, : 5 8.27 (s, 1H), 7.67—7.63 (m, 4H), .36 (m, 7H), 5.37 (s,
1H), 4.56—4.54 (m, 1H), 3.82 (d, .1: 5.2 Hz, 1H), 3.44 (t, .1: 7.6 Hz, 2H), 3.35 (d, .1: 5.2 Hz,
1H), 3.21 (s, 1H), 2.09—2.06 (m, 2H), 2.03 (d, J= 4.8 Hz, 2H), 1.44 (s, 9H), 1.08 (s, 9H).
LCMS (M/Z) m/z: 214 [M++1].
S nthesis oftert-but 12- amin0h drox ox0 ro an-Z- l-l-oxo-Z S-diazas iro
|3.4 loctanecarboxylate (ZS-16):
To a stirring solution of compound 2S-15 (1g, 1.81 mmol) in THF (10 mL) was
added TBAF (0.943 g, 3.62 mmol) at 0°C and the reaction mixture was slowly warmed to RT
and stirred for 2 h. After consumption of the starting material (by TLC), the reaction e
was diluted with water (5 mL) and extracted with EtOAc (2x 15 mL). The separated organic
layer was washed with brine, dried over anhydrous NaZSO4, filtered and trated under
reduced pressure. Obtained crude material was purified by silica gel column chromatography
by eluting 3% MeOHzDCM to afford 2S-16 (0. 13 g, 23%) as white solid.
_9()_
1H—NMR: (400 MHz, D20): 5 4.53 (t, J: 6.8 Hz, 1H), 4.03 (d, J: 4.8, 1H), 3.96—3.91 (m,
2H), 3.85 (t, J: 5.8 Hz, 1H), 3.82 (s, 2H), 2.30 (t, J: 4Hz, 2H), 2.15-1.82 (m, 2H), 1.49 (s,
9H).
LCMS (M/Z) m/z: 314.2 [M++1]
S nthesis of 2S h drox l-oxo-Z 5-diazas iro 3.4 octan-Z- 1 r0 e 2S-
FNL-Zl):
To a stirring solution of 28-16 (0.13 g, 0.415 mmol) in CHzClz (3 mL) was
added TFA (1 mL) at 0 °C and stirred at RT for 2 h. The reaction mixture was concentrated
under reduced pressure to afford (ZS-FNL-Zl) (100 mg, crude) as TFA salt.
1H-NMR: (400 MHz, D20): 5 4.58 (t, J: 5.8 Hz, 1H), 4.09—4.03 (m, 3H), 3.92 (d, J: 7.2 Hz,
1H), 3.57-3.52 (m, 2H), 2.55-2.41 (m, 2H), 2.28-2.19 (m, 2H);
LCMS (M/Z) m/z: 214[M++1].
Scheme 2S-II:
0 0
DQ§OH &, 8%NH2 N CH N OH
BOCO NH4CI, EDCI I
BocO
28-AF 28-FNL-22
S nthesis of tert—bu 12- noh drox 0X0 r0 an-Z- l0X0-2 5-diazas iro
3.4 octane-S-carbox late 2S-FNL-22 :
To a stirring on of compound 2S—AF (250 mg, 0.79 mmol) in DCM (10
mL) were added DIPEA (0.5 mL, 2.38 mmol), EDCI (181 mg, 0.94 mmol), HOBT (127 mg,
0.94 mmol) followed by NH4Cl (84.5 mg, 1.58 mmol) at 0 °C and stirred to RT for 12 h. After
consumption of the starting material (by TLC), the reaction mixture was diluted with water (20
mL) and washed with citric acid (1 x 30 mL) followed by brine solution (1 x 30 mL). The
organic layer was dried over anhydrous Na2S04, filtered and concentrated under reduced
pressure. Obtained crude material was purified by silica gel column chromatography g
with 5% MeOH/DCM to afford (2S-FNL-22) (150 mg, 60.7%) as yellow thick syrup.
1H-NMR: (400 MHz, CD30D): 5 4.13—4.07 (m, 2H), 3.96—3.88 (m, 1H), 3.87—3.77 (m, 1H),
.47 (m, 2H), 3.44—3.30 (m, 1H), 2.31—2.26 (m, 2H), 1.97—1.88 (m, 2H), 1.47 (s, 9H);
LCMS (ESI): m/z 314.3 [M*+1],
HPLC: 98.3 8%
Scheme 28—12:
_ 91 _
m{OH Step 1
NI I-
ZS-YEDCI WN- “QENHVWStep 2N —> OH
0H N _\> %W§:H/OH N_N\> Iiioc 0 B000
28-FNL-23
23-AF
28-FNL-24
Step3
' NI? NHVN/ N OH \
isobutyryl N
chloride 0
2- l-l-oxo-Z 5-diazas iro 3.4 octane-S-carbox late -23:
To a ng solution of compound 2S-AF (1.3 g, 4.14 mmol) in DCM (25 mL)
were added DIPEA (2.15 mL, 12.42 mmol), HOBT (760 mg, 4.96 mmol), EDCI ( 1 g, 4.96
mmol) ed by 2S-Y (715 mg, 4.96 mmol) at 0 °C and stirred for 16 h at RT. After
consumption of the starting material (by TLC), the reaction mixture was diluted with water (50
mL). The organic layer was washed with citric acid (1 x 30 mL) followed by bicarbonate
solution (1 x 30 mL). The organic layer was dried over anhydrous NagsO4, filtered and
concentrated under reduced pressure. Obtained crude material was purified by silica gel column
chromatography eluting with 2% MeOH/DCM to afford (2S-FNL-23) (800 mg, 50%) as white
solid.
: (400 MHz, CD30D): 5 8.75—8.71 (m, 2H), 7.37—7.34 (m, 1H), 4.66—4.49 (m, 2H),
4.27—4.24 (m, 1H), 4.19—4.14 (m, 1H), 4.03—3.99 (m, 1H), 3.97—3.92 (m, 1H), 3.66—3.54 (m,
1H), 3.49-3.45 (m, 1H), 3.40—3.36 (m, 1H), .27 (m, 2H), 1.97—1.88 (m, 2H), 1.47 (s, 9H);
Mass (ESI): m/z 406.4 [M++1].
HPLC:97.1%
S nthesis of 2 h drox Z 5-diazas iro 3.4 octan-Z- l -N- rimidin-Z-
ylmethyl) propanamide 12S—FNL-24):
To a ng solution of compound (2S-FNL-23) (350 mg, 0.86 mmol) in DCM
(5 mL) was added TFA (985 mg, 0.86 mmol) at 0 °C and stirred to RT for 3 h. The reaction
mixture was brought to RT and concentrated under vacuum to afford (2S-FNL-24) (250 mg,
95.4%) as white solid.
-92_
1H-NMR: (400 MHz, D20): 5 8.84 (d, J: 5.2 Hz, 2H), 7.55 (t, J: 4.8 Hz, 1H), 4.90—4.67 (m,
3H), 4.10—4.06 (m, 3H), 3.94—3.92 (m, 1H), .51 (m, 2H), 2.54—2.43 (m, 2H), 2.28-2.19
(m, 2H);
LCMS: m/z 306.4 [M++1];
HPLC: 90.07%.
S nthesis 0f 2 h drox 5—isobut r 0-2 5-diazas iro 3.4 octan l-N—
rimidin lmeth 1 r0 anamide 2S-FNL-25 :
To a stirring solution of compound (2S-FNL-24) (500 mg, 1.63 mmol) in DCM
(5 mL) was added TEA (0.7 mL, 4.91 mmol) at 0 °C. After added Int-F (207 mg, 1.95 mmol)
slowly and d to RT for 3 h. After consumption of the starting material (by TLC), the
reaction e was diluted with water (20 mL). The organic layer was washed with citric acid
(1 x 30 mL) followed by brine solution (1 x 30 mL). The organic layer was dried over
anhydrous Na2SO4, filtered and concentrated under reduced pressure. Obtained crude material
was purified by silica gel column chromatography eluting with 5% MeOH/DCM to afford (2S-
FNL-25) (100 mg, 16.3%) as white solid.
1H-NMR: (400 MHz, CD30D): 5 8.73 (t, J= 4.8 Hz, 2H), 7.37 (d, J= 5.2 Hz, 1H), 4.56—4.51
(m, 2H), 4.32-4.29 (m, 1H), .12 (m, 1H), 4.05—3.98 (m, 2H), 3.74-3.68 (m, 1H), 3.63-
3.58 (m, 1H), .51 (m, 1H), 2.77-2.69 (m, 1H), 2.31—2.26 (m, 2H), 2.08—1.95 (m, 2H),
1.05-0.98 (m, 6H);
LCMS: m/z 376.4 ;
HPLC: 89.6% (both isomers)
Scheme 2S-I3 :
Step 1 Step 2 Step 3
Boc/figjn
/NO N1...
EDCIHOBt 300/“10qu pd..c/H2 Boc Mitsunobu WNWO
Condition BO! 0 'OA0
23—BK OAC OAC
ZS-H 23—17 ZS- 18 23—19
Step 6 ‘0Dioxane. HCI
Step 4 EWING TWMOStep 5 5);.., N3
AqNH3 ”QOH ”GHQ ’OAc
ZS-20 28—FNL26
ZS-FNL-27
S nthesis 0f tert—but 12- 2S 3R -3—acetox ox0 rrolidin-l- l 2—
llcarbamoyl {-21 g benzyloxy )methylmyrrolidine-l-carboxylate (ZS-171:
To a stirring solution of nd 2S-BK (1 g, 2.90 mmol) in DMF (8 mL) was
added EDCIHCI (0.63 g, 3.28 mmol) followed by HOBt (0.44 g, 3.28 mmol) at 0 °C. After
being stirred for 5 min, DIPEA (1.3 mL, 7.46 mmol) followed by compound 2S—H (0.74 g, 3.58
mmol) was added to the reaction mixture and stirring was continued for another 16 h at RT.
The reaction mixture was washed with water and extracted with EtOAc (2x 500 mL). The
organic layer was washed with brine, dried over ous NaZSO4 and concentrated under
vacuum. The crude was purified by column tography to afford nd 2S-17 (0.6 g,
38%).
1H-NMR: (400 MHz, CDC13) (Rotamers): 57.34 (s, 5H), 5.37-5.34 (m, 1H), 4.84-4.80 (m, 1H),
4.72-4.65 (m, 2H), 4.09-4.02 (m, 1H), 3.91-3.87 (m, 1H), 3.65-3.61 (m, 3H), 3.52-3.46 (m,
3H), 2.41 (br s, 1H), 2.22-2.15 (m, 1H), 1.98 (d, 5H), .84 (m, 4H), 1.50-1.42 (m, 9H).
LCMS m/z: 532 [M++1].
S 'nthesis of tart-but 12- 2S 3R acetox 0xo rrolidin-l- '1 butan-Z-
To a stirring solution of compound 2S-l7 (4.5 g, 8.40 mmol) in MeOH (40 mL)
was added wet 10% Pd/C (1.5 g) under inert atmosphere and stirred for 4 h under H2
atmosphere (balloon re). The reaction mixture was filtered through celite pad and
concentrated under reduced pressure to afford nd 2S-18 (3.0 g, 81%).
LCMS m/z: 442.5 [M++1].
S nthesis of tert-bu l 2— 2S 3R acet0x ox0 rrolidin-l- lbutan l-l-oxo-
2,5—diazaspirol3.4 |0ctanecarb0xylate 12S-191:
To a stirring on of compound 2S-18 (3 g, 6.70 mmol) in THF (25 mL) was
added triphenylphosphine (2 g, 7.40 mmol) followed by DTAD (2.5 g, 10.2 mmol). The
reaction mixture was d at RT for 16 h. After consumption of the starting material (by
TLC), the reaction was concentrated under reduced pressure. The crude material was purified
by silica gel column chromatography eluting with10% MeOH/CH2C12 to afford compound 2S-
19 (1.2 g with TPPO, 43%).
1H-NMR: (400 MHz, DMSO-d6): 5 5.25—5.19 (m, 1H), 4.65 (d, 1H), 3.61-3.57 (m, 3H), 3.47—
3.42 (m, 2H), 3.41-3.25 (m, 4H), 2.05 (s, 4H), 1.95-1.71 (m, 7H), 1.42 (s, 10H).
LCMS m/z: 424.4 [M++1].
S nthesis 0f ut 12- 2S 3R h drox 0xo—1- rrolidin-l- l butan l-l-oxo-
2: 5-diazaspir0 |3.4| octane-S-carboxylate [ZS-20]:
A solution of compound 2S-19 (0.15 g, 0.41 mmol) in aqueous NH3 (2 mL) was
stirred at RT for 4 h. After consumption of the starting material (by TLC), the reaction diluted
with CHzClz (75 mL). The separated organic layer was dried over ous Na2S04 and
concentrated under reduced pressure to afford compound 2S-20 (0.1 g, 76%).
LCMS m/z: 382 [M*+1] .
S nthesis of 2- 2S 3R h drox -l-ox0 rrolidin-l- l butan l -2 5 diazas iro 3.4
l-one. [2S-FNL-26]:
[00227] To a stirring solution of compound 2S-20 (0.2 g, 0.63 mmol) in CHzClz (2 mL)
was added TFA (0.3 mL) at 0 °C and stirred at RT for 1 h. The reaction mixture was
concentrated under vacuum. Obtained residue was diluted with water and extracted with
CH2C12 (2x 25 mL). The separated organic layer was dried over anhydrous NaZSO4, filtered and
concentrated under vacuum to afford (2S-FNL—26) (0.2 g, 80%) as TFA salt.
1H-NMR: (400 MHz, D20): 5 4.64 (t, 1H), 4.25—4.21 (m, 1H), 4.09 (d, 1H), 3.99-3.87 (m, 1H),
3.70 (t, 2H), .47 (m, 5H), 2.52—2.34 (m, 2H), 2.25—2.22 (m, 2H), 2.08—1.98 (m, 5H), 1.25
(t, 3H).
LCMS (ESI) m/z: 282.4 [M++1].
S nthesis 0f 2R 3 0x0 1-0x0-2 5-diazas iro 3.4 0ctan l rrolidin-l- l
butan l e 2S-FNL—27 :
A stirring solution of compound 2S-19 (0.4 g, 0.94 mmol) in 1,4-dioxane/HC1 (5
mL) was cooled to 0 °C and stirred at RT for 1 h. After ption of the starting material (by
TLC), the reaction mixture was concentrated under reduced re. Obtained crude material
was washed with n-pentane followed by EtOAc to afford (2S-FNL-27) (0.22 g, 65%).
1H-NMR: (400 MHz, D20): 5 4.62 (d, 1H), .29 (m, 2H), 4.24 (d, 1H), 3.89—3.77 (m,
3H), 3.54—3.49 (m, 3H), 2.57-2.52 (m, 1H), 2.49 (s, 3H), 2.42—2.00 (m, 8H), 1.30 (d, 3H).
LCMS m/z: 324.3 [M++1].
HPLC Purity: 99.37%.
Scheme 2S-I4:
_ 95 _
Nlllll' Step1 Step 2
T "'OH
EDCI NH4C|
BOC BOCO O
28-AQ 23-21 23-FNL-28
S nthesis 0f tert-but l 2— 2S 3R amin0h drox ox0butan th l-l-oxo-
2 as iro 3.4 octane-S-carbox late 2S-21 :
To a stirring solution of nd 2S-AQ (480mg, 1.40 mmol) in CHzClz (15
mL) were added DIPEA (543 mg, 4.20 mmol), EDCI.HC1 (382 mg, 2.0 mmol) followed by
HOBt (280 mg, 2.0 mmol), NH4C1 (111mg, 2.0 mmol) at 0 °C and stirred at RT for 16 h. After
consumption of the starting material (by TLC), the reaction mixture was diluted with water (20
mL) and extracted with CH2C12 (2 x 30 mL). The combined organic layer was washed with
brine (2 x 50 mL), dried over anhydrous NaZSO4, filtered and concentrated under reduced
pressure. Obtained crude material was purified by silica gel column chromatography eluting
2% MeOH/DCM to afford compound 2S-21 (150mg, 31%) as colorless thick syrup.
1H-NMR: (500 MHz, DMSO-d6): 5500—488 (m, 1H), 4.05—3.94 (m, 4H), 3.37 (t, J= 10.5 Hz,
2H), 2.10-1.93 (m, 4H), 1.45 (s, 9H), 1.39-1.27 (m, 1H), .16 (m, 6H);
Mass (ESI): m/z364.3 [M++Na]
S nthesis of 2S 3R h drox l-meth l0x0-2 5-diazas iro 3.4 0ctan l
butanamide L-28):
To a stirring solution of compound 28-21 (150 mg, 0.43 mmol) in CHZClz (5
mL) was added TFA (0.4 mL, 4.39 mmol) at 0 °C and stirred at RT for 2 h. After completion of
reaction (by TLC), the reaction mixture was concentrated under reduced re to obtained
crude compound which was triturated with diethylether/n—pentane (5 mL/5 mL) to afford (ZS-
) (100 mg, 65.7 %) as sticky solid (TFA salt). HPLC (purity): 99.7%
1H-NMR: (400 MHz, D20): 5450—446 (m, 3H), 3.63—3.49 (m, 2H), 2.56—2.49 (m, 2H), 2.35—
2.29 (m, 2H), 1.57 (d, J= 6.8 Hz, 3H), 1.36 (d, J= 6.0 Hz, 3H);
Mass (ESI): m/z 483.1 [2M++1]
_ 96 _
Scheme 2S-I5:
N’/ \>
NHT>_N Step2 O _N
Step 1 NH—)—
EDCI -'OH N _\>
N...
BOGO 28-Y 3060 "‘0“
28-FNL-29
ZS AQ .TFA 0
ZS-FNL-30
N/ \
o —N
Step 3
—> N-IH
isobutyryl "'OH
de 0
28-FNL-31
S s of tert-but l 2- 2R 3 h drox -l-0x0 rimidin-Z- lmeth 1 amino
butan-Z- l-l-meth loxo-2 5-diazas iro 3.4 octane-S-carbox late ZS-FNL-29:
To a stirring solution of compound 2S-AQ (500 mg, 1.46 mmol) in CH2C12 (15
mL) were added DIPEA (0.76 mL, 4.38 mmol), EDCI.HC1 (334 mg, 1.75 mmol), HOBt (334
mg, 1.75 mmol) followed by ZS-Y (252 mg, 1.75 mmol) at 0 °C and stirred at RT for 16 h.
After consumption of the starting material (by TLC), the reaction mixture was diluted with
water (20 mL) and extracted with CH2C12 (2 x 30 mL). The combined organic layer was
washed with citric acid solution (20 mL), NaHCO3 (l x 30 mL) followed by brine (1 x 50 mL).
The organic layer was dried over anhydrous NaZSO4, d and concentrated under reduced
pressure. Obtained crude material was d by silica gel column chromatography eluting
2% MeOH/DCM to afford (ZS-FNL-29) (200 mg, 31.6%) as white solid.
1H-NMR: (400 MHz, CD30D): 5 8.74—8.70 (m, 2H), 7.37—7.32 (m, 1H), 4.72—4.43 (m, 3H),
4.24-4.14 (m, 1H), 4.10-3.88 (m, 2H),3.52-3.36 (m, 2H), 2.22-2.19 (m, 2H), .94 (m, 1H),
1.88—1.79 (m, 1H), 1.45-1.41 (m, 3H), 1.40 (s, 9H), 1.29—1.26 (m, 3H),
Mass (ESI): 434.5 [M++1], HPLC:92.8%
S nthesis of 2S 3R h drox l-meth l0x0-2 5-diazas iro 3.4 octan-Z- l-N-
myrimidin-Z-ylmethyl) butanamide gZS-FNL-301:
To a stirring solution of nd (2S-FNL-29) (250 mg, 0.57 mmol) in DCM
(10 mL) was added TFA (0.44 mL) under N2 atmosphere and stirred for 2 h at RT. After
consumption of the starting material (by TLC), the on e was concentrated under
WO 20783
-97_
reduced pressure. The obtained crude material was triturated with diethylether/n—pentane (5
mL/5 mL) and dried under reduced pressure to afford (ZS-FNL-30) (180 mg, 94.7%) as semi
solid (TFA salt).
1H-NMR: (400 MHz, D20): 5 8.82 (d, .1: 2.0 Hz, 2H), 7.53 (t, J= 4.8 Hz, 1H), 4.67—4.62 (m,
2H), 4.44—4.40 (m, 1H), 4.34—4.32 (m, 2H), .56 (m, 2H), 2.51—2.20 (m, 4H), 1.55—1.46
(m, 3H), .29 (m, 3H)
LCMS (ESI) : m/z 333.3
HPLC: 90.7%
To a stirring solution of compound (2S-FNL-30) (150 mg, 0.45 mmol) in DCM
(5 mL) was added TEA (0.18 mL, 1.35 mmol) followed by isobutyryl chloride (57 mg, 0.54
mmol) at 0 °C under N2 atmosphere and stirred for 2 h at RT. After consumption of the starting
al (by TLC), the reaction mixture was diluted with water (5 mL) and extracted with
CHZClz (2 x 10 mL). The combined organic layer was dried over anhydrous NaZSO4, filtered
and concentrated under reduced pressure. Obtained crude material was purified by silica gel
column chromatography eluting 2% MeOH/DCM to afford (2S-FNL-31) (85 mg, 47%) as semi
solid.
1H-NMR: (400 MHz, CD30D): 5 8.73 (d, .1: 4.8 Hz, 2H), 7.36 (t, .1: 4.8 Hz, 1H), 4.83—4.54
(m, 3H), 4.35—4.32 (m, 1H), 4.22—4.11 (m, 1H), .88 (m, 1H), 3.76—3.71 (m, 1H), 3.67—
3.60 (m, 2H), .76 (m, 1H), 2.21—2.07 (m, 3H), 1.96—1.91 (m, 1H), 1.29-1.26 (m, 6H),
1.05—1.02 (m, 6H)
LCMS (ESI) : m/Z 404.4
HPLC:93.57%
_ 98 _
Scheme 2S-I6:
Ste 1 Ste 2
N 23-BM DTAD
Boc’ O
023-22 'OBn
'OBn
23-AN 23-23
Step 3
N Step 4
—» N: —» N
N .. I
Pd-C/H2 I
800 TFA
0 "'OH 0 ”'OH
23-24 23-FNL-32
S nthesis of tert-but l 2- 2S 3R ben 10x 0x0 rrolidin-l- l butan l
carbamo 1 l-h drox eth l rrolidine-l-carbox late 2S-22 :
To a stirring solution of compound 2S-AN (2.5 g, 9.65 mmol) in CHzClz (50
mL) were added compound ZS-BM (2.7 g, 10.6 mmol), EDCI.HC1 (2.7 g, 14.4 mmol) followed
by HOBt (1.9 g, 14.4 mmol) and DIPEA (5.3 mL, 28.9 mmol) at 0 °C and stirred for 12 h.
After consumption of the sta1ting material (by TLC), the reaction mixture was d with
water (30 mL) and extracted with CHzClz (2 x 50 mL). The separated organic layer was washed
with brine, dried over anhydrous NaZSO4, filtered and concentrated under reduced re.
ed crude material was purified by silica gel column chromatography eluting 2%
CM to afford compound 28-22 (3.5 g, 73%) as colorless liquid.
1H-NMR: (500 MHz, DMSO—dé): 6 8.11 (d, J: 9.0 Hz, 1H), 7.82 (d, J: 8.5 Hz, 1H), 7.33—
7.26 (m, 5H), 6.56 (s, 1H), 4.68—4.63 (m, 1H), 4.56 (s, 2H), 3.80—3.74 (m, 1H), 3.55—3.33 (m,
5H), 1.76-1.66 (m, 7H), 1.40 (s, 9H), 1.37—1.24 (m, 2H), 1.08—0.97 (m, 6H).
Mass (ESI): m/Z 504 [M++1].
S nthesis 0f tert—but l 2- 2S 3R ben 10x 0x0 rrolidin-l- l butan l
To a stirring solution of compound 2S-22 (3.5 g, 6.95 mmol) in THF (50 mL)
was added triphenylphosphine (3.6 g, 13.9 mmol) and DTAD (3.2 g, 13.9 mmol). The reaction
mixture was stirred at RT for 16 h. After consumption of the ng material (by TLC), the
on was concentrated under reduced pressure. The crude material was purified by silica gel
column chromatography eluting 30% hexane to afford compound 2S-23 (1.0 g, 30%) as
pale yellow liquid.
-99_
1H—NMR: (500 MHz, DMSO—dg): 5 7.63—7.54 (m, 1H), 7.41—7.24 (m, 4H), .37 (m, 3H),
3.98 (d, J= 10.0 Hz, 1H), 3.91 (d, J= 7.0 Hz, 1H), 3.77 (d, J= 7.0 Hz, 2H), 3.44-3.34 (m, 4H),
2.01—1.91 (m, 2H), 1.85—1.68 (m, 6H), 1.40 (s, 9H), 1.20—1.11 (m, 6H).
Mass (ESI): m/z 486.6 [M++1].
S nthesis of 2S 3R 5- tert-butox carbon 1 0xo-2 as iro 3.4 octan-Z- l
hydroxybutanoic acid {ZS-24 1:
To a stirring solution of compound 2S-23 (1 g) in methanol (30 mL) was added
% Pd/C (400 mg) at RT and d for 12 h under H2 atmosphere (balloon re). After
consumption of the starting material (by TLC), the reaction mixture was filtered through a pad
of celite and the pad was washed with methanol. Obtained filtrate was concentrated under
reduced pressure to afford compound 28-24 (230 mg, 28%) as white solid.
1H-NMR: (500 MHz, DMSO—dg): 5 4.79 (br s, 1H), 4.34 (br s, 1H), 4.27 (d, J= 8.5 Hz, 1H),
4.03-3.95 (m, 1H), 3.78 (d, J= 6.5 Hz, 1H), 3.67-3.63 (m, 1H), 3.53-3.49 (m, 2H), 3.39 (t, J=
9.0 Hz, 2H), 2.04—1.67 (m, 8H), 1.36 (s, 9H), 1.26 (d, J: 6.0 Hz, 3H), 1.08, 1.06 (dd, J: 6.5
Hz, 3H).
LCMS: 396.4 [M++1].
S nthesis of 2- 2S 3R h drox oxo—1- rrolidin-l- l butan-Z- lmeth 1-2 5-
diazaspiro |3.4| l-one 12S-FNL-32):
To a stirring solution of compound 2S—24 (230 mg, 0.58 mmol) in CHZCIZ (2
mL) was added TFA (0.44 mL, 5.82 mmol) at 0 OC and stirred at RT for 2 h. After tion
of reaction (by TLC), the reaction mixture was concentrated under d pressure to afford
(2S-FNL-32) was triturated with e and diethyl ether (5 mL/5 mL) (210 mg, 92%) as
sticky solid (TFA salt).
1H-NMR: (400 MHz, D20): 5 4.27 (d, J= 8.0 Hz, 1H), 4.07-4.03 (m, 1H), 4.01-3.97 (m, 1H),
3.52-3.48 (m, 1H), 3.39-3.35 (m, 2H), 3.32-3.20 (m, 3H), 2.16 (t, J = 7.6 Hz, 2H), 2.06—1.96
(m, 2H), 1.89—1.80 (m, 2H), 1.78—1.74 (m, 2H), 1.43 (d, J= 6.4 Hz, 3H), 1.06 (d, J= 6.0 Hz,
3H);
- 100 —
Scheme 2S-I 7:
N --IOH 'OH
| EDCI NH4C| TFA
Boc BocO
ZS-BC 28-FNL-33 28-FNL-34
S nthesis 0f tert-but 12- 2S 3R amin0h drox butan-2— lmeth l-l-oxo-Z
-diazas iro 3.4 octane-S-carbox late 2S-FNL-33:
To a stirring solution of nd 2S-BC (1.5 g, 4.38 mmol) in DCM (25 mL)
were added N, N-diisopropylethylamine (2.35 mL, 13.14 mmol), NH4Cl (310 mg, 8.76 mmol),
followed by EDCI (l g, 5.25 mmol), HOBT (793 mg, 5.25 mmol) at 0 °C and stirred at RT for
16 h. After consumption of the starting material (by TLC), the reaction mixture was diluted
with water (20 mL). The separated organic layer was washed with citric acid solution (1 x 30
mL) followed by brine solution (1 x 30 mL). The organic layer was dried over ous
NaZSO4 and concentrated under reduced pressure to afford crude compound which was d
by column chromatography by eluting 5% MeOH/DCM to ed compound (2S-FNL-33)
(600 mg, 41%) as white solid.
1H-NMR: (400 MHz, CDgOD): 5 4.24-4.17 (m, 1H), 4.03—3.99 (m, 3H), 3.67—3.46 (m, 1H),
2.40—1.99 (m, 3H), 1.68—1.62 (m, 1H), 1.46 (s, 9H), 1.24-1.18 (m, 6H);
LCMS (ESI): m/z 342.5 [M++1]
S nthesis of 2S 3R h drox 6-meth l-l-oxo-Z 5-diazas iro 3.4 octan-Z- l
butanamide 12S-FNL-34):
[00239] To a stirring solution of nd (2S-FNL-33) (200 mg, 0.58 mmol) in DCM
(10 mL) was added trifluoroacetic acid (0.5 mL), at 0° C under N2 atmosphere. The reaction
e was stirred at RT for 2h. After consumption of the starting material (by TLC), the
reaction mixture was concentrated under reduced re to afford crude, which was triturated
with n-pentane (10mL) to afford (2S-FNL-34) (100 mg, 71%) as white solid.
1H-NMR: (400 MHz, D20): 5 4.35-4.27 (m, 2H), 4.08—3.93 (m, 3H), 2.58—2.52 (m, 1H), 2.48—
2.44 (m, 2H), 1.92—1.86 (m, 1H), 1.51, 1.48 (dd, J: 6.8 Hz, 6.4 Hz, 3H), 1.31, 1.28 (dd, J= 6.0
Hz, 6.4 Hz, 3H);
LCMS (ESI): 241.3 [M++1]
Scheme 2S-I8:
- 101 —
NBocO 28-BMEDCI I
., 'OBn
Boco '“OBn DTAD PPh3 BoCO
28-25 28-26
28-AZ
Step 3 Step 4”MM”GOO
Pd/C 8060 CONS
23-27 23-FNL-35
S nthesis of tert-but l 2- 2S 3R ben 10x 0x0 rrolidin-l- l butan-Z- l
carbamo l h drox meth l-S-meth l rrolidine—l-carbox late 2S-25 :
To a stirring solution of compound 2S-AZ (1.1 g, 4.28 mmol) in DCM (20 mL)
were added N, N-diisopropylethylamine (2.2 mL, 12.8 mmol), ZS-BM (1.2 g, 4.78 mmol),
followed by EDCI (2.45 g, 12.8 mmol), HOBT (1.7 g, 12.8 mmol) at 0 OC and stirred at RT for
12 h. After consumption of the starting material (by TLC), the reaction mixture was diluted
with water (10 mL). The separated organic layer was washed with saturated NaHCO; solution
(1x25 mL), followed by brine solution (1x30 mL). The separated organic layer was dried over
anhydrous Na2S04 and trated under reduced pressure to afford crude compound which
was purified by column chromatography eluting 5% MeOH/DCM to obtained compound 2S-25
(1.2 g, 57%) as a thick white syrup.
1H-NMR: (400 MHZ, DMSO—dg): 5 7.93 (t, J= 7.6 Hz, 1H), 7.71—7.26 (m, 5H), 5.30 (br s, 1H),
4.65—4.61 (m, 1H), 4.57 (s, 2H), 3.93—3.85 (m, 2H), 3.57—3.34 (m, 2H), 3.17—3.09 (m, 2H), 2.07—
1.94 (m, 2H), .73 (m, 4H), .28 (m, 10H), 1.20 (s, 9H);
LCMS: m/z 504.7 [M++1].
S nthesis of tert—bu l 2- 2S 3R ben 10x 0x0 rrolidin-l- l butan-Z- l
meth l-l-oxo-Z 5-diazas iro 3.4 octane-S-carbox late 2S-26:
To a stirring solution of compound 2S-25 (0.6 g, 1.19 mmol) in THF (10 mL)
was added nylphosphine (0.46 g, 1.78 mmol) and DTAD (0.4 g, 1.78 mmol). The
reaction mixture was stirred at RT for 16 h. After consumption of the starting material (by
TLC), the reaction mixture was diluted with water (10 mL). The ted organic layer was
washed with brine solution (1x30 mL). The separated c layer was dried over anhydrous
Na2SO4 and trated under reduced pressure to afford crude compound which was purified
by column chromatography eluting 2% CM to obtained compound 2S-26 (0.2 g, 35%)
as white solid.
-102—
1H-NMR: (500 MHz, DMSO—d6): 5 7.63—7.26 (m, 5H), 4.52 (s, 2H), 3.91—3.77 (m, 3H), 3.56—
3.36 (m, 4H), 2.35—2.11 (m, 4H), 1.94—1.68 (m, 6H), 1.39 (s, 9H), 1.13, 1.09 (dd, J: 6.0 Hz,
.5 Hz, 3H), 1.04 (d, J: 6.5 Hz, 3H);
LCMS: m/z 486.6 [M++1].
S nthesis 0f tert—but 1 2- 2S 3R ben 10x 0x0 rrolidin-l- 1 butan-Z- 1
To a ng on of compound 2S-26 (1.5 g, 3.09 mmol) in methanol (20
mL) was added 10%Pd/C (200 mg) under N2 atmosphere. The reaction mixture was d
under H2 atmosphere (balloon pressure) at RT for 4 h. After consumption of the starting
material (by TLC), the reaction mixture was filtered through a pad of celite and the pad was
washed with methanol. Obtained filtrate was concentrated under reduced re to afford
crude compound which was purified by column chromatography to obtained compound 2S-27
(0.9 g, 90.9%) as white solid.
1H-NMR: (500 MHz, CDC13): 5 4.11 (d, J= 7.0 Hz, 1H), 3.96—3.90 (m, 1H), 3.73 (s, 2H), 3.49
(d, J= 13.0 Hz, 2H), 3.40-3.34 (m, 2H), 2.50—2.28 (m, 4H), 2.17—1.82 (m, 6H), 1.53 (s, 9H),
1.52—1.41 (m, 3H), 1.36—1.18 (m, 3H);
LCMS: 396.5 [M++1].
S nthesis of 2- 2S 3R h drox ox0 rrolidin-l- 1 butan-Z- l-6—meth 1-2 5-
diazaspiro |3.4| octan-l-one gZS-FNL-352:
[00243] To a ng solution of compound 2S-27 (0.18 g, 0.45 mmol) in methanol (10
mL) was added TFA (3 mL) under N2 here at 0 °C. After ption of the starting
material (by TLC), the reaction mixture was concentrated under reduced pressure to afford
crude compound which was triturated with n-pentane (10 mL) to obtained (2S-FNL-35) (0.1 g,
74.6%) as white solid.
1H-NMR: (400 MHZ, s): 5 9.99 (br s, 1H), 9.57 (br s, 1H), 4.32 (d, J: 7.6 Hz, 1H),
3.93 (t, J= 6.0 Hz, 1H), 3.81—3.75 (m, 3H), 3.51—3.46 (m, 2H), 3.30 (t, J= 6.8 Hz, 2H), 2.29—
2.20 (m, 3H), 1.93-1.75 (m, 4H), 1.68-1.63 (m, 1H), 1.34 (d, J: 6.8 Hz, 3H), 1.13 (d, J= 6.4
Hz, 3H);
Mass (ESI): m/z 296.3 [M++l]
Scheme 2S-I9:
- 103 —
IIII“
T "'OH
EDCI NH4C|
ZS-BH 028-FNL-36 28-FNL-37
S nthesis 0f tert—but l 2- 2S 3R amin0h drox 0x0butan l-1 6-dimeth 1
oxo—Z 5-diazas iro 3.4 octane-S-carbox late 2S-FNL-36 :
To a stirring solution of compound 2S—BH (1.8 g, 5.05 mmol) in CH2C12 (50
mL) were added DIPEA (2.62 mL, 15.15 mmol), EDCI (1.92 g, 10.1 mmol), HOBt (1.36 g,
.1 mmol) followed by NH4C1 (803mg, 15.15mmol) at 0 °C and stirred for 12 h at RT. After
consumption of the starting material (by TLC), the reaction mixture was diluted with water (30
mL). The separated organic layer was washed with citric acid solution (1 x 50 mL) ed by
brine solution (1 x 50 mL). The organic layer was dried over anhydrous NaZSO4 and
concentrated under d pressure to afford crude compound which was purified by column
chromatography by g 4% MeOH/DCM to afford (2S-FNL-36) (468 mg, 26%) as white
solid.
1H-NMR: (400 MHz, DMSO—dg):57.25 (s, 2H), 4.92—4.48 (m, 1H), 4.34—4.01(m, 1H), 3.97—
3.72 (m, 3H), 2.32—1.88 (m,3H), 1.58-1.51 (m, 1H), 1.4l(s, 9H), 1.36—1.20 (m, 6H), 1.16-1.07
(m, 3H);
LCMS (ESI): 356.4 [M++1];
HPLCI99. 19%
S nthesis of 2S 3R 1 6—dimeth 0-2 as iro 3.4 octan-Z- l h drox
butanamide gZS-FNL-37):
[00245] To a stirring on of (2S-FNL-36) (200 mg, 0.56 mmol) in DCM (5 mL) was
added TFA (0.45 mL, 5.63 mmol) at 0 OC and stirred at RT for 2 h. After consumption of the
starting material (by TLC), the reaction mixture was trated under reduced pressure. The
crude material was triturated with diethyl ether/n-pentane (50 mL/50 mL) and dried under
d pressure to afford (2S-FNL-37) (140 mg, 98%) as hygroscopic white solid (TFA salt).
1H-NMR: (400 MHz, D20):54.42—4.36 (m, 1H), 4.34-4.28 (m, 1H), 4.27—4.15 (m, 1H), 4.07—
4.01 (m, 1H), 2.57—2.49 (m, 1H), 2.46—2.36 (m, 2H), 2.01—1.90 (m, 1H), 1.56—1.50 (m, 6H),
1.32—1.29 (m, 3H);
LCMS (ESI): 256.4 [M++l];
—104—
HPLC (ELSD):93.86%.
Scheme 2S-20:
OH O
Step 1 H N Step 2
OH I NH.
N N
| ZS-BM I DIAD PPh3
B000 B000 "'OBn Boco "'OBn
ZS-BE 28-28 28-29
Step 3 ONOQ Step 4
Pd-C/H2
Boo O CONS
TFAO
28-30 28-FNL-38
To a stirring solution of nd 2S-BE (2 g, 7.32 mmol) in DMF (20 mL)
were added N,N—diisopropylethylamine (6.7 mL, 36.5 mmol), 2S-BM (2.6 g, 8.7 mmol),
ed by HATU (3.3g, 8.7 mmol) at 0 °C and stirred at RT for 16 h. After consumption of
the starting material (by TLC), the reaction mixture was diluted with water (100 mL) and
EtOAc (200 mL). The separated organic layer was washed with sodium bicarbonate solution (2
x 75 mL), citric acid on (2 x 50 mL) followed by brine solution (1x 50 mL). The
separated organic layer was dried over anhydrous Na2SO4 and concentrated under reduced
pressure to afford crude compound which was purified by column chromatography by eluting
40% EtOAc/n—hexane to obtain compound 2S-28 (1 g, 27%) as pale yellow liquid;
LCMS 518 [M++1]
S nthesis of tert-bu l 2- 2S 3R benz 10x ox0 rrolidin-l- l butan—Z- l -1 6-
[00247] To a stirring solution of triphenylphosphine (1.5 g, 5.7 mmol) in THF (10 mL)
was added DIAD (976 mg 4.8 mmol) as portion-wise and stirred for 20 min at RT. To this
was added compound 2S-28 (1 g, 1.93 mmol) in THF (10 mL) slowly at RT and stirred for 4 h.
After consumption of the starting material (by LCMS), the reaction mixture was concentrated
under reduced re. The crude material was purified by silica gel column chromatography
eluting 30% hexane to afford compound 2S-29 (500 mg, 63%) as yellow liquid.
WO 20783
-105—
1H-NMR: (400 MHZ, CDC13):57.69-7.66 (m, 1H), .43 (m, 1H), 7.32—7.29 (m, 3H), 4.68
(s, 2H), 4.46—4.40 (m,1H), 4.26—4.05 (m, 2H), 3.97—3.91 (m,0.5H), 3.87-3.81 (m, 0.5H), 3.58—
3.53 (m, 1H), 3.40—3.32 (m, 2H), 2.16—2.11 (m, 1H), 2.04—1.90 (m, 2H), .71 (m, 2H),
1.41 (s, 9H), 1.32—1.21 (m, 10H), 1.17—1.15 (m, 3H).
LCMS (ESI): 500 [M++1].
S nthesis oftert-but 12- 2S3R h drox rrolidin-l- l butan-Z- l-1 6-
To a stirring solution of compound 2S-29 (200 mg, 0.40 mmol) in methanol (5
mL) was added 10% Pd/C (50 mg) under N2 atmosphere. The reaction mixture was stirred
under H2 atmosphere at RT for 4 h. After consumption of the starting al (by TLC), the
reaction mixture was filtered through a pad of celite and the pad was washed with methanol (10
mL). Obtained filtrate was concentrated under reduced pressure to obtained crude nd,
which was purified by column chromatography eluting 1% MeOH/DCM to afford compound
2S-30 (100 g, 61%) as yellow syrup.
1H—NMR: (400 MHz, s): 6 4.93 (d, J= 5.6 Hz, 1H), 4.26 (d, J: 9.2 Hz, 0.5 H), 4.17
(d,.]= 7.2 Hz, 0.5 H), 4.02—3.99 (m, 1H), 3.91—3.66 , 3.33—3.30 (m, 1H), 3.55—3.50 (m,
1H), 3.19-3.16 (m, 1H), 2.69 (s, 1H), 2.13—2.03 (m, 1H), 1.99-1.87 (m, 3H), 1.81—1.75 (m, 2H),
1.56—1.50 (m, 1H), 1.39 (s, 9H), 1.19 (d, J= 5.6 Hz, 3H), 1.13 (d,J= 6.4 Hz, 6H).
LCMS: 410.5 [Mt+1].
S nthesis of 2- 2S 3R h drox ox0 rrolidin-l- lbutan-Z- l-3 6-dimeth l-2 5-
diazaspiro|3.4|octan0ne gZS-FNL—38):
To a stirring solution of compound 2S—30 (300 mg, 0.73 mmol) in DCM (20
mL) was added TFA (418 mg, ol) at 0 °C under N2 atmosphere. The reaction mixture
was stirred at RT for 4 h. After consumption of the starting material (by TLC), the reaction
mixture was ated under reduced pressure to afford crude, which was purified by
preparative HPLC method to afford (2S-FNL-38) (140 mg, 46%) as thick syrup.
1H-NMR: (400 MHz, D20):54.53-4.46 (m, 1H), 4.34—4.22 (m, 2H), 4.03 (d, J: 6.4 Hz, 1H),
3.68 (s, 2H), 3.52—3.41 (m,2H), 2.44—2.37 (m, 3H), 2.03—1.94 (m, 5H), 1.56 (d, J= 6.4 Hz, 6H),
1.27 (d, J= 6.0 Hz, 3H).
LCMS (ESI): 310 [M++1].
Scheme 2S-I-15
- 106 —
0 O
NHO Step 1 Step 2 03“ Step 3
H—ZSAC EDCI NH“ —> N""{0H
DIAD PPh3 N Pd—C/H2 N
03,, OH
13°C BocN ELOBH I I
Bee 0 Bee 0
23-BE 23BN ZS—BO ZS—BP
S nthesis 0f tert-but l 2- -1 3-bis benz lox oxo r0 an l carbamo l 1-
h drox eth l-S-meth l ine—l-carbox late 2S-BN:
To a stirring solution of ZS-BE (3 g, 10.98 mmol) in DCM (30 mL) were added
N. N—diisopropylethylamine (5.73 mL, 32.96 mmol), 28—AC (3.75 g, 13.17 mmol) followed by
HATU (5 g, 13.17 mmol) at 0 °C and stirred at RT for 16 h. After consumption of the starting
material (by TLC), the reaction mixture was d with water (20 mL). The separated organic
layer was washed with brine solution (30 mL). The organic layer was dried over anhydrous
NaZSO4 and concentrated under reduced pressure to afford crude compound which was purified
by column chromatography by eluting 20% EtOAc/n-hexane to obtained compound ZS-BN
(2.9 g, 49%) as brown thick syrup.
1H-NMR: (500 MHz, DMSO-d6): 5 8.50 (m, 1H), 7.33—7.27 (m, 10H), 5.68—5.60 (m, 1H),
.22—5.09 (m, 2H), 4.72—4.43 (m, 3H), 3.89-3.63 (m, 3H), 2.28—1.78 (m, 3H), 1.45—1.42 (m,
1H), 1.36 (s, 9H), 1.26—1.04 (m, 6H);
LCMS (ESI): m/z 541.6 [M*+1]
S nthesis of tert—bu 12- -1 3-bis ben 10X oxo r0 an l-1 6-dimeth l0X0-2 5-
piro|3.4|octane-5—carb0xylate (ZS-BO):
] To a stirring on of triphenylphosphine (3.51 g, 13.42 mmol) in dry THF
(30 mL) was added DIAD (2.21 g, 10.74 mmol) as portionwise and stirred for 15 min at RT. To
this precipitated solution added 2S-BN (2.9 g, 5.37 mmol) in dry THF (15 mL) slowly at RT
and stirred for 16 h. After consumption of the ng material (by TLC), the reaction mixture
was concentrated under reduced pressure. The crude material was triturated with 30% di
her/n-pentane. The filterate was concentrated under d pressure to obtained crude
compound which was purified by silica gel column chromatography eluting 30%
EtOAc/hexane to afford 28-30 (2.5 g, 89.2%) as brown thick syrup.
1H-NMR: (500 MHz, DMSO-dg): 5 7.38-7.25 (m, 10H), 5.22—5.15 (m, 2H), 4.80-4.73 (m, 2H),
4.56-4.43 (m, 2H), 3.92-3.60 (m, 3H), 1.89-1.83 (m, 3H), 1.50—1.44 (m, 1H), 1.40 (s, 9H), 1.22—
1.18 (s, 3H), 1.16—1.13 (m, 3H);
—107—
LCMS (ESI): m/z 523.6 [M++1]
S nthesis of 2 5- utox carbon l-1 6-dimeth o-2 5-diazas iro 3.4
octan-Z-ylQhydr0xypropanoic acid gZS-BP I:
] To a stirring solution of ZS-BO (2.5 g, 4.78 mmol) in methanol (50 mL) was
added 10% Pd/C (800 mg) under N2 atmosphere. The reaction mixture was stirred under H2
atmosphere at RT for 16 h. After consumption of the starting al (by TLC), the reaction
mixture was filtered through a pad of celite and the pad was washed with methanol (30 mL).
Obtained filtrate was trated under reduced pressure to afford crude which was triturated
with n-pentane (30 mL) to afford 2S-BP (900 mg, 56.2%) as sticky solid.
1H-NMR: (400 MHz, g): 5 4.78-4.75 (m, 1H), 4.24-4.18 (m, 1H), 3.86-3.81 (m, 1H),
3.80-3.72 (m, 2H), 3.64-3.59 (m, 1H), 2.15-1.93 (m, 3H), 1.55-1.50 (m, 1H), 1.39 (s, 9H), 1.24-
1.10 (m, 6H);
LCMS (ESI): m/z 343.3 [M++1]
Scheme 2S—21:
Step 1
NI . 2:
I}! OH Isopropylami thifl-l:
B00 O ne HATU Boco
28-AF ZS-FNL—39
S nthesis 0f tert—but 12- S h drox iso r0 lamino oxo r0 an loxo—2 5-
diazas iro 3.4 octane-S-carbox late 2S-FNL-39:
To a stirring solution of 2S-AF (200 mg, 0.63 mmol) in CH2C12 (10 mL) were
added DIPEA (0.32 mL, 1.90 mmol), isopropyl amine (0.08 mL, 0.94 mmol), HATU (287 mg,
0.75 mmol) at 0 °C and stirred to RT for 5 h. After consumption of the starting material (by
TLC), the reaction mixture was diluted with water (10 mL). The separated organic layer was
washed with citric acid (1 x 20 mL) ed by brine solution (1 x 20 mL). The organic layer
was dried over anhydrous NaZSO4, filtered and concentrated under reduced pressure. Obtained
crude material was purified by preparative HPLC ation to afford (ZS-FNL-39) (150 mg,
67.2%) as white solid.
1H-NMR: (400 MHz, DMSO—dg): 6 7.76 (d, J: 8.4 Hz, 1H), 5.01—4.91 (m, 1H), 4.70 (t, J= 6.0
Hz, 1H), 4.14—4.07 (m, 1H), 3.99—3.80 (m, 2H), 3.78-3.61 (m, 2H), 3.58—3.35 (m, 2H), 2.20—
2.05 (m, 2H), 1.85-1.77 (m, 2H), 1.43 (s, 9H), 1.10-1.00 (m, 6H)
-108—
Mass (ESI): m/Z 356.6 [M++1]
HPLC: 99.27%
Scheme 2S—22:
OH N/—Ph
T "'OH EDCI ,Benylamine
0 Bee0
28-FNL-40
ZS-BH
To a stirring on of 2S-BH (250 mg, 0.70 mmol) in CH2C12 (10 mL) were
added DIPEA (0.36 mL, 2.11 mmol), EDCI (161 mg, 0.84 mmol), HOBt (129 mg, 0.84 mmol)
followed by benzylamine (82 mg, 0.77 mmol) at 0 °C and stirred for 12 h at RT. After
consumption of the starting material (by TLC), the reaction mixture was diluted with water (10
mL). The separated organic layer was dried over anhydrous NaZSO4 and concentrated under
reduced re to afford crude compound which was purified by column chromatography by
eluting 5% MeOH/DCM to afford (2S-FNL-40) (55 mg, 16%) as an off—white solid.
1H-NMR: (400 MHz, DMSO—dg): 5 7.31—7.20 (m, 5H), 4.92—4.87 (m, 1H), 4.64—4.55 (m, 1H),
.37 (m, 2H), 4.22—4.10 (m, 1H), 4.02—3.90 (m, 2H), 2.39—1.95 (m, 3H), 1.70—1.60 (m,
1H), 1.37 (s, 9H), .22 (m, 9H);
LCMS (ESI): m/z 446.56 [M++1];
HPLC: 89.54%
Scheme 2S—23:
Step1
Nun"
T --IOH EDCI 4-fluoro
O benylamine
ZS-BH CZS-FNL-41
S nthesis of tert—bu l 2- 2S 3R 4-flu0roben lamino h drox butan l-
1 6-dimeth loxo—2 5-diazas iro 3.4 octane-S-carbox late 2S-FNL—41 :
-109—
To a stirring solution of ZS-BH (500 mg, 1.40 mmol) in CH2C12 (10 mL) were
added DIPEA (0.73 mL, 4.21 mmol), EDCI (321 mg, 1.68 mmol), HOBt (257 mg, 1.68 mmol)
followed by 4—fluoro benzylamine (175 mg, 1.40 mmol) at 0 °C and d for 12 h at RT.
After consumption of the starting material (by TLC), the reaction mixture was diluted with
water (15 mL). The separated organic layer was washed with citric acid on (1 x 25 mL)
followed by brine solution (1 x 25 mL). The organic layer was dried over ous NaZSO4
and concentrated under reduced pressure to afford crude compound which was purified by
column chromatography by eluting 5% MeOH/DCM followed by preparative HPLC
purification to afford (ZS-FNL-41) (150 mg, 23.07%) as white solid.
1H-NMR: (400 MHZ, CD30D): 5 7.34—7.30 (m, 2H), 7.02—6.98 (m, 2H), 4.65—4.59 (m, 1H),
4.55—4.36 (m, 2H), 4.34—4.20 (m, 1H), 4.12-3.99 (m, 2H), 2.39—2.31 (m, 1H), 2.19—2.01 (m,
2H), 1.71—1.62 (m, 1H), 1.40 (s, 9H), 1.29—1.13 (m, 9H);
LCMS (ESI): m/z 464.5 [M++1];
HPLC: 96.32%
Scheme 2S—24:
WNIII Step 1
EDCI 4- N ...0H
methoxy
benylamine
2S—BH 28-FNL-42
S nthesis of ut l 2- 2S 3R h drox 4-methox benz lamino oxobutan
l-1 6-dimeth 0-2 5-diazas iro 3.4 octane-S-carbox late ZS-FNL-42:
[00256] To a stirring solution of ZS-BH (250 mg, 0.70 mmol) in CH2C12 (10 mL) were
added DIPEA (0.36 mL, 2.11 mmol), EDCI (161 mg, 0.84 mmol), HOBt (129 mg, 0.84 mmol)
followed by 4—methoxy benzylamine (106 mg, 0.77 mmol) at 0 °C and stirred for 12 h at RT.
After consumption of the starting material (by TLC), the reaction mixture was diluted with
water (10 mL). The separated organic layer was washed with citric acid solution (1 x 20 mL)
followed by brine on (1 x 25 mL). The c layer was dried over anhydrous NaZSO4
and concentrated under reduced pressure to afford crude compound which was purified by
WO 20783
-110—
column chromatography by eluting 5% CM to afford (2S-FNL—42) (60 mg, 17.9%) as
an off—white solid.
1H-NMR: (400 MHz, CDgOD): 5 7.24 (d, J: 1.6 Hz, 2H), 6.85 (d, J: 1.6 Hz, 2H), 4.64—4.58
(m, 1H), 4.39—4.28 (m, 1H), 4.21—4.08 (m, 2H), 4.06—3.99 (m, 1H), 3.98-3.88 (m, 1H), 3.83 (s,
3H), 2.39-2.28 (m, 1H), 2.22—2.13 (m, 1H), 2.09—1.97 (m, 1H), .61 (m, 1H), 1.40 (s, 9H),
1.31—1.22 (m, 9H);
LCMS (ESI): m/z 476.6 [M*+1];
HPLC: 90.29%
Scheme 2S—25:
Step 1
NW Y
HATU -'|OH
BocO isopropyl
amine
ZS-BH 23-FNL-43
To a stirring solution of 2S-BH (500 mg, 1.40 mmol) in CH2C12 (10 mL) were
added DIPEA (0.73 mL, 4.21 mmol), isopropyl amine (100 mg, 1.68 mmol), HATU (798 mg,
2.1 mmol) at 0 °C and stirred for 12 h at RT. After consumption of the starting material (by
TLC), the on mixture was diluted with water (10 mL). The separated organic layer was
washed with citric acid solution (15 mL) followed by brine solution (15 mL). The organic
layer was dried over anhydrous NaZSO4 and trated under reduced pressure to afford
crude compound which was purified by column chromatography by eluting 2% MeOH/DCM
followed by preparative HPLC purification to afford (2S-FNL—43) (100 mg, 18%) as white
solid.
1H-NMR: (400 MHz, D20): 5 4.42-3.89 (m, 5H), 2.38-2.04 (m, 3H), 1.77-1.72 (m, 1H), 1.40
(s, 9H), 1.36—1.17 (m, 15H)
LCMS (ESI): m/z 398.5 [M++1];
HPLC: 93.36%
Scheme 2S—26:
-111—
WM”. NH
Step1
NI----- \lr
.. HATU tert- N --IOH
BocO butyl amine I o
ZS-BH 28-FNL-44
To a stirring solution of 2S-BH (500 mg, 1.40 mmol) in CHZClz (10 mL) were
added DIPEA (0.62 mL, 3.51 mmol), tert—butyl amine (125 mg, 1.68 mmol), HATU (798 mg,
2.1 mmol) at 0 °C and stirred for 12 h at RT. After consumption of the starting material (by
TLC), the reaction mixture was diluted with water (10 mL). The ted organic layer was
washed with citric acid on (15 mL) followed by brine solution (15 mL). The organic
layer was dried over anhydrous NaZSO4 and concentrated under reduced pressure to afford
crude compound which was purified by column chromatography by eluting 2% MeOH/DCM
followed by preparative HPLC purification to afford (2S-FNL—44) (100 mg, 17.3%) as white
solid.
1H-NMR: (500 MHz, CD30D): 5 4.53—4.50 (m, 1H), 4.08—3.99 (m, 2H), 3.82—3.79 (m, 1H),
.34 (m, 1H), 2.20—2.17 (m, 2H), 2.09—2.01 (m, 1H), 1.71—1.67 (m, 1H), 1.40 (s, 9H), 1.38
(s, 9H), 1.33—1.21 (m, 9H);
LCMS (ESI): m/z 412.5 [M++1];
HPLC: 93.91%
Scheme 2S—27:
1“ 0H EDCI 4-fluoro 0H
B00 0 benzylylamine BocN
ZS-BP 28-FNL-45
] To a stirring solution of ZS-BP (200 mg, 0.58 mmol) in DCM (10 mL) were
added N. N-diisopropylethylamine (0.3 mL, 1.75 mmol), EDCI (133 mg, 0.69 mmol), HOBT
(93 mg, 0.69 mmol) followed by 4—fluoro benzylamine (79.7 mg, 0.63 mmol) at 0 °C and
-112—
d at RT for 16 h. After consumption of the starting material (by TLC), the reaction
mixture was d with water (20 mL). The separated organic layer was washed with citric
acid (20 mL) followed by brine solution (30 mL). The separated organic layer was dried over
anhydrous NaZSO4 and concentrated under reduced pressure to afford crude compound which
was purified by column chromatography by eluting 3% MeOH/DCM to obtained (2S-FNL-45)
(46 mg, 17.7%) as thick syrup.
1H—NMR: (500 MHz, DMSO—dé): 6 8.63—8.59 (m, 1H), 7.30—7.26 (m, 2H), 7.15—7.07 (m, 2H),
.07—5.00 (m, 1H), 4.31—4.21 (m, 3H), .62 (m, 4H), 2.13—1.84 (m, 3H), 1.58—1.52 (m,
1H), 1.36 (s, 9H), 1.32—1.20 (m, 3H), 1.18—1.13 (m, 3H);
LCMS (ESI): m/z 450.5 [M++1]
HPLC: 93%
Scheme 2S—28:
l“ OH HATU, 1‘1 OH
Boc 0 Cyclo B00 0
butyllamine
ZS-BP 28-FNL—46
To a stirring solution of ZS-BP (500 mg, 1.46 mmol) in DCM (15 mL) were
added N, N—-diisopropylethylamine (0.76 mL, 4.38 mmol), cyclobutylamine (124 mg, 1.75
mmol) followed by HATU (665 mg, 1.75 mmol) at 0 °C and d at RT for 16 h. After
consumption of the starting material (by TLC), the reaction mixture was diluted with water (20
mL). The separated organic layer was washed with citric acid (20 mL) followed by brine
solution (30 mL). The organic layer was dried over anhydrous NaZSO4, d and
concentrated under reduced pressure to afford crude compound which was d by column
chromatography by eluting 3% MeOH/DCM to obtained (2S-FNL-46) (110 mg, 19%) as an
off—white solid.
1H-NMR: (400 MHz, DMSO—ds): 6 8.23 (d, J: 8.0 Hz, 1H), 4.98—4.83 (m, 1H), 4.30—4.13 (m,
2H), 3.95—3.76 (m, 2H), 3.72—3.66 (m, 2H), 2.49—1.89 (m, 3H), 1.64—1.54 (m, 3H), 1.48 (s, 9H),
1.19—1.12(m, 10H);
LCMS (ESI): m/z 396.5 [M++1]
HPLC: 96.6%
-113—
Example 3 — 3H MK-801 binding assay
Methods
Assays were conducted as described in Moskal et al. (Moskal, J.R., Kuo, A.G.,
Weiss, C., Wood, P.L., O'Connor , A., Kelso, S., Harris, R.B., Disterhoft, J.F., 2005.
GLYX—13: a monoclonal antibody—derived peptide that acts as an N—methyl-D—aspartate
receptor modulator. Neuropharmacology. 49, 7) The potentiation of [3H]MK—801
binding (5 nM; 22.5 Ci / mmol) to well washed rat cortical membranes (200 pg) was measured
under non-equilibrium conditions (15 min @ 25 0C) in the presence of increasing
concentrations of test compounds and 50uM glutamate. Zero levels were determined in the
e of any glycine ligand and in the presence of 30uM 5,7 DCKA. Maximal stimulation
was measured in the presence of 1 mM glycine, and 50uM glutamate was present in all
samples. The facilitation of [3H]MK-801 binding by tests compounds was ated by using
a 3 parameter log agonist vs. response equation (Graph pad Prism, USA) and potency (EC50
expressed in pM) and maximal activity (% maximal stimulation) were calculated for the test
compound.
Results
As shown in Table 2 and Figure l, the pEC50 and maximal activity for Compound
X are -7.4 and 38%.
Table 2.
Act1v1ty
nd pEC50
Table 3. Additional Biological Data
nd [3H] MK- Unified Unified Unified Unified Unified Unified Unified
801 Activity Data: Activity Data: Activity Activity Activity ty Activity
binding LTP LTP Data: LTP, Data: Data: Data: Data:
assay: Augmentation Concentration Significant Porsolt Porsolt t Porsolt
EC50 (M) (Percent) (uM) (S) or Non- Floating Dose Dose, Time Post
significant Time (mg/kg) route Dose
(NS) Inhibition (Hours)
(Percent)
.43E-08 130 80
—114—
FNL—21
- LIE-08
FNL—7
25_ 34913—12
FNL—27
FNL—34
Exam 1e 4— Lon Term Potentiation in Hi ocam a1 Slices
Methods
Assays were conducted as described in Zhang et a1. (Zhang, X.L., Sullivan, J.A.,
Moskal, J.R., Stanton, P.K., 2008. A NMDA receptor e site partial agonist, GLYX-l3,
simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in
hippocampus. Neuropharmacology. 55, 123 8—50) Sprague—Dawley rats (12—18 days old;
Taconic Farms) were deeply anesthetized with isoflurane and decapitated. Rat brains were
removed rapidly, submerged in ice—cold artificial cerebrospinal fluid (ACSF, 2—4 0C), which
contained (in mM): 124 NaCl, 4 KCl, 2 MgSO4, 2 CaCl2, 1.25 NaH2PO4, 26 NaHCO3, 10
glucose; at pH 7.4, gassed continuously with 95% 02/5% C02). The rat brains were
hemisected, the l lobes cut off, and individual heres glued using crylate
adhesive onto a stage immersed in ice—cold ACSF gassed continuously with 95% 02/5% CO2
during slicing. Coronal slices (400 pm thick) were cut using a Vibratome (Leica S),
and transferred to an interface holding chamber for incubation at room temperature for a
m of one hour before transferring to a Haas-style interface ing chamber
continuously perfused at 3 ml/min with oxygenated ACSF at 32 i 0.5 °C. Low resistance
recording electrodes were made from thin—walled borosilicate glass (1—2 M!) after filling with
ACSF) and inserted into the apical dendritic region of the Schaffer collateral ation field
in stratum radiatum of field CA1 region to record field excitatory postsynaptic potentials
(fEPSPs). A bipolar stainless steel stimulating electrode (FHC Co.) was placed on Schaffer
collateral-commissural fibers in CA3 stratum radiatum, and constant current stimulus intensity
adjusted to evoke approximately half—maximal fEPSPs once each 30 s 0 pA; 100 us
duration). fEPSP slope was measured before and after induction of LTP by linear interpolation
from 20 to 80% of maximum negative deflection, and slopes confirmed to be stable to within ::
% for at least 15 min before cing an experiment. Bath application of the test
compound (1 uM) was applied 30 min prior to ation of Schaffer collateral stimulus trains
-115—
to elicit LTP. LTP was induced by stimulation of Schaffer collateral axons with four high
frequency theta burst stimulus trains of 10 X 100 Hz/5 pulse bursts each, d at an inter-
burst interval of 200 ms. Each train was 2 seconds in duration, and trains were applied 15
seconds apart. The signals were recorded using a Multiclamp 700B amplifier and digitized with
a Digidata 1322 (Axon Instruments, USA). Data were analyzed using pClamp software
(version 9, Axon Instruments) on an IBM-compatible personal computer.
] As shown in Figure 2, Compound X tested at 1 uM increased long-term potentiation
after high frequency stimulation of rat er collateral—evoked NMDA e.p.s.c.s recorded in
CA1 pyramidal neurons.
Table 4. Additional ical Data
Compound MK-801 Glycine LTP: LTP LTP: LTP LTP; LTP
Site Binding Augmentation (%) Concentration Significance, S or
Assay: Rat Cortex (uM) NS
EC50 M
-FNL—38 3.313E-09
—FNL_2 -08
-FNL—10 1.188E-12
-FNL-14 6.133E-11
—FNL—33 1.89E-08
EQUIVALENTS
Those skilled in the art will recognize, or be able to ascertain using no more than
e experimentation, many equivalents to the specific embodiments of the ion
described herein. Such equivalents are intended to be encompassed by the following claims.
INCORPORATION BY REFERENCE
] The entire contents of all patents, published patent applications, websites, and
other references cited herein are hereby expressly incorporated herein in their entireties by
reference.
Claims (60)
1. A compound represented by formula I: or a pharmaceutically acceptable salt, a isomer, or an N-oxide thereof, wherein Rb is selected from the group consisting of H, halogen, hydroxyl, cyano and C1-C6 alkyl; R1 is H or C1-C6 alkyl; R2 is H or C1-C6 alkyl; R3 is selected from the group consisting of H, C1-C6 alkyl and a nitrogen protecting group; n the nitrogen protecting group is selected from the group consisting of 9- fluorenylmethyloxycarbonyl, tert-butoxycarbonyl, benzyloxycarbonyl, pmethoxybenzyloxycarbonyl , acetyl, trifluoroacetyl, benzoyl, benzyl, p-methoxybenzyl, pmethoxyphenyl , 3,4-dimethoxybenzyl, triphenylmethyl, p-toluenesulfonyl, –C(O)OR31 and – C(O)R32; wherein R31 is selected from the group ting of C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C10 cycloalkyl, -CH2-C3-C10 lkyl, -CH2-phenyl, and –CH2-pyridyl, wherein any aforementioned cycloalkyl is optionally substituted with from 1-3 independently selected C1-C3 alkyl, and n the phenyl is optionally substituted with from 1-2 tuents independently selected from C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, nitro, halo, SO2Me, cyano, and -OC(O)CH3; and R32 is selected from the group consisting of H, C1-C6 alkyl, C1-C6 kyl, phenyl, and pyridyl, wherein the phenyl is optionally substituted with from 1-2 substituents independently selected from C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, nitro, halo, SO2Me, cyano, and -OC(O)CH3; R4 and R5 are each independently selected from the group consisting of H, C1-C6 alkyl, X, and –C1-C6 alkylene-X, wherein X is selected from the group consisting of: (i) C3-C6 cycloalkyl; (ii) heteroaryl including from 5 to 6 ring atoms wherein 1, 2, or 3 of the ring atoms are independently selected from the group ting of N, NH, N(C1-C3 alkyl), O, and S; (iii) heterocyclyl including from 3 to 6 ring atoms wherein 1, 2, or 3 of the ring atoms are independently selected from the group consisting of N, NH, N(C1-C3 alkyl), O, and S; and (iv) phenyl; wherein C3-C6 lkyl and heterocyclyl are each unsubstituted or substituted with from 1-3 substituents independently selected from the group consisting of n, cyano, oxo, C1-C6 alkyl, hydroxyl, C1-C6 alkoxy, and -N(R’)R’; and aryl and phenyl are each unsubstituted or substituted with from 1-3 substituents independently selected from the group consisting of halogen, cyano, C1-C6 alkyl, hydroxyl, C1-C6 , and -N(R’)R’; or R4 and R5 er with the nitrogen to which they are attached form: heterocyclyl including from 4 to 6 ring atoms; wherein the heterocyclyl includes not more than two ring heteroatoms (including the nitrogen atom attached to R4 and R5), and the second ring heteroatom, when present, is independently selected from the group consisting of N, NH, N(C1-C3 alkyl), O, and S; and wherein the heterocyclyl is unsubstituted or substituted with from 1-3 substituents independently ed from the group consisting of halogen, cyano, oxo, C1-C6 alkyl, hydroxyl, C1-C6 alkoxy, and -N(R’)R’; or heteroaryl including from 5 to 6 ring atoms; wherein the heteroaryl includes not more than four ring heteroatoms (including the nitrogen atom attached to R4 and R5), and each additional ring heteroatom, when present, is independently selected from the group consisting of N, NH, N(C1-C3 alkyl), O, and S; and wherein the heteroaryl is unsubstituted or substituted with from 1-3 substituents ndently ed from the group consisting of halogen, cyano, C1-C6 alkyl, hydroxyl, C1-C6 , and -N(R’)R’; R6 is selected from the group consisting of -OH, C1-C6 alkoxy, -OC(O)-C1-C6 alkyl, - OC(O)phenyl, and -N(R’)R’; R7 is H or C1-C6 alkyl; and R’ is independently selected for each occurrence from H and C1-C6 alkyl.
2. The compound of claim 1, wherein R1 is H.
3. The compound of claim 1 or claim 2, wherein R2 is H.
4. The compound of any one of claims 1 to 3, n R3 is H.
5. The compound of any one of claims 1 to 3, wherein R3 is a en protecting group.
6. The compound of claim 5, wherein R3 has formula R31.
7. The compound of claim 6, wherein R31 is C1-C6 alkyl.
8. The nd of claim 7, wherein R31 is tert-butyl.
9. The compound of claim 5, wherein R3 has formula –C(O)R32.
10. The compound of claim 9, n R32 is C1-C6 alkyl.
11. The compound of claim 10, wherein R32 is –CH3 or iso-propyl.
12. The compound of any one of claims 1 to 11, wherein R4 and R5 are each independently selected from the group consisting of H, C1-C6 alkyl, and –C1-C6 alkylene-X.
13. The nd of claim 12, wherein R4 and R5 are each independently selected from the group consisting of H and –C1-C6 alkylene-X.
14. The compound of claim 13, wherein one of R4 and R5 is H, and the other is –C1-C6 alkylene-X.
15. The compound of any one of claims 1 or claims 12 to 14, wherein –C1-C6 alkylene-X is
16. The compound of any one of claims 1 or claims 12 to 15, wherein X is phenyl or heteroaryl including from 5 to 6 ring atoms n 1, 2, or 3 of the ring atoms are ndently selected from the group consisting of N, NH, N(C1-C3 alkyl), O, and S; each unsubstituted or substituted with from 1-3 substituents independently selected from the group consisting of halogen, cyano, C1-C6 alkyl, hydroxyl, C1-C6 alkoxy, and -N(R’)R’.
17. The compound of any one of claims 1 to 13, n R4 and R5 are H.
18. The compound of any one of claims 1 to 11, wherein R4 and R5 together with the nitrogen to which they are attached form: heterocyclyl including from 4 to 6 ring atoms; wherein the heterocyclyl includes not more than two ring heteroatoms (including the en atom attached to R4 and R5), and the second ring heteroatom, when present, is independently selected from the group consisting of N, NH, N(C1-C3 alkyl), O, and S; and wherein the heterocyclyl is unsubstituted or substituted with from 1-3 substituents independently selected from the group consisting of halogen, cyano, oxo, C1-C6 alkyl, hydroxyl, C1-C6 alkoxy, and -N(R’)R’; or heteroaryl including from 5 to 6 ring atoms; wherein the heteroaryl includes not more than four ring heteroatoms (including the nitrogen atom attached to R4 and R5), and each additional ring heteroatom, when present, is independently selected from the group consisting of N, NH, N( C1-C3 alkyl), O, and S; and wherein the heteroaryl is unsubstituted or substituted with from 1-3 substituents independently ed from the group consisting of halogen, cyano, C1-C6 alkyl, hydroxyl, C1-C6 alkoxy, and -N(R’)R’.
19. The compound of claim 18, wherein R4 and R5 taken together with the nitrogen to which they are attached form a ring selected from the group consisting of azetidinyl, pyrrolidinyl, pyrazolidinyl, isooxazolidinyl, imidazolidinyl, oxazolidinyl, lidinyl, and azolidinyl.
20. The compound of claim 19, wherein R4 and R5 taken together with the en to which they are attached form a pyrrolidinyl ring.
21. The nd of claim 18, wherein R4 and R5 taken together with the nitrogen to which they are attached form a ring selected from the group consisting of imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridinyl, diazinyl, oxazinyl, and thiazinyl.
22. The compound of claim 1, wherein R1 is H or CH3; R2 is H or CH3; R3 is H; and R4 and R5 taken together form a pyrrolidinyl ring.
23. The compound of claim 1, wherein R1 is H or CH3; R2 is H or CH3; R3 is H; and R4 and R5 are H.
24. The nd of claim 1, wherein R1 is H or CH3; R2 is H or CH3; R3 is H; and one of R4 and R5 is H, and the other is , wherein X is phenyl or heteroaryl including from 5 to 6 ring atoms wherein 1, 2, or 3 of the ring atoms are independently selected from the group consisting of N, NH, N(C1-C3 alkyl), O, and S; each tituted or substituted with from 1-3 substituents independently selected from the group consisting of halogen, cyano, C1-C6 alkyl, yl, C1-C6 alkoxy, and -N(R’)R’.
25. The compound of claim 1, wherein R1 is H or CH3; R2 is H or CH3; R3 is nitrogen protecting group; and R4 and R5 taken together form a pyrrolidinyl ring.
26. The compound of claim 1, wherein R1 is H or CH3; R2 is H or CH3; R3 is nitrogen protecting group; and R4 and R5 are H.
27. The compound of claim 1, wherein R1 is H or CH3; R2 is H or CH3; R3 is nitrogen protecting group; and one of R4 and R5 is H, and the other is –CH2-X, wherein X is phenyl or heteroaryl including from 5 to 6 ring atoms wherein 1, 2, or 3 of the ring atoms are independently selected from the group consisting of N, NH, N(C1-C3 alkyl), O, and S; each unsubstituted or substituted with from 1-3 substituents independently ed from the group ting of halogen, cyano, C1-C6 alkyl, hydroxyl, C1-C6 alkoxy, and -N(R’)R’.
28. The compound of any one of claims 1 to 27, wherein R6 is selected from the group consisting of -OH, C1-C6 alkoxy, -OC(O)-C1-C6 alkyl, and -OC(O)phenyl.
29. The compound of claim 28, n R6 is –OH.
30. The compound of any one of claims 1 to 29, wherein R7 is C1-C6 alkyl.
31. The compound of claim 30, wherein R7 is –CH3.
32. The compound of claim 1, wherein the compound is selected from the group consisting , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , and , or a pharmaceutically acceptable salt, a isomer, or an N-oxide thereof.
33. A pharmaceutical composition comprising a compound of any one of claims 1 to 32, and a pharmaceutically acceptable excipient.
34. The pharmaceutical composition of claim 33, suitable for oral administration.
35. The pharmaceutical composition of claim 33, le for intravenous administration.
36. Use of a nd of any one of claims 1 to 32 in the manufacture of a medicament for treating depression, Alzheimer’s disease, attention deficit disorder, schizophrenia, or anxiety.
37. The compound of claim 1, represented by formula I: or a pharmaceutically acceptable salt, a stereoisomer, or an N-oxides thereof, wherein Rb is selected from the group consisting of H, halogen, hydroxyl, cyano and C1-C6 alkyl; R1 is H or C1-C6 alkyl; R2 is H or C1-C6 alkyl; R3 is selected from the group consisting of H, C1-C6 alkyl and a nitrogen protecting group; R4 and R5 are independently H or C1-C6 alkyl, or R4 and R5 taken er with the en to which they are attached form a 4-, 5- or 6-membered heterocyclic or 5-6 membered heteroaryl ring, unsubstituted or substituted with 1-3 substituents ed from the group ting of halogen, cyano, C1-C6 alkyl, -OH, C1-C6 alkoxy, and -N(R’)R’, wherein R’ is independently selected for each occurrence from H or C1-C6 alkyl; R6 is selected from the group consisting of -OH, C1-C6 , -OC(O)-C1-C6 alkyl, and -OC(O)phenyl; and R7 is H or C1-C6 alkyl.
38. The compound of claim 37, wherein R1 is H.
39. The compound of claim 37 or claim 38, wherein R2 is H.
40. The compound of any one of claims 37 to 39, wherein R3 is H.
41. The compound of any one of claims 37 to 40, wherein R4 and R5 are H.
42. The compound of any one of claims 37 to 40, wherein R4 and R5 taken together form a 4 or 5-membered heterocyclic ring selected from the group consisting of azetidinyl, pyrrolidinyl, pyrazolidinyl, isooxazolidinyl, imidazolidinyl, oxazolidinyl, thiazolidinyl, and isothiazolidinyl.
43. The compound of any one of claims 37 to 40, wherein R4 and R5 taken together form a pyrrolidine ring.
44. The compound of any one of claims 37 to 40, wherein R4 and R5 taken together form a heteroaromatic ring selected from the group consisting of imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridinyl, diazinyl, oxazinyl, and thiazinyl.
45. The compound of claim 37, wherein R1 is H; R2 is H; R3 is H; and R4 and R5 taken together form a pyrrolidinyl ring.
46. The compound of claim 37, n R1 is H; R2 is H; R3 is H; and R4 and R5 are H.
47. The compound of claim 37, wherein the nd is selected from the group consisting of: , and .
48. The compound of claim 37, wherein the compound is: or a pharmaceutically acceptable salt, a stereoisomer, or an N-oxide thereof.
49. The compound of claim 48, wherein the compound is: or a pharmaceutically acceptable salt thereof.
50. The nd of claim 48, n the compound is: or a pharmaceutically acceptable salt thereof.
51. The compound of claim 37, wherein the compound is: or a pharmaceutically acceptable salt, a stereoisomer, or an N-oxide f.
52. The compound of claim 51, wherein the nd is: or a pharmaceutically acceptable salt thereof.
53. The compound of claim 51, wherein the compound is: or a pharmaceutically acceptable salt thereof.
54. A pharmaceutical composition comprising a compound of any one of claims 37 to 53, and a pharmaceutically acceptable excipient.
55. The pharmaceutical composition of claim 54, suitable for oral administration.
56. The pharmaceutical composition of claim 54, le for intravenous administration.
57. Use of a compound of any one of claims 37 to 53 in the manufacture of a medicament for treating depression, Alzheimer’s disease, attention deficit disorder, schizophrenia, or anxiety.
58. A compound according to any one of claims 1 to 32 or claims 37 to 53, substantially as herein described with reference to any one or more of the examples but excluding comparative examples.
59. A pharmaceutical composition according to any one of claims 33 to 35 or claims 54 to 56, ntially as herein described with nce to any one or more of the examples but excluding comparative examples.
60. Use of claim 36 or claim 57, substantially as herein described with reference to any one or more of the examples but excluding comparative examples.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361757903P | 2013-01-29 | 2013-01-29 | |
US61/757,903 | 2013-01-29 | ||
PCT/US2014/013619 WO2014120783A1 (en) | 2013-01-29 | 2014-01-29 | Spiro-lactam nmda receptor modulators and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ709870A NZ709870A (en) | 2020-09-25 |
NZ709870B2 true NZ709870B2 (en) | 2021-01-06 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10316041B2 (en) | Spiro-lactam NMDA receptor modulators and uses thereof | |
US20220151992A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
US10273239B2 (en) | Spiro-lactam NMDA receptor modulators and uses thereof | |
AU2017306158B2 (en) | Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof | |
AU2014212485A1 (en) | Spiro-lactam NMDA receptor modulators and uses thereof | |
NZ709870B2 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
NZ709872B2 (en) | Spiro-lactam nmda receptor modulators and uses thereof |